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Abstract
The repair of bone defects and fracture non-unions remain a substantial
challenge for clinicians. The current materials used to treat these injuries have
limitations with regard to quality, availability and there are also long-term
complications associated with them. This has resulted in research efforts to
identify alternative graft materials that are able to aid tissue regeneration.
Many of these tissue engineered materials include the use of growth factors to
induce cell migration, proliferation, differentiation and matrix production.
However, current delivery methods are limited by poor retention of growth
factors upon implantation due to short plasma half lives resulting in low
bioactivity. These limiting factors have lead to the clinical use of high doses
and/or frequent injections, putting the patient at risk of adverse effects.
The aim of the work presented in this thesis was to develop and evaluate a
controlled bone morphogenetic protein-2 (BMP-2) delivery system based on
poly(lactide-co-glycolide) (PLGA) that would improve current therapies by
controlling the dose and the localisation of BMP-2 at the treatment site as well
as providing biodegradable scaffold to support the newly formed tissue.
Reproducible procedures were developed to manufacture spherical PLGA
microparticles of defined sizes within a 1-100 µm range by a double emulsion,
solvent evaporation method. Lysozyme was used as model protein for the
growth factor BMP-2 and it was successfully encapsulated within the
microparticles. The entrapment efficiency positively correlated with
microparticle size with the largest microparticles regularly achieving greater
than 70% entrapment efficiency. The optimal total protein loading was 1% (w/w)
and as loading increased, the entrapment efficiency decreased.
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Lysozyme released from PLGA microparticles retained its activity in-vitro. The
rate of release was manipulated by the novel use of a PLGA-polyethylene
glycol-PLGA triblock copolymer added at the point of microparticle
manufacture to achieve a number of distinctly different but reproducible
cumulative release curves. The common problem of tri-phasic release from
PLGA systems was overcome and the rate of release was accelerated over
the rate of polymer degradation.
The release profiles achieved were applicable to the delivery of different
growth factors to mimic in-vivo kinetics. A sustained release profile over a one
month period was chosen for translation to recombinant human BMP-2
(rhBMP-2) delivery and the growth factor was shown to remain active
throughout its incorporation into the microparticles and after its subsequent
release. In-vitro studies demonstrated that released rhBMP-2 could up
regulate alkaline phosphate expression in murine C2C12 myoblast cells and
human mesenchymal stem cells, as well as causing murine primary calvarial
cells to produce a mineralised matrix. The rhBMP-2 loaded microparticles
were used in an ex-vivo embryonic chick femur model of bone repair and
caused localised ossification by chondrogenic cells in the epiphysis as
determined by positive picrosirius red staining.
The results presented in this thesis build on published data regarding PLGA
delivery systems for growth factors by demonstrating a robust, novel method
of tailoring their release. Work was focussed on rhBMP-2 but it is feasible that
the technology could be transferred to different growth factors. These
microparticles would therefore be valuable tools not only in pre-clinical studies
of bone repair but could also be applied to the regeneration of other tissues.
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Chapter 1: Introduction to the field of regenerative medicine and bone
tissue engineering
1.1 The growth of regenerative medicine and tissue engineering
Regenerative medicine is defined as the process of replacing or regenerating
human cells, tissues or organs to restore or establish normal function. In the
early twentieth century, transplants of bone, soft tissue and corneas were
developed leading to the first successful kidney transplant being performed in
1954 (Merrill, 1954, Merrill, 1984). Transplant surgery gained pace with
successful pancreas and liver transplants in the 1960s and by the 1980s the
first heart and lung transplants were performed. However, the high doses of
immunosuppressant drugs that were required to prevent graft rejection meant
that the risk of infection was high. But, the aging post war baby boom
generation fuelled the demand for donor organs which far exceeded the
supply and many patients died before surgical intervention (Kemp, 2006).
There was a need to search for alternatives to donor organs and the field of
tissue engineering emerged in the late 20th century. One of the first
breakthroughs was to expand and grow the patients own skin cells in the
laboratory to form constructs. These were used to treat burns and ulcers, thus
overcoming immunocompatibility issues (Munster, 1996). Other autologous
tissues (for example bone chips) were used in regenerative applications but
these often had variable levels of success due to poor quality tissue, low
tissue yield, infection and required two surgical procedures which added to
potential pain and side effects (Arrington 1996).
The development of biomaterials for regenerative medicine gained importance
and one of the first non human materials, pioneered by Dr Stephen Badylak,
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was porcine small intestinal submucosa. This was prepared by removing the
mucosal, serosal and muscular layers of the intestine, isolating the
collagenous matrix then, after decellularisation and sterilisation, the resulting
extracellular matrix based biomaterial would provide a rich environment for
tissue repair and could be used for a number of structural applications from
repairing ligaments and vasculature to closing severe wounds (Sandusky,
1995, Lindberg, 2001). Continued research led to the discovery of synthetic
and naturally occurring polymers as scaffolds to encourage three-dimensional
growth of tissue. The work of Professor Robert Langer was at the forefront of
this field and has provided the foundations for further research (Langer, 1990,
Cohen, 1991, Kumar, 2002, Sokolsky-Papkov, 2007, Zimmermann, 2011).
The discovery and isolation of stem cells was of major importance and human
embryonic stem cells were isolated in 1998 (Thomson, 1998). The
differentiation pathway of stem cells can be directed by in-vitro manipulation to
form a number of tissues which has obvious benefit for regenerative
applications (Pountos, 2005). In addition to cells and a three dimensional
scaffold, the cytokines and growth factors that orchestrate the complex
signalling pathways within tissues are essential components to successful
tissue regeneration. Manufacture of these molecules through bacterial genetic
engineering has pushed forward tissue engineering research (Terpe, 2006).
The importance of mechanical stimulation on regenerating tissue to recreate
the in-vivo environment has resulted in the creation of bioreactors to mimic in-
vivo forces to improve the tissue construct (El Haj, 2010). More recently,
computer controlled three-dimensional printing devices have been developed
with the potential to create made to measure biomaterials with incorporated
cells and growth factors for implantation (Seitz, 2005, Butscher, 2012, Ozbolat,
2013).
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The long term goal of tissue engineering and regenerative medicine is to
combine stem cells and biomaterials to transform the treatment of human
disease through the development of innovative new therapies that offer a
faster, more complete recovery with significantly fewer side effects or risk of
complications (Murphy, 2012, Mallick, 2013).
1.2 Orthopaedic applications for regenerative medicine
The orthopaedic sector of the biomaterials market is large and is expanding
due to the demographics of an increasingly ageing population as well as bone
loss through trauma and disease. The cost of treatment for osteoporotic
fractures alone in the United States alone exceeded $17 billion in 2005 and is
estimated to increase to $25 billion per year by 2025 (Burge, 2007). New
surgical techniques and medical devices have emerged and biomaterials have
been developed for use as fixative devices such as pins, screws and plates as
well as bone cements. Biomaterials for bone filling applications are being used
to provide an alternative to autograft (harvested from the patient) and allograft
(obtained from donor), as both of these types of material have their limitations.
Autografts despite having high immunocompatibility require major surgery and
often the availability and yield is low with risk of infection and recurrent pain.
Allografts including demineralised bone matrices run the risk of graft rejection
by the immune system and transmission of donor pathogens (Braun, 1992,
Arrington 1996).
Many synthetic bone void fillers have been developed but for them to be
completely successful they need to be able to i): provide mechanical support,
ii): act as a substrate for osteoid deposition, iii): have a porous architecture, iv):
encourage bone cell migration into the scaffold, v): support and promote
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osteoinduction, vi): support and promote osseointegration, vii): degrade in a
controlled manner viii): produce non-toxic degradation products, ix): not cause
an inflammatory response x): be sterilised without loss of bioactivity and xi):
deliver bioactive molecules or drugs in a controlled manner to accelerate
healing (Porter, 2009).
As yet no synthetic bone filler is available that meets all these criteria but work
by many groups is focussed on integrating biomaterials with stem cells and
growth factors to facilitate tissue regeneration (Jain, 2000, Dawson, 2008,
Howard, 2008, Martino, 2012, Mehta, 2012).
1.3 Structure and natural growth of bone
1.3.1 Bone structure
Bone is a complex tissue which provides structural support for the body for
movement and also provides protection for internal organs. It plays a role in
regulating calcium levels, storing fat and producing red blood cells. Bone is a
strong composite material consisting of collagen fibres and hydroxyapatite
crystals and has a porous structure with the pores being mostly
interconnected to allow infusion of body fluids. The periosteum is the fibrous
membrane found on the outer surface of the bone.
There are two types of bone with distinct structures (Figure 1.1). Cortical bone
is compact and dense consisting of parallel concentric columns (osteons)
which house the Haversian canal system linked by Volkmanns canals. This
type of bone is mainly found in the shafts of long bones where they play a load
bearing role. Cancellous bone is more lightweight and porous and consists of
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a network of randomly arranged fine plates of lamellar bone called trabeculae
that are separated by interconnecting pores up to 1mm in size. Cancellous
bone is highly vascularised and houses two types of bone marrow, yellow that
acts as a fat storage and red which is the site of erythropoeisis.
Figure 1.1 A schematic showing the typical structure of a long bone. The
cortical or compact bone structure is shown at the circumference with the
more porous cancellous or spongy bone structure within the centre of the long
bone (Flint, 2007)
Osteon of compact bone
Trabeculae of
cancellous bone
Haversian canalOsteon
Volkmanns canal
Lacunae containing osteocytes
Lamellae
Periosteum
Canaliculi
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1.3.2 Bone development, growth and remodelling
Bone has a number of inherent cell types and these play an important role in
development, growth and maintenance. Osteoblasts are formed from
osteoprogenitor cells and lay down osteoid and mineralised matrix. Once
osteoblasts become trapped in the bone matrix they either differentiate into
osteocytes and have a paracrine role on active osteoblasts or undergo
apoptosis. Osteoclasts play a role in bone resorption by secreting acids and
proteolytic enzymes which dissolve crystalline hydroxyapatite and degrade
bone matrix rich in collagen fibres. This bone remodelling is a constant
process which is controlled by complex signalling pathways (Crockett, 2011).
A simplified cartoon of the process is shown in Figure 1.2
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Figure 1.2 A schematic to demonstrate the processes involved in bone
remodelling. Pre-osteoclasts are activated and form the osteoclasts that
initiate bone resorption. The reversal of this occurs by the action of
osteoblasts which deposisit osteoid that becomes mineralised over
time.Osteocytes which have a praracrine role in osteogenesis become
embedded in the matrix. (Crockett, 2011)
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In the early developing foetus, most of the skeleton is composed of hyaline
cartilage, a tough, flexible connective tissue that has no minerals or salts. As
the foetus grows, osteoblasts and osteoclasts slowly replace cartilage cells
through endochondral ossification (Mackie, 2008). Calcium compounds must
be present in the blood for ossification to take place. The primary ossification
centre is in the bone diaphysis where initially, a bone collar forms followed by
cavity formation and vascularisation. As blood vessels, osteoclasts, and
osteocytes continue to invade, the medullary cavity is formed and the
diaphysis slowly continues to lengthen during embryonic development.
Vessels also bud into the hyaline cartilage at the epiphysis of the long bones
forming secondary ossification centres (Figure 1.3)(Flint, 2007).
Cartilage remains at the epiphyseal plates (growth plates) and at the end of
the bones. This cartilage is the only remains of the original hyaline cartilage
model. The epiphyseal plates allow continued growth of the bones into
adulthood and the articular cartilage at the end of the bone facilitates
movement. In humans the epiphyseal growth plate has a distinct zonal
arrangement of cells, resting, proliferative, hypertrophic cartilage, calcified
cartilage and the ossification zone (Burdan, 2009). By adulthood the
epiphyseal plates close to form an epiphyseal line.
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fibroblasts form granulation tissue. The inflammation stage lasts for around
seven days. The damaged bone tissue at the edges of the fracture fragments
die back and osteoclasts work to remove the dead bone cells and phagocytes
ingest the necrotic tissue. However, osteoblasts are unable to work to lay
down new bone tissue at this stage because of the movement of the fracture
fragments. Thirdly, the repair stage, soft callous formation occurs as
fibroblasts begin to lay down cartilage to form a 'scaffold' between the two
fragments. Despite being quite fragile, the soft callus provides sufficient
stability at the fracture site for new blood vessels to form and for osteoblasts at
the periosteum to begin laying down woven bone at the margins of the
fracture. The bone has a disorganised structure, but it's the first bone contact
between the two fracture fragments. A hard callous forms from two to three
weeks after the fracture by endochondral ossification and is encouraged by
gentle mechanical loading. The resulting union of the bones restores cortical
continuity but the callous is often enlarged. The fourth stage is therefore bone
remodelling and can occur over many weeks. The remodelling process as
described in Section 1.3.2 ensures that the woven osteoid bone is remodelled
into lamellar bone and restores full functional integrity.
Clinical invervention is required to stabilise the damaged bone and often
mechanical fixings are used inconjunction with biomaterials such as cements.
It is not only trauma that requires intervention. Other conditions such as
vertebral disc degeneration causing extreme lower back pain can be alleviated
by spinal fusion using bone graft and/or biomaterials to fuse adjacent
vertebrae together often in conjunction with a spinal cage. The inclusion of
bioactive growth factors into the procedure has also been cited (Even, 2012).
Other specialised applications such as kyphoplasty is minimally invasive and
would lend itself to a load bearing microparticulate therapy (Bornemann, 2013).
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suffer from delayed bone healing and be susceptible to infections which can
cause further complications.
Swift medical intervention after trauma is important and if not available, this
could lead to a poor blood supply to the area or insufficient stabilisation of the
fracture which would be detrimental to healing. This can result in a non-union
or mal-union and bone graft materials along with medical fixation devices are
often needed. Another main detractor to bone healing is the advancing age of
the patient and can often result in many people being confined to wheelchairs
as mobility is lost after osteoporotic fractures which are slow or unable to heal.
1.4 Biomaterials for orthopaedic regenerative applications
To improve the prognosis of the patient, a number of biomaterials have been
used clinically to augment bone healing. The biomaterials have different
origins and are described briefly in the following Sections.
1.4.1 Inorganic materials
There are many inorganic materials that have been used for bone tissue
engineering applications each having their own advantages and drawbacks. A
lot of research has focussed on combining materials to produce composites to
improve the overall performance of the material (Rezwan, 2006). Some of the
main component materials are described below.
Hydroxyapatite is chemically similar to the mineral component of bones and is
a complex phosphate of calcium with a chemical formula of Ca10(PO4)6(OH)2.
It is classed as bioactive because osteoblasts will adhere to it and therefore it
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is often used as a coating for orthopaedic implants promoting osseointegration
between bone and the medical device so allowing for cement-less implants
(Akizuki, 2003). A disadvantage is that hydroxyapatite will only degrade very
slowly by dissolution or fragmentation followed by phagocytosis by
macrophages and/or by the action of osteoclasts (Rumpel, 2006). A slow
degradation rate may inhibit the developing tissue.
Beta-tricalcium phosphate (Ca3(PO4)2) like hydroxyapaptite, is biocompatible,
non-toxic and resorbable but it degrades much faster mainly by the action of
osteoclasts and has also been used in many bone substitute materials
(Horowitz, 2009). The drawback with these materials is that they are not
macroporous and have a low porosity which does not encourage cell in-growth
nor do they mimic the mechanical properties of bone.
Calcium based phosphate cements (CPCs) are another class of biomaterials
often used in bone augmentation. These mainly consist of tetra-calcium
phosphate (Ca4(PO4)2O) combined with anhydrous di-calcium phosphate
(CaHPO4) which when mixed with water will create a workable paste that will
harden quickly producing nanocrystalline hydroxyapatite. CPCs were
approved by the Federal Drug Administration of the United States for use in
non-load bearing bone defects in 1996 (Larsson, 2002). The potential for use
as an injectable treatment is advantageous but they are not macroporous in
structure and can produce heat during the hardening process and have
handling problems (Oda, 2006).
Calcium sulphates have been used for many years and are used in bone
tissue engineering where faster resorption of the material is an advantage
over and above providing structural support (Larsson, 2011). They do not
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have good mechanical properties, but, have been used in conjunction with
antibiotics where control of infection was more important than structural
support (Bajada, 2007, Kluin, 2013).
Bioactive glasses were discovered as long ago as 1969 (Hench, 2006) and
have been in clinical use since 1985 (45S5Bioglass®) for interfacial bonding of
implant with host tissue. The first bioactive glasses consisted of a combination
of SiO2, Na2O, CaO and P2O5 and these developed hydroxyapatite crystals
in-vivo which bonded to layers of collagen fibres produced by osteoblasts.
Further research into bioactive glasses has resulted in more sophisticated
formulations which can bond to both soft and hard tissues and play a role in
regulating gene expression in osteoprogenitor cells (Hench, 2009). The
disadvantages of some bioglasses is their mechanical weakness but this can
be overcome by high temperature (>950 oC) thermal treatment which
crystallises the glass (Bellucci, 2011). In addition, the porosity of the bioglass
is problematic but a foaming step during manufacture can overcome this
problem (Sepulveda, 2001, Jones, 2006).
Metals such as titanium, stainless steel and cobalt-chromium alloys are used
by orthopaedic surgeons in the form of plates, pins and screws to aid bone
reconstruction. Metals are also used total joint replacements (for example hip
replacements) often with osteoinduction coatings for better integration. The
company Zimmer introduced trabecular metal TM in 2010 for dental
application and for knee replacement surgery in 2011 (Collins, 2012). This
material was constructed from the metal tantalum and resembles the structure
and strength of cancellous bone being 80% porous. However, it only has
limited application and is not biodegradable.
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1.4.2 Organic materials
Collagen is an obvious candidate for bone graft applications due to its
abundance in natural bone although, in isolation, it has limited mechanical
properties and is often used in conjunction with inorganic materials (Zimmer
Collagraft®) or growth fractures such as bone morphogenetic protein-2
(Medtronic Infuse®) for non-load bearing applications. Growth factors tend to
have a low affinity for collagen which results in a low loading and a fast
release from the scaffold. This can be addressed by cross-linking the collagen
fibres and has shown some success in proving a more sustained release rate
(Zhang, 2012).
Gelatin is material derived from partial hydrolysis of collagen and is widely
used in the food industry but also been used in research into bone graft
materials. Alone, gelatin is not osteoconductive, osteoinductive nor does it
have great mechanical strength but can be used as an inert material in
conjunction with other materials. For example, calcium silicate-gelatin
composites demonstrated high compressive strength (141 MPa) and provided
a favourable environment for cell growth (Ding, 2011). Recently, gelatin has
been conjugated with heparin to improve growth factor immobilisation with
some success (Nakamura, 2012).
Hyaluronic acid is a high molecular weight polysaccharide and an essential
component of extracellular matrix. It has extensively used as a dermal filler but
it has been reported that it increases osteoblastic bone formation in-vivo
through increased mesenchymal stem cell differentiation and migration
(Sasaki, 1995). It is therefore an interesting candidate for bone graft
applications. Hyaluronic acid has been successfully used to augment bone
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graft material to promote callous formation. A study in 2006 (Aslan, 2006)
showed bone allograft material (Tutoplast® cancellous particles) performed
better when administered with hyaluronic acid than when used in isolation in a
rabbit tibial defect model. However, alone hyaluronic acid has poor
mechanical strength for a bone void filler, but its viscoelastic properties may
be of more use as a treatment to relieve osteoarthritis by direct injection into
the joint (Iannitti, 2012).
Fibrin is formed from fibrinogen by the protease thrombin and polymerises to
form a mesh which is the basis of the blood clotting mechanism. The
administration of fibrinogen and thrombin is the basis of a fibrin glue which
acts as a tissue adhesive and has been used in conjunction with bone graft
materials, although there have been conflicting reports as to its effect on
osseointegration (Le Guehennec, 2004). Fibrin is often used in conjunction
with other materials such as calcium phosphate cements to improve its
functional and physical properties (Lopez-Heredia, 2013).
Alginates, extracted from seaweed and brown algae, are hydrogels and have
many uses in bioengineering because of their biocompatibility and controlled
stiffness. Alginate is a linear polysaccharide consisting of ȕ-D-mannuronic acid
(M) and Į-L-guluronic acid (G) monomers. The monomers are ionically
crosslinked with a non-toxic divalent cation such as calcium chloride and the
consistency of the gel can be manipulated for the required application (Jeong,
2012) . In particular, they are good cell delivery vehicles as they can be
manufactured to form microspheres (Zhai, 2013) but in isolation they are not
osteoconductive. If required for bone graft applications they tend to be used
with other biomaterials due to their poor mechanical strength and rapid
degradation.
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Agarose is another gelling polysaccharide, extracted from red algae, which
has similar advantages and disadvantages to those of alginate. Its stiffness
can be controlled, but it is not osteoconductive. It is mainly used for soft tissue
engineering applications. However it has been used in bone-grafting studies
as a component in a composite material. For example, hydroxyapatite/agarose
gels have been identified as good candidates for bone graft material (Tabata,
2003) and chitosan/agarose/gelatin scaffolds show promise for scaffolds in
general tissue engineering applications (Bhat, 2012).
Chitin is a polysaccharide and a component of the exoskeleton of insects and
the outer shell of crustaceans. The removal of its acetyl group results in
chitosan which has a positive charge and is more biocompatible and is also
osteoconductive (Di Martino, 2005). It also has the advantage of being
intrinsically antibacterial and biocompatible (Venkatesan, 2010). To improve
its physical characteristics, chitosan has been used in conjunction with
calcium sulphate and BMP-2 in a rabbit segmental defect model (Cui, 2009)
as well as with hydroxyapatite (Danilchenko, 2011) and has showed
encouraging results for bone regeneration.
Corals have been investigated as bone graft substitutes in particular the coral
Porites which has a structure and strength similar to that of cancellous bone.
The coral is biocompatible, osteoconductive and biodegradable at different
rates depending on the porosity (Demers, 2002). However, coral is not
osteoinductive nor osteogenic and showed no advantage over hydroxyapatite
when compared directly in conjunction with platelet rich plasma in a rabbit
study (Shafiei-Sarvestani, 2012).
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Finally, silk is a naturally occurring material with good tensile strength which
has interested scientists working in bone graft research. Recently, protein
isolated from silkworms has been combined with silk fibres to create scaffolds
which are biodegradable with high compressive strength (Mandal, 2012). The
material has also been used to develop a more realistic model of lamella bone
by growing mesenchymal stem cells on patterned silk films (Tien, 2012).
Research is ongoing at Oxford Biomaterials to develop silkbone which is a
load bearing bone graft material.
The main disadvantage of all naturally occurring polymers is that the batch to
batch variation is generally high and the yields achieved can be quite variable.
1.4.3 Synthetic polymers
Although, naturally occurring inorganic and organic materials have been the
basis of much research into bone graft substitutes, synthetic materials have
also grown in importance due to the ability to tailor their degradation rates and
cut down on batch to batch and processing variability. Research has
concentrated on a number of different polymer types, many of which have
been developed as drug delivery devices as well as bone graft substitutes
(Gunatillake, 2006).
Polyanhydrides are attractive as a biomaterial for short term delivery of
bioactive agents although they do not possess great mechanical strength
(Kumar, 2002). However, if they are synthesised with methacrylate end groups
that readily photopolymerise then they will produced highly cross-linked
polyanhydrous networks with significant mechanical strength (Muggli, 1999).
Polyanhydrides are biodegradable and are not affected by gamma irradiation.
Chapter 1
19
The main disadvantage of this material is its hydrolytic instability and it
therefore requires low temperature dry storage in order to avoid molecular
weight loss (Kumar, 2002).
Biodegradable polyphosphazenes have been identified as materials for drug
delivery matrices and scaffolds for tissue engineering. The most common
being aminated polyphosphazenes and alkoxy-substituted phosphazenes
(Lakshmi, 2003). The degradation products of ammonia and phosphates are
non-toxic at low doses, but are likely to cause toxicity at higher concentrations
The rate of degradation can be altered by substituting different side-groups
and this is advantageous both for use as a delivery device as well as a
scaffold matrix. Polyphosphazenes have been used in composite materials for
bone tissue engineering, for example with polyesters where they can buffer
their acidic degradation products (Deng, 2010).
Polyphosphate polymers have a phosphodiester backbone which remains
anionic over a wide range of pH and thus when it degrades, the local
environment is less susceptible to pH change. Polyphosphates have been
synthesised to deliver rh-osteogenic protein-1 to stimulate osteoblast
proliferation in-vitro and have the potential for use in bone graft materials
(Renier, 1997). Calcium polyphosphate was successfully used as a delivery
vehicle for cultured articular chondrocytes in a sheep femoral defect model.
The degradation products from this porous material were calcium and
phosphate which elicited no inflammatory responses (Kandel, 2006). Recently,
this group has shown the potential for this material in high load bearing
applications but the scaffolds must be pre-sintered and are therefore could not
be delivered as an injectable product (Pilliar, 2013).
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Polypropylene fumarate is an unsaturated linear polyester that can be
modified or cross-linked through its fumarate double bonds to give it strength
and it degrades by hydrolysis of the ester bonds. Fine tuning of physical
parameters during synthesis will result in a candidate material for bone
grafting (Wang, 2006) and it has been used for craniofacial applications where
the disadvantage of heat generation by exothermic crosslinking was overcome
by the addition of crosslinked microparticles (Henslee, 2012).
Acrylic polymers such as poly(methylmethacrylate) have been widely used as
bone cements for decades and are still an important material today. The
viscosity of poly(methylmethacrylate) can be controlled by a number of
methods during manufacture and this gives surgeons flexibility to use different
delivery systems (Webb, 2007).The enduring problem with this biomaterial is
that polymerisation of the monomers is exothermic with temperatures over
70oC recorded, the temperature rise is not always consistent, but can be
sufficient to cause thermal necrosis which can compromise tissue repair
(Reckling, 1977). However, this material hardens quickly (working time of 10-
15 minutes), exhibits high compressive strength and is still commonly used as
a bone cement.
Poly(İ-caprolactone) which is a hydrophobic aliphatic polyester and has a
very slow degradation rate and so it is useful as a long term orthopaedic
implantable devices (Lam, 2009). As well are being used alone as either
electrospun scaffolds or as microparticles for drug delivery (Balmayor, 2009,
Cirillo, 2012), it is also often used as a composite material for example with
calcium sulphate or tricalcium phosphate to improve its physical properties
and osteoconduction (Zhou, 2007, Liu, 2011). Poly(İ-caprolactone) has also
been used in conjunction with growth factors such as bone morphogenetic
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growth factor -2 where the growth factor was attached to the polymer by a
crosslinking conjugation method to encourage osteogenic activity in bone
marrow stromal cells (Zhang, 2010).
1.4.3.1 Poly (Į- hydroxy acid) polymers
Poly (Į- hydroxy acid) polymers are thermoplastic poly(Į- esters) and have
emerged as the most prominent candidates in the field of bone regeneration
especially where glycolide and lactide are the monomers used. Polyglycolide
(poly(glycolic acid)) has high crystallinity (45 -55 %), good mechanical strength
and stiffness but, it degrades quickly and is not soluble in a number of organic
solvents (Middleton, 2000). Polylactide (poly(lactic acid)) is more amorphous
in structure and exists as both D- and L- entantiomers. Poly(L)-lactide has a
much lower crystallinity and slower degradation profile and has good tensile
strength. Poly[DL]-lactide has an amorphous structure and a much lower
strength and a higher degradation rate (Middleton, 2000). To achieve the best
qualities of both polymers, their monomers can be combined by random ring-
opening copolymerisation in the presence of a catalyst to create poly(lactide-
co-glycolide) also known as poly(lactic-co-glycolic acid) or PLGA (Figure 1.5).
Figure 1.5 Synthesis of poly(lactic-co-glycolic acid) (PLGA) (Middleton, 2000)
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PLGA has been used extensively for research into controlled release as it can
be tailored to degrade at different rates by altering factors such as the
lactide:glycolide monomer ratio, molecular weight and end-group chemistry
(Makadia, 2011). The degradation products of PLGA (lactic and glycolic acid),
are metabolised naturally by the tri-carboxylic acid cycle and are ultimately
excreted as water and carbon dioxide. PLGA is therefore considered
biocompatible, non-toxic and is approved by the Food and Drug Administration
for certain applications.
1.5 Parameters to control PLGA degradation
The general mechanism of PLGA degradation is by hydrolysis of its ester
linkages into shorter oligomers and finally into the monomers lactic and
glycolic acid (Korber, 2010). The degradation is described as bulk erosion as it
takes place throughout the whole of the sample and the rate at which water
penetrates exceeds the rate at which the polymer is converted into water
soluble materials. However, initially degradation will occur more rapidly at the
polymer surface due to the greater availability of water (Middleton, 2000).
As already suggested, altering the chemical composition of the polymer will
alter its degradation rate. Having higher lactide content will result in a slower
degradation rate due to its higher hydrophobicity and lower crystallinity. For
example, PLGA with and L:G ratio of 50 50 will degrade in the order of weeks
but PLGA with an L:G ratio of 85 15 will take months to degrade (Anderson,
1997, Wu, 2001). The molecular weight of PLGA will also affect the
degradation rate as the initial drop in molecular weight (a measure of
degradation) is greater for higher molecular weight PLGA than for lower
molecular weight PLGA (Wu, 2001). The end group chemistry plays a role as
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PLGA, a carboxylic acid end group will degrade faster than and ester end
group and degradation products may autocatalyse further degradation
(Sokolsky-Papkov, 2007, Yu, 2010).
In addition to the above, other important factors affecting the degradation rate
of PLGA were summarised by Anderson in 1997 as follows: i) water
permeability and solubility (hydrophobicity), ii) chemical composition, iii)
mechanism of hydrolysis, (noncatalyic, autocatalytic, enzymatic), iv) additives
(acids, bases, monomers, solvents, drugs), v) morphology (crystalline or
amorphous), vi) device dimension (size, shape, surface to volume ratio), vii)
porosity, viii) glass transition temperature, ix) molecular weight and molecular
weight distribution, x) physico-chemical factors (ion exchange, ionic strength,
pH), xi) sterilisation and xii) site of implantation (Anderson, 1997).
Although all of these parameters should be considered when developing a
new biodegradable medical device, in practice they cannot all be addressed
and the required application may influence the prioritisation of the parameters.
1.6 Fabrication of polymeric microparticles and scaffolds as delivery
devices
PLGA is clearly a potentially useful material for tissue engineering applications
but, it needs to be fabricated into a workable product. This could be an
injection moulded device (e.g. an interference screw or stent), a three
dimensional porous scaffold to support tissue growth or drug loaded
microparticles for targeted release of a therapeutic. The following Sections
briefly introduce some of the current manufacturing methods.
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1.6.1 Fabrication techniques without organic solvents
Many different fabrication techniques are available to create workable
scaffolds from PLGA that are suitable for bone tissue engineering. Amongst
these are hot melt extrusion (Singhal, 2011) and jet milling (Nykamp, 2002).
The advantage of these is that there is no aqueous interface for potential
degradation of the bioactive (especially important for water soluble proteins)
and no solvents are required. But, the temperature may be detrimental to
many biological molecules. Nevertheless, it has been shown that lysozyme will
remain active using this method (Ghalanbor, 2010).
Supercritical fluid technology has also been exploited to manufacture foamed
polymer scaffolds for orthopaedic applications using supercritical carbon
dioxide (Tai, 2007, Kang, 2008). An advantage is that these scaffolds tend to
have an open porous architecture which is an important factor for cell growth
and transfer of nutrients across the scaffold.
1.6.2 Fabrication techniques with organic solvents
Most fabrication techniques to manufacture scaffolds or microparticles do
require the use of organic solvents. During electrospinning, the dissolved
polymer is subjected to an electrical change whilst being ejected from a
syringe. The jet of polymer solution is attracted to a collector plate where it
solidifies to leave polymer fibres which will form a scaffold mesh on which cells
can be seeded (Kenawy, 2002, Huber, 2007).
Spray drying is a popular technique for the production of microparticles. The
polymer solution is fed into a chamber through an atomiser where it is rapdly
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dried by a hot gas (Patel, 2009). The resulting microparticles are of a
consistent size but the cost of spray drying equipment is prohibitive for
research use. In order to encapsulate active molecules, emulsions can also be
successfully spray dried (Giunchedi, 2001).
Microfluidic and solvent exchange techniques have resulted in the
manufacture of polymer microparticles of uniform size both in the research
and commercial sector (Yeo, 2004a) but generally, despite producing good
monodispersed microparticles, these techniques are very slow to produce a
workable yield (Zhu, 2009).
The most popular method of manufacturing polymer microparticles is by using
a variety of emulsion techniques and these will be discussed in detail in the
next Section.
1.7 Emulsion techniques for PLGA microparticle manufacture
The use of biodegradable microparticles as a drug delivery system has grown
in importance over the last few years and using different emulsion techniques,
both hydrophilic and hydrophobic molecules can be encapsulated. A
microparticulate system has the potential to be minimally invasive and deliver
the bioactive to the desired site within the body.
1.7.1 The principle of emulsion formation
An emulsion is formed when two immiscible liquids (e.g. an oil and water) are
mixed together to disperse one liquid into the other in the form of drops
(Figure 1.6). Emulsions can either be oil-in-water (O/W) or water-in-oil (W/O),
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depending on whether the continuous phase is the water or the oil. Once
mixing stops, the drops may coalesce and the two phases can therefore
separate and destabilise the emulsion. To form a stable emulsion, an
emulsifying agent must be added into the system. This is usually in the form of
a surfactant which forms a film at the interface of the droplet and resists
coalescence. The stability of an emulsion is dependent on interfacial viscosity,
electric charge on drops, droplet size and concentration, and viscosity of the
continuous phase. Walstra gave a detailed review of the principles of emulsion
formation (Walstra, 1993).
Figure 1.6 The principle of oil in water emulsion
http://people.umass.edu/mcclemen/FoodEmulsions2008/Presentations
1.7.2 Microparticle manufacture by emulsion and solvent evaporation
The principle of emulsion formation has been exploited to manufacture drug
encapsulated polymer microparticles for use in drug delivery and tissue
engineering applications. This section will focus primarily on encapsulation of
proteins as these have complex structures which are directly related to their
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function and thus pose challenges to avoid denaturation and loss of bioactivity
during the encapsulation process.
There are two major methods developed to encapsulate proteins into polymer
microparticles, solid-in-oil-in-water (S/O/W) emulsion and water-in-oil-in-water
emulsion (W/O/W) (Morita, 2000a, Castellanos, 2001, Wischke, 2008, Dawes,
2009, Bible, 2009). Proteins tend to adsorb at water/organic solvent interfaces
and this is thought not only to disturb the delicate conformation of proteins but
also to trigger various physico-chemical transformations leading to protein
destabilization reactions (Sah, 1999, Fu, 2000). Therefore the S/O/W method
which maintains proteins in their solid state and only subjects them to one oil-
water interface would therefore seem more appropriate to maintain protein
function. A novel method of protein micronisation with polyethylene gycol by
lyophilisation was suggested by Morita to improve protein encapsulation and
stability (Morita, 2000b).
The W/O/W method of microparticle production is widely used and involves
dissolving the required drug or protein in a small volume of water then creating
a primary water-in-oil emulsion by homogenising the protein solution with a
solution of the required polymer in an organic solvent such as
dichloromethane. The primary emulsion is then transferred into another
aqueous solution comprising of an emulsion stabiliser such as polyvinyl
alcohol where it is homogenised for a second time. The organic solvent must
then be removed by solvent extraction or evaporation to leave protein loaded
microparticles (Figure 1.7).
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Figure 1.7 Schematic showing the water-in-oil-in-water double emulsion
method of polymer microparticle manufacture (Bible, 2009)
Although the double emulsion is relative simple, it encompasses a number of
variables all of which will affect the parameters of the resulting microparticles.
Without tight control of the method the microparticles will have a broad size
distribution and variable protein content (Ye, 2010). The challenge would be to
develop reproducible and robust protocols to manufacture microparticles in
defined size ranges for different applications with good entrapment efficiencies
and no loss of biological activity of the entrapped molecule by adapting and
optimising the parameters in the double emulsion protocol.
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1.8 Injectable and non-injectable systems
The great advantage of a microparticlulate system is that it has the potential to
be injectable and can therefore be used for minimally invasive surgical
procedures which would improve patient recovery times. A recent review
describes the chemistry behind many of the current injectable scaffold
systems in development (Rahman, 2012b). Most injectable bone fillers
available on the market are cement based and so must be prepared at the
point of use and generally need a high force for delivery, often requiring
specialist delivery devices (e.g Depuy, Confidence spinal cement system®).
Other polymer based products are usually supplied in specialist syringes and
as such they rarely pass through a typically sized syringe bore of 2 mm (Smith
and Nephew, Trugraft®). A product with properties that improve injectability
would be advantageous for a number of orthopaedic applications (for example
kyphoplasty).
Bone graft products are available as a malleable formulation which although
not minimally invasive, gives the surgeon the opportunity to mould the graft to
exactly fit the the defect (Novabone, Nova bone putty® and Apatech,
ActifuseShape ). Other bone graft materials are pre-formed into rigid porous
scaffolds prior to use. These can infer maximum strength to the defect
immediately but drawbacks involve shaping the scaffold to the correct size
during surgery (Smith and Nephew Truwedge®). The number of different
systems available both injectable and non-injectable gives the surgeon a
choice for the required application.
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1.9 Surface modifications to improve cell attachment
Although PLGA is a widely used material for tissue engineering, its surface
chemistry is not ideal for cell attachment. The surface of untreated PLGA
microparticles is hydrophobic, negatively charged and with very few functional
carboxyl groups. But, the surface chemistry can be modified to encourage
receptor-mediated cellular interactions which will further promote tissue
regeneration. Plasma polymerisation followed by allylamine deposition and
attachment of extracellular matrix components such as RGD-peptides or by
covalent grafting of poly(N-vinylpyrrolidone) are some methods to achieve this
aim (Verrier, 2002, Kallrot, 2006, Guerrouani, 2007, Bible, 2009). Improved
osteoblast attachment to PLGA scaffolds and cell differentiation was also
demonstrated by modifying the polymer surface with a thin layer of natural
biomaterials such as collagen (Wu, 2006).
Cells will more readily attach to a roughened surface and a simple treatment
to etch the surface for example with sodium hydroxide is reported (Park, 2005).
However, the disadvantage of this is that the treatment will open up surface
pores allowing entrapped protein to be released prematurely. It therefore may
only be pertinent to methods to create porous microparticles.
1.10 Model Protein and Growth Factors
1.10.1 Model proteins
Model proteins are often used for preliminary research to represent the
molecule of interest as closely as possible. Model proteins are usually chosen
based on molecular weight and electric charge and are used as they tend to
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be readily available and cost effective for the researcher for use in
optimisation assays.
A number of different model proteins have been cited in the literature as being
used in studies to determine release rates from polymeric microparticles. In
particular, those that have been used with regard to bone regeneration are
ovalbumin for transforming growth factor ȕ3 (TGF ȕ3), horseradish peroxidise
for vascular endothelial growth factor (VEGF), ribonuclease A for insulin-like
growth factor 1 and 2 (IGF 1/2) and lysozyme for fibroblast growth factor 8
(FGF8), platelet derived growth factor (PDGF) and BMP-2 (Simon, 1999,
Hiemstra, 2007, Wells, 2007, Yilgor, 2010).
The water/oil interface during microparticle manufacture by emulsion
techniques can be detrimental to maintaining structure and function of the
protein being encapsulated. A number of studies have endeavoured to
improve the entrapment efficiency and retain the structure/function relationship
of the protein (Yeo, 2004b, Giteau, 2008). Serum albumins have been shown
to limit the emulsification induced aggregation of several different proteins,
including lysozyme, ovalbumin and recombinant human erythropoietin.(van
de Weert, 2000a, Perez, 2002). Human serum albumin has also been used in
a similar way (Kang, 2002).
1.10.2 Growth factors
The term growth factor is a broad description for several families of
intracellular signalling proteins which have a number of different defined roles
involving cell recruitment, migration and differentiation (Blackwood, 2012).
Bone regeneration and repair is a complex process which is regulated by a
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large number of bioactive molecules. Both growth factors and cytokines are
involved in natural bone healing and some molecules have been identified as
candidates to enhance the repair process. The key players in angiogenesis
and osteoinduction have been identified as bone morphogenetic proteins
(BMPs), transforming growth factor ȕ (TGFȕ), fibroblast growth factor (FGF),
insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), epidermal growth factor (EGF),
parathyroid hormone (PTH), interleukins (IL), hypoxia inducible factor-2-alpha
(HIF2-Į) and Wingless&int 3/3a (wint 3/3a) (Kelpke, 2004, Kanczler, 2007,
Kousteni, 2008, McMahon, 2008, Yang, 2010, Tamura, 2010).
A review by Kempen highlighted that to be successful in stimulating the auto-
inductive capacity of bone, multiple growth factors should be delivered with
temporal control to allow molecular interactions but successful research in this
area is limited due to inconsistent or unknown pharmacokinetic release
profiles from the delivery device (Kempen, 2010).
1.10.2.1 The BMP-2 signalling pathway
BMP-2 induces osteoblast differentiation via SMAD proteins which are
intracellular proteins that transduce extracellular signals from ligand binding at
the cell membrane to the nucleus where they activate gene transcription
(Figure 1.8). In brief, initiation of the BMP-2 signalling pathway occurs at the
cell surface by the binding of BMP-2 to a BMP type II receptor resulting in the
phosphorylation and activation of the BMP type I receptor. This in turn,
propagates the signal by phosphorylating a family of proteins known as SMAD
proteins (Yamamoto, 1997). These proteins are intracellular proteins that
transduce extracellular signals from ligand binding to the nucleus where gene
transcription is activated. The type I receptor will firstly phosphorylate the
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receptor-regulated SMADs (R-SMADs) which then bind the coSMAD SMAD4.
R-SMAD/coSMAD complexes accumulate in the nucleus where they act as
transcription factors and participate in the regulation of target gene expression.
A number of transcription factors Runx2/CbfĮ1, Osx, Dlx5 and Msx2 work
synergistically to regulate the gene expression of downstream proteins to
induce several types of osteoblasts and therefore play a prominent role in
skeletal development. The system is regulated by antagonist to BMP-2
blocking binding at the cell surface as well as anti-smad proteins which inhibit
smad signaling. The main components of the BMP-2 signalling system are
shown in Figure 1.8.
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Figure 1.8 The main components of the smad signalling pathways of BMP-2 in
osteogenesis. Phosphorylation steps are highlighted by [ ]
(Wu, 2008).
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1.11 Release kinetics
If tissue engineering of bone is to be successful, the bioactive molecules
required to orchestrate its regeneration and repair must be presented in a
manner similar to the in-vivo kinetics. It is therefore of utmost importance that
the release of growth factors from the delivery device can be temporally
controlled.
1.11.1 Cumulative release profiles
There are a number of mathematical models of drug release kinetics including
zero order (release independent of concentration), first order (release
dependent on concentration), Hixson-Crowell (release by dissolution) and
Higuchi (release by diffusion) amongst others (Kalam, 2007). However, it is
well documented that drug release from PLGA microparticles follows a tri-
phasic profile involving both diffusion and erosion (Cohen, 1991, Jiang, 2002,
Ye, 2010, Dawes, 2010). Firstly, there is a burst release followed by a lag
phase with little or no drug release and then a second release phase. In the
early burst and lag phase, protein release is governed by diffusion through a
network of water filled pores and channels.
The burst is caused by the rapid diffusion of surface bound and near surface
entrapped protein and the lag is caused by the inability of entrapped protein to
diffuse out due to being protected by hydrophobic PLGA. The lag phase
continues until erosion of the polymer matrix by hydrolysis of the ester
backbone occurs releasing more protein from the structure (Li, 2001, Paillard-
Giteau, 2010). The tri-phasic profile is not optimum for drug delivery as
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therapeutic levels may be too high during the burst and will not be maintained
during the lag phase.
An alternative method of using PLGA microparticles for drug delivery is to add
the drug within a carrier solution to empty PLGA microparticles to form a
paste. They can then be sintered at their glass transition temperature to
produce scaffolds of defined size from which the active will leach after
implantation. This approach has been effective at delivering antibiotics to
combat otitis media with effusion (Daniel, 2012).
Cumulative release profiles are often plotted showing the percentage of drug
released against time as this highlights different rates of release. Figure 1.9
shows some of the typical traces seen. The most common traces achieved
from polymeric systems are diminishing profiles, tri-phasic or bi-phasic profiles.
For some applications such as arthritis, a pulsatile release is more applicable
and there are ways to achieve this by developing a biomaterial in which the
active is layered or a biomaterial that is sensitive to for example, pH or
temperature (Sharma, 2010). For many drugs or growth factors the optimal
release would be linear zero order with the option of different rates of release.
For example, it would be advantageous for angiogenic growth factors to be
delivered in a sustained manner but quicker than osteogenic growth factors for
optimal tissue repair (Kempen, 2009).
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Figure1.9 Typical cumulative release traces from delivery systems
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1.11.2 Reducing burst and creating a sustained release profile
The avoidance of a high burst release is important and especially so for the
delivery of rhBMP-2, as recently, complications have been highlighted with
the clinical use of rhBMP-2 and these are mainly due to poorly controlled
doses leading to overgrowth and uncontrolled bone formation, soft tissue
swelling, pain, bladder retention, male infertility and osteolysis (Perri, 2007,
Zara, 2011, Carragee, 2011, Helgeson, 2011).
Strategies adopted to reduce the initial burst have involved altering
microparticle manufacture procedures to modify internal morphology (Igartua,
1997, Mao, 2007), altering the protein molecular weight and/or loading
(Sandor, 2001, Boerckel, 2011), modifying protein with additives to improve
stability (Diwan, 2001, Morita, 2001) or modifying the PLGA with the addition
of a hydrophilic component (Cleek, 1997, Kirby, 2011). There are two review
papers written in 2004 and 2008 which summarise all of the above strategies
to reduce burst release and improve protein release profiles (Yeo, 2004b,
Giteau, 2008).
Creating a sustained release profile which is linear with time is often the ideal
for in-vivo delivery of growth factors but it is rarely reported and incomplete
protein release is often cited as a problem (Giteau, 2008, Wischke, 2008).
Different strategies have been applied to further understand profiles ranging
from the use of continuous flow systems (Hernandez, 1998, Aubert-Pouessel,
2002), the comparison of static and dynamic systems (Hernandez, 1998), the
effect of release medium and embedding PLGA spheres in hydrogel
composites (Galeska, 2005). Progress has also been made in releasing
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multiple growth factors simultaneously from a single scaffold (Raiche, 2004,
Jaklenec, 2008, Saif, 2010).
The understanding of the processes involved in encapsulation and releasing
proteins from microspheres for sustained delivery has improved over the years
but there is no standard protocol that can be applied to all proteins due to their
unique structure, molecular weight and charge and so substantial
development is required to achieve successful delivery systems for a number
of therapeutic proteins.
1.12 Determining the efficacy of microparticulate delivery systems by
in-vitro, ex-vivo and in-vivo models for bone regeneration.
The discovery and development of new biomaterials for drug or growth factor
delivery requires extensive research to determine the chemistry and the
release profiles of the delivery device. It is then important to ensure that the
bioactivity of growth factor is retained post release. Most in-vitro growth factor
bioassays rely on cell proliferation, for example, commercial assays are
available to detect various forms of FGF and PDGF which utilise the
proliferation potential of the NR6R-3T3 mouse fibroblast cell line to respond to
the growth factors (Rizzino, 1988).
The advantage of rhBMP-2 is that it will inhibit the differentiation pathway of
the C2C12 myoblast cell line into myotubes and drive the differentiation into
an osteoblast lineage (Katagiri, 1994). C2C12 cells exposed to rhBMP-2 will
express alkaline phosphatase (ALP) activity with the levels of activity being
directly proportional to rhBMP-2 concentration (Kim, 2004) and can be
measured by changes in absorbance at 405 nm.
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Although the enzyme linked immunosorbent assay (ELISA) is often used to
detect released growth factors, it is a technique that can only quantify the
presence of the active molecule and is not a measure of its biological function.
The middle ground between in-vitro assays and animal studies is usually ex-
vivo assays and the fertile chicken egg has become a useful tool in this
research area. Once the chorioallantoic membrane (CAM) has developed, its
blood vessel network provides an optimal environment for research. Since the
lymphoid system is not fully developed, the CAM can sustain tissues being
grafted onto it without rejection. Researchers have used the CAM model to
assess bone repair and the effect of biomaterials on repair using the CAM
assay (Vargas, 2009, Wei, 2011). The assay is very labour intensive and often
gives variable results but it provides a useful tool for screening formulations
prior to animal studies.
Although studies on small animal models to determine bone repair have been
performed (Lee, 1994, Rahman, 2012a), there are issues with self healing and
therefore most animal models of bone repair involve the use of large animals
such as sheep to investigate the repair of critical sized defects (Pilliar, 2007)
or spinal fusion (Khan, 2004). The nature and the cost of such studies is
prohibitive for screening a large number of formulations and therefore, it is
essential that the early laboratory research and development is performed to
the highest standard to give value to pre-clinical studies.
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1.13 Summary of introduction and future aims
Regenerative medicine has gained prominence in recent years leading to
innovative approaches to many aspects of tissue engineering. In particular,
there is a high clinical need within the orthopaedic market for bone void fillers.
Improvements over products currently available would potentially give the
surgeon the chance deliver growth factors or even stem cells to the patient
within a scaffold to improve their prognosis. This introduction has highlighted
the wide range of naturally occurring and synthetic materials available for use
in bone tissue engineering as well as discussing different methods of
fabricating them into potential medical devices.
The thrust of the project described within this thesis, is to create novel
microparticulate scaffolds to deliver selected growth factors in a controlled
manner with the potential to serve as injectable biomaterials for skeletal repair.
The aims of the following results Chapters are as follows:
Chapter 2
x To develop a protocol to create biodegradable microparticles
x To control microparticle size and morphology
x To investigate PLGA degradation
x To optimise the entrapment efficiency of model protein
Chapter 3
x To characterise a PLGA-PEG-PLGA triblock copolymer
x To assess the degradation of PLGA/copolymer blends
x To control the release of model protein from microspheres
x To determine reproducibility of the release profiles
x To ensure that the model protein remains biologically active throughout
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Chapter 4
x To translate the technology from model protein to rhBMP-2 delivery
x To use a thermosensitive scaffold to support to the microparticles
x To determine that biological activity of rhBMP-2 is retained post
release from microparticles.
Chapter 5
x To investigate chick embryonic bone growth both in-ovo and in-vitro
x To develop an ex-vivo model of bone repair using the chick embryo
x To determine to effect of growth factor loaded microparticles on the
chick femur defect model.
The key theme that will run throughout the course of the work within this thesis
will be the need to produce high quality results that are reproducible from one
study to the next to give confidence in the data and added value to future
studies. If successful, the biomaterials developed during the course of this
work will go forward to a large animal critical sized defect model of bone
regeneration and repair.
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Chapter 2: Development of techniques to fabricate protein loaded
PLGA microparticles with control over size, morphology
and entrapment efficiency
2.1 Introduction
Biodegradable polymer microspheres have been used for many years in the
field of tissue engineering as three dimensional scaffolds for tissue support as
well as for drug delivery devices. However, despite extensive research, there
still remains a requirement for an efficient tissue-engineered substitute for
autologous bone grafting that will provide an adequate environment for
successful new tissue growth.
The method for fabricating spherical polymer microparticles (MPs) via
emulsion is a relatively straightforward procedure but, there are a number of
variables which are inter-related and these will have an impact on the MPs
with regard to their size distribution and the encapsulation efficiency of the
loaded drug all of which will in turn, impact on the efficiency of the biomaterial.
Some research groups that have investigated a few of the formulation
variables involved within the emulsion process such as, the continuous and
dispersed phase volumes, the stabiliser concentration, the freeze drying
process and amongst others, the fabrication temperature (Igartua, 1997, Yang
and Chung, 2000, Mao, 2007). But, most of the research has been related to
the subsequent release profile of loaded molecule and the fine control of MP
size within the 1 to 100 micron size range is not well documented even though
this parameter may be paramount to understanding the release profiles
(Namur, 2006).
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Being able to finely tune the MP size range would be of considerable benefit.
A tight microparticle population would be more likely to release the loaded
growth factor or drug in a predictable and reproducible manner and would
therefore give more confidence that the correct dose is being delivered to the
patient. Also, having a tighter control over the size range would also improve
the efficiency of new injectable devices allowing the localised administration of
MPs in a minimally invasive manner (Hou, 2004). The narrowly defined MP
size would also cut down wastage as post manufacture processing such as
sieving would not be required thus the manufacturing process would be more
cost effective.
Researchers at the University of Nottingham had previously used PLGA MPs
for in-vitro studies of drug release but the MPs that were used had a
population range from 50 to 500 µm (Figure 3.1). The procedures to
manufacture the MPs were not standardised or tightly controlled, thus, the size
of the resulting MPs was variable. This method employed a vortex mixer to
create emulsions and was very user dependent and therefore a difficult
process to control. The quality of emulsion was influenced by how the tube
was held on the vortex mixer and the speed at which the mixer was set.
Sieving the MPs post manufacture to the desired size could result in up to 50%
loss of yield. Clearly, this method required investigation and improvement to
optimise the MP yield.
Although, the control of size had not been the main goal for this previous work,
having robust protocols in place for MP production would not only potentially
improve work on growth factor release but, also give added value to other
projects within the Tissue Engineering group at Nottingham by minimising time
spent on development. The acquisition of a Silverson L5M homogeniser was
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the chief driver for this work, the advantage of this machine over other
homogenisers was the fine control over speed and its ability to operate at
speeds as low as 500 rpm.
Figure 2.1 Representative particle size distribution of MPs
(taken from A. Olaye thesis submitted February 2009)
Many other groups have worked with PLGA MPs as tools for drug delivery but
although nearly all characterise them by size often only the average size is
stated rather than the complete size range of the MPs. Amongst others,
typical sizes that have been reported are 26.6 µm (Jiang, 2002), 23 -31 µm
(Morlock, 1996) or 35-40 µm (Morita, 2000b). Other groups have
manufactured larger MPs for example 266 ± 100 µm (Friess, 2002) or 89.38 ±
28.05 µm (Chun, 2004). However, in each case the MP size had not been
tailored for the application but seemed to be merely a result of the adopted
protocol. A published protocol using the double emulsion method to create
MPs specifically in the size range of 50  100 µm required a sieving step post
manufacture. This would have been detrimental to final yield which is
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especially important to avoid if the MPs have an expensive growth factor as
cargo (Bible, 2009).
The objectives for the first part of this Chapter were therefore to thoroughly
interrogate the double emulsion process to enable the reproducible production
of spherical MPs with defined size ranges. The use of a homogeniser rather
than vortex mixer will be investigated for the production of all the size ranges
required for planned studies. The aim was to cut down both inter-batch and
intra-batch variability by standardising the protocol wherever possible.
As well as standardising MP size, the method of protein loading required
optimisation. It is reported that protein denaturation occurs at a water oil
interface and therefore single emulsion techniques are potentially better than
double emulsion techniques (Sah, 1999, van de Weert, 2000b). Although, a
wide range of entrapment efficiencies have been reported using both
techniques. Diwan and Park used the W/O/W method and recorded an
entrapment efficiency of lysozyme in PLGA MPs of 39% but this was improved
with pegylation of the molecule to 76% (Diwan, 2001). Work by Kang reported
entrapment efficiency values for bovine serum albumin (BSA) into PLGA MPs
of 40-50% (Kang, 2001). Yang showed that encapsulation efficiency increased
as BSA concentration was reduced but values of around 50% for
encapsulation efficiency were typical (Yang, 2001). The S/O/W emulsion
technique is reported to improve the entrapment efficiency over W/O/W
techniques (Morita, 2000b). In addition, S/O/O techniques along with
pegylation of the protein have been reported to give entrapment efficiencies of
73 - 98% (Al-Azzam, 2002). An MP manufacture technique that does not
require pre-treatment of the active molecule and has good entrapment
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efficiency will ensure that any loss of the active ingredient during processing is
kept to a minimum.
Therefore, the aim of the second part of this Chapter was to achieve
entrapment efficiencies of a model protein that were as high as possible and
above values reported in the literature. We aimed to achieve entrapment
efficiencies of greater that 50% and hypothesised a higher entrapment
efficiency could be achieved by altering manufacture parameters.
To achieve this firstly, a bulk carrier protein was added to the model protein to
shield it from the water/oil interface (He, 2011) and secondly, manufacturing
parameters were controlled and standardised for optimisation of entrapment
efficiency.
Lysozyme is a common model protein for cytokine and growth factor research
and it was selected for this work to model the growth factor recombinant human
bone morphogenetic protein -2 (rhBMP-2) due to the similarity of isoelectric
points (lysozyme: 9, BMP-2: >8.5) and molecular weights (lysozyme: 14 kD,
BMP-2: 26 kD). It is widely available and cheap to purchase but importantly,
its activity and therefore stability can be detected in-vitro by using a
Micrococcus lysodeikticus bioassay (Saint-Blancard, 1970, Sah, 1997).
2.2 Materials and methods
2.2.1 Equipment, consumables and materials
All the laboratory equipment, consumables and chemicals used during the
work for this Chapter can be sourced in Appendix I, tables A1, A2 and A3
where the manufacture, model, catalogue number and supplier are stated.
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Where microparticle (MP) batch numbers are stated, the details of the
manufacturing parameters can be found in Appendix II.
2.2.2 Micronisation of lysozyme and human serum albumin (HSA) with
PEG6000
This method was adapted from that of Morita (Morita, 2000a) and was used to
manufacture MPs containing lysozyme alone, HSA alone and a combination of
lysozyme and HSA. Twenty batches of micronised protein were made at one
time to reduce batch to batch variability with the intention of using this for a 5%
total protein loading into 1 g of PLGA. A 40% (w/v) PEG6000 solution was made
by weighing 40g of PEG6000 and adding 100 ml of distilled water. This was
kept under magnetic stirring at a gentle speed for 2 hours. Lysozyme (1 g),
HSA (1 g) or a combination of lysozyme (0.02 g) and HSA (0.98 g) was
weighed into a 50 ml volumetric flask and 20 ml of the 40% PEG6000 solution
was added. Distilled water was then added up to a volume of 50 ml and the
solution was stirred for 1 hour. The (w/v) 40% PEG6000/protein solution was
added (2.5 ml) to twenty glass scintillation vials and these were covered, snap
frozen in liquid nitrogen and freeze dried overnight. The vials were vacuum
packed and stored frozen until required. Each vial contained 50 mg of protein
sample in 400 mg of PEG6000. Batches of PEG6000 alone were prepared for
loading into MPs to act as blank controls. Acknowledgement goes to Giles
Kirby (PhD student, School of Pharmacy, University of Nottingham) for
preparing the batches.
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2.2.3 Preparation of lysozyme in human serum albumin (HSA)
Ten batches of lysozyme/HSA were made at one time to reduce batch to
batch variation. For a 5% (w/w) total loading into 1 g of PLGA, 450 mg of HSA
was weighed into a microcentrifuge tube followed by 50 mg of lysozyme to
which 1 ml of distilled water was added. The tube was gently rocked until all
the protein was dissolved, the contents were then stored frozen in 100 µl
aliquots each containing 45 mg HSA and 5 mg lysozyme.
For a 1% (w/w) total loading into 1 g of PLGA, 90 mg of HSA and 10 mg of
lysozyme were weighed and stored in the same way.
2.2.4 Microparticle manufacture
2.2.4.1 Solid in oil in water emulsion method (S/O/W)
Previously prepared batches of micronized lysozyme were use for the S/O/W
emulsion method of MP manufacture (Section 2.2.2) and the method was
modified from Morita (Morita, 2000b) and a schematic of the method is shown
in Figure 2.2A. An aqueous solution of polyvinyl alcohol (PVA) at 0.3% (w/v)
was prepared by adding 3 g of PVA to 1 litre of distilled water and gently
stirring overnight. Generally, MP batch sizes of 1 g were prepared and so 1 g
of PLGA of the required Latide: Glycolide (L: G) ratio and molecular weight
was weighed into a glass vial. If any PLGA-PEG-PLGA was to be added to
PLGA then the mass was reduced to accommodate the triblock copolymer
(e.g. 10% (w/w) triblock would be 100 mg triblock and 900 mg of PLGA) and the
organic solvent dichloromethane (DCM) added.
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The volume of DCM affected the resulting MP size but generally for most
batches 5 ml was added (PLGA concentration 20% (w/v)) where other volumes
are used it will be stated in the results. Once dissolved (approximately 30
minutes on an orbital shaker), the PLGA/DCM was added to the lyophilised
PEG/lysozyme and placed on a vortex mixer set at 2,200 rpm for 45 seconds
to thoroughly disperse the protein within the oil phase. The 0.3% (w/v) aqueous
solution of PVA was passed through a 0.2 um filter unit under vacuum and
200 ml was measured into a 250 ml beaker.
The PLGA/DCM/Lysozyme/PEG6000 solution was transferred to the PVA
solution and mixed using a Silverson L5M homogeniser fitted with a square
hole high shear screen for 2 minutes at 2,000 rpm. A 50 mm glass magnetic
follower was added and the beaker was stirred at 300 rpm for 4 hours on a
magnetic stirring plate to allow the solvent to evaporate. The MPs poured into
a Nalgene 0.2 µm filter unit and were washed with 1 litre of distilled water,
before being collected in a small volume using a Pastette. The tubes were
covered then snap frozen in liquid nitrogen and freeze dried. For storage, the
tubes were vacuum packed and kept frozen until required.
2.2.4.2Water in oil in water emulsion method (W/O/W)
This method was adapted from that of Bible (Bible, 2009) and a schematic of
the process is shown in Figure 2.2B. Previously prepared protein solution was
supplied in 100 µl aliquots used for MP manufacture (Section 2.2.3). PVA
solution (0.3% (w/v)) was prepared by adding 3 g of PVA to 1 litre of distilled
water and stirring gently overnight. The PVA solution was then passed through
a 0.2 µm filter and 200 ml measured into a 250 ml beaker (one per batch).
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The required polymer composition (e.g. PLGA ± PLGA-PEG-PLGA triblock
copolymer) was weighed, to give a total of 1 g, into a PTFE screw top jar and
DCM added. The volume of DCM affected the resulting MP size but in general,
5 ml was added (PLGA concentration 20% (w/v)) where other volumes are used
it will be stated in the results. The jars were placed on an orbital shaker for 30
minutes for the polymer to dissolve. The 100 µl aliquot of prepared protein
(HSA/lysozyme) was added to the PLGA/DCM and homogenised using the
Silverson L5M for 2 minutes. The speed would affect the MP size but in most
cases 4,000 rpm was used for the primary emulsion. This emulsion was then
transferred to 200 ml of 0.3% (w/v) PVA and further homogenised for 2 minutes
to produce a secondary emulsion. The speed was set at either 2,000 or 9,000
rpm depending on MP size required. A 50 mm glass magnetic follower was
added and the beaker was stirred at 300 rpm on a magnetic stirring plate for 4
hours to allow the solvent to evaporate.
Depending on the expected size of the MPs they were collected by filtration
(for >30 µm MPs) or by centrifugation (for <30 µm MPs). The filtration method
is described in Section 2.2.4.1 and for centrifugation, the beaker contents
were split into four 50 ml centrifuge tubes, spun at 3,000 rpm (MSE Mistral
1000) for 3 minutes and washed 5 times with 50 ml distilled water, eventually
transferring the MPs into just one tube where they were covered, snap frozen
in liquid nitrogen and freeze dried. For storage, the tubes were vacuum
packed a kept frozen until required.
2.2.4.3 Oil in water emulsion method (O/W)
The oil in water method of MP manufacture can be used if the active to be
encapsulated is soluble in oil phase or, as in this case, it can be used to
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prepare PLGA MPs that have no protein loading. For a single batch, 1 g of
PLGA was weighed into a glass vial and the required amount of DCM added
(usually 5 ml). Once the polymer had dissolved, it could be added to a 200 ml
bath of 0.3% (w/v) PVA and homogenised at 2,000 rpm for 2 minutes. The
resulting emulsion was then stirred at 300 rpm on a magnetic stirrer for 4
hours to allow the DCM to evaporate. The MPs were then washed and
collected by either centrifugation or filtration and freeze dried (as described
above).
Figure 2.2 Schem
method of PLGA
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2.2.5 Microparticle sizing: Laser diffraction
MPs were sized using a Coulter LS230 machine by suspending a
representative population of MPs in water in a micro volume cell under stirring.
MPs were added until the optimal amount was achieved which was indicated
by the obscuration value which must be between 8 and 12 %. Obscuration is a
measure of the percentage of light that is attenuated due to extinction
(scattering and/or absorption) by the particles. A broadened beam of laser
light was then passed through the MPs, the scattered light was focussed by a
Fourier lens onto a detector array and, using an inversion algorithm, a particle
size distribution was inferred from the collected diffracted light data using a
garnet optical model (Micromeritics, 2000).
A number of tests were performed to determine the length of the run required
and whether repeat runs on the same sample were necessary. This data is
shown in AppendixIV. As a result, runs were measured for 30 seconds with
just one reading for each batch. Traces of MP diameter were plotted against
the diffraction percentage as a function of volume.
2.2.6 Microparticle imaging: Scanning electron microscopy
Thin layers of MPs were attached to an adhesive stub and gold sputter coated
for six minutes at 30 mA using a Balzers SCD 030 sputter coater. MPs were
imaged at a range of magnifications using a JSM 6060LV Scanning Electron
Microscope (SEM) (JEOL, Welwyn Garden City, UK) with the accelerating
voltage set to 10 kV. Acknowledgement goes to Dr Lisa White for performing
some of the imaging.
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2.2.7 PLGA degradation studies
2.2.7.1 pH study: Comparison of PLGA lactide: glycolide ratio
MPs in the size range of 50-100 µm were manufactured from PLGA 85 15 (56
KDa) and PLGA 50 50 (59 KDa) with the incorporation of 30% (w/w) PLGA-
PEG-PLGA triblock copolymer (TBII-C). The MPs (100 mg) were suspended
in 3 ml of PBS in a 15 ml tube and allowed to rock at 5 rpm on a 3D rocker. At
various time-points over a 60 day period, the PBS was collected and replaced
with fresh. The pH of these supernatants was determined using a calibrated
pH meter. A scatter-plot of pH against time was prepared for both batches of
MPs.
2.2.7.2 Mass loss study: Effect of temperature and PLGA-PEG-PLGA
content on degradation
MPs were manufactured using PLGA 5:50 (59 KDa) in the 20-30 µm size
range without and modification with triblock copolymer (10, 20 and 30% (w/w)).
MPs (20 mg) were weighed (in triplicate) into microcentrifuge tubes and 1.5 ml
of PBS was added. The MPs were thoroughly re-suspended and the tubes
were placed on their side at either 37oC or 45oC. At weekly intervals, the tubes
were centrifuged at 3000 rpm (MSE Mistral 1000) for 3 minutes and the
supernatants removed. The MPs were dried overnight on a freeze drier and
the tubes were then re-weighed. Once weighed, fresh PBS was added, the
MPs re-suspended and replaced in their incubation conditions. Mass loss over
time was determined by calculating the remaining mass in each tube as
follows:
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(Mass of tube + MPs at each time-point)  (original mass of tube)
The remaining mass of MPs was plotted against time for both temperatures
2.2.7.3 Morphology study: Effect of degradation on microparticle
morphology
MPs were manufactured using PLGA 5:50 (56 KDa) in the 20-30 µm size
range with the incorporation of 10% (w/w) PLGA-PEG-PLGA triblock copolymer
(TBII-C). A number of replicates of MPs (25 mg) were suspended in 1.5 ml
PBS in microcentrifuge tubes and placed on a 3-D rocker set at 5 rpm in a
37oC humidified incubator. After 3, 9, 14, 20 and 28 days, some of the PBS
was removed and the remainder was removed by drying the MPs overnight on
a freeze drier. The MPs were then imaged using a JSM 6060LV SEM to
determine any changes in their morphology.
2.2.8 Total protein detection: Bicinchoninic acid assay (BCA)
The BCA assay was used to assess the entrapment efficiency of MPs as
described below as well as measuring total protein release from MPs which is
described in the following Chapter.
2.2.8.1 Assessment of encapsulation efficiency of microparticles
Measurement of the protein encapsulation efficiency was adapted from the
method by Sah (Sah, 1997) and determined by dissolving 10 mg of protein
loaded PLGA microspheres in 750 µl DMSO followed by the addition of 2150
µl of 0.02 % (w/v) SDS in 0.2M NaOH. The micro BCA protein assay kit which
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detects protein by the reduction of Cu 2+ to Cu 1+ and subsequent chelation of
Cu 1+ with BCA to give a colourmetric response, was used. The BCA working
solution (150 µl) was plated out with 150 µl of the dissolved MP solution with
appropriate calibration standards (i.e HSA/lysozyme in a range of 1-40 µg/ml)
using DMSO/NaOH/SDS solution as the diluent. Absorbance was measured
after 2 hours of incubation at 37oC at 562 nm on a plate reader (Tecan, Infinite
M200). The total protein was calculated from the polynomial equation of the
standard curve. Entrapment efficiency can then be calculated as follows:
Actual mass of protein in a 10 mg sample of MPs
Expected mass of protein in 10 mg sample based on loading
2.2.9 Lysozyme activity: Micrococcus lysodeikticus assay
The determination of lysozyme activity was based on the fact that lysozyme
would preferentially hydrolyze the ȕ-1,4 glycosidic linkages between N-
acetylmuramic acid and N-acetylglucosamine which occur in the mucopeptide
cell wall structure of the bacterium Micrococcus lysodeikticus. Therefore, a
turbid bacterial solution will become clear upon bacterial cell lysis and the
reduction in the absorbance measurement at 450 nm would be directly
proportional to lysozyme concentration (Saint-Blancard, 1970). Each test
sample in triplicate (150 µl) was added to 100 µl of an aqueous solution of M.
lysodeikticus at 2.3 mg/ml and the absorbance at 450 nm was measured at 0
and 1 minute. The difference between the two readings indicated lysozyme
activity. A standard curve was drawn (linear between 0.1-10 µg/ml) and the
concentration of the lysozyme in the test samples was calculated from the
equation of the straight line.
X 100
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2.2.10 Statistical analysis
Where error bars are presented on figures, they were calculated from the
standard deviation of the mean with a minimum replicate number of three.
Values for protein concentration were calculated from either the polynomial
equation or the straight line equation of the appropriate standard curve as
stated.
Where statistical analysis was stated, unpaired, two-tailed t-tests were
performed using Graphpad quickcalcs software. The probability value of P
denotes the likelihood that the results were achieved by chance (e.g. p<0.05
equates to a probability of the results being obtained by chance being less
than one in twenty). Significant was apportioned as follows: * equals P<0.05,
** equals P<0.01 and *** P<0.0001 and >0.05 is not significant (ns).
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2.3 Results and Discussion
2.3.1 Control of microparticle size
The initial investigation into MP size was to manufacture PLGA MPs without
any drug or protein loading by using the oil in water (O/W) emulsion technique.
Three batches were made with a 20%(w/v)PLGA 85 15 solution in DCM and
were mixed using the homogeniser set at 9,000 rpm in a 0.3%(w/v) polyvinyl
alcohol solution (PVA). DCM was the chosen organic solvent as it is widely
used and has been shown to produce MPs with good entrapment efficiencies
(Birnbaum, 2000).The DCM was allowed to evaporate overnight under
continuous stirring. The only difference between the three batches was the
magnetic stirring speed which were attributed as fast, medium or slow as
the stirrers used did not have an rpm readout. The difference in stirring speed
during evaporation had a profound effect on the MP size. The fast group had
a mean diameter of 31 µm, the medium group were 44 µm and the slow
group had a mean diameter of 59 µm. This parameter was soon standardised
to 300 rpm for all subsequent MPs manufactured by the acquisition of a
multiway stirrer plate with controlled stirring speed. It was also necessary to
standardise the method to measure MP size at an early stage of the project to
ensure that all future size distributions were comparable. The administration of
sample, the run time and the settings on the Coulter LS230 were optimised
through experimentation, written up as a standard protocol and used for all
future size analysis.
As discussed earlier (Chapter 1 Section 1.7.2), the S/O/W emulsion method of
protein encapsulation was predicted to be the best method for MP
manufacture due to there being only one aqueous interface and therefore this
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method was initially chosen to make MPs that were used for size distribution
comparisons. The original vortex mixer method was directly compared to a
method developed using a Silverson homogeniser both set at 2,000 rpm and
the size distribution results are shown in Figure 2.3. Upon visual inspection,
there was a clear difference between the size distribution profiles with the
vortex prepared batch having a much wider distribution. The deviation about
the mean for the vortex mixer batch was 36% compared to 23% for the
homogeniser made MP batch. The mean MP size for the homogeniser batch
was 111 ± 33 µm with the median being 114 µm (data direct from Coulter
L5M). The mean MP size for the vortex mixer batch was 84 ± 47 µm with the
median being much lower at 68 µm.The MPs manufactured using the
homogeniser demonstrated a mathematically more normal size distribution.
A further advantage of the homogeniser is that the rotor can be set and left to
run without intervention, therefore potentially cutting down on batch to batch
variation as well as improving the size distribution of MPs within each batch.
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Figure 2.3: MP size distribution comparing manufacture by vortex mixer ( )
and manufacture by homogeniser ( ). The mean MP size for the vortex mixer
batch was 83 ± 47 µm and for the homogenised batch 112 ± 33 µm. Both
batches were loaded with 5% lysozyme/PEG6000 following S/O/W method
and manufactured from PLGA 50 50 Mwt 59KDa
Batches: BN 81 and 83
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These results meant that the manufacture of MPs using the Silverson L5M
homogeniser was now the preferred method over the vortex mixer and further
studies were performed to standardise the protocol. This work was part of a
mini-project by MPharm students performed under my joint supervision and
investigated the effect of rotor speed, rotor position and mixing time on the
size distribution of the resulting MPs. Figure 2.4 shows the main findings of
this work. In short, the homogeniser speed setting has an effect on the MPs
size with the fastest speed resulting in the smallest MPs (Figure 2.4A) when a
2 cm rotor height and a 2 minute homogenisation time was used. This is a
logical result as the increased shear forces involved with higher rotor speed
will result in smaller W/O droplets being formed (Walstra, 1993) and therefore
this parameter would be important to control in future studies of MP size.
The height of the rotor in the emulsifying bath did not affect the MP size at all
when a speed of 2,000 rpm and a time of 2 minutes were used (Figure 2.4B).
However, this is not to say that rotor height should not be controlled as other
speeds and times may have had an effect on MP size. The rotor height was
therefore fixed at 2 cm for all future batches.
Finally, the time of homogenisation was tested against a 2 cm rotor height and
a 2,000 rpm rotor speed (Figure 2.4C). The results showed that this did have
an effect on MP size. MPs produced after 3 minutes of mixing were less than
half the size (40 ± 16 µm) than those produced after 2 minutes of mixing (100
± 42 µm). Although, just 1 minute of mixing did not produce any larger MPs,
the distribution was wider (93 ± 46 µm). This was obviously a key parameter to
control and therefore a 2 minute homogenisation time was adopted for all
future batches.
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Figure 2.4: Optimisation of MP manufacture process. [A]shows the effect of
homogeniser speed [B] shows the effect of rotor height and [C] shows the
effect of homogenisation time. The red dashed line crosse through the peak
values and highlights the affect on size due to the variable tested. All MPs
were manufactured with PLGA 50 50 Mwt 62 KDa and were loaded with 5%
HSA/lysozyme following the S/O/W method.
(Batches from MPharm student project 2010 courtesy of Charlotte Walker,
Annette Chen and Ria Godhania)
A B C
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Data that will be discussed later in Section 2.3.5 will show that despite the
literature citations, the S/O/W method of MP manufacture in our hands, did not
give the best entrapment efficiencies and as a result the W/O/W emulsion
method for entrapment of lysozyme was adopted and so MPs made by the
two different methods were compared.
Triplicate batches of MPs were manufactured using the S/O/W and the W/O/W
method to investigate the MPs size and the batch to batch variability of the
protocols. The data for MPs loaded with 5% (w/w) lysozyme is shown in Figure
2.5. The average size of the MPs manufactured using the S/O/W method was
larger than those manufactured using the W/O/W method (118 ± 34 µm
compared to 93 ± 28 µm) when a homogeniser speed of 2,000 rpm was used.
This was not unexpected as the micronized lysozyme would have a particle
size of around 5 µm (Morita, 2000a) and this would bulk out the MP during
manufacture, whereas in the W/O/W method, the lysozyme is fully dissolved in
an aqueous solution (Giunchedi, 1998). However, there was no statistical
significance between the sizes of the MPs manufactured by each of the two
methods.
The variation between the batches was acceptable as indicated by the
standard deviation. The variability between the W/O/W batches in this case
appeared greater than the variation between the S/O/W batches but it is
important to note that the S/O/W batches were all made on the same day and
the W/O/W batches were made on different days which would be likely to
introduce more error due to for example, different batches of polvinyl alcohol
being used to stabilise the emulsion.
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Figure 2.5: MP size distribution comparing the S/O/W method of manufacture
( ) with the W/O/W method of manufacture ( ). Each trace represents the
mean of three separate MP batches (PLGA 50 50 59 or 62 KDa each with 5%
total protein loading). The mean size distribution shifts from 118 ± 34 µm for
the S/O/W batch to 93 ± 28 µm for the W/O/W batch.
(Batches: BN 69, 70 and 71 (SOW) and BN 117, 120, 96 (WOW))
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The data has shown that the MP manufacture method and a number of
parameters within the manufacture process will affect the outcome of the MP
size. However until now, only a single PLGA concentration had been tested
and it was thought that this variable would play a significant role in size
distribution (Devrim, 2011). A comparative study was therefore carried out to
look at the size distribution profiles of MPs manufactured with a number of
PLGA concentrations but with all other manufacturing parameters kept
constant. In this case the W/O/W method was used with a primary
homogenisation speed of 4,000 rpm and a secondary homogenisation speed
of 9,000 rpm both for 2 minutes duration. All of the MPs had a 1% (w/w) total
protein loading PLGA solutions of 2, 5, 10, 15 and 20% (w/v) were used to
manufacture MPs and their size distributions are shown in Figure 2.6.
As hypothesised, there was a clear effect on the MP size caused by PLGA
concentration with the lowest PLGA concentration producing the smallest MPs
(2.4 µm) and the highest PLGA concentration producing the MPs nearly ten
times larger (21.6 µm). The effect is clearly shown by the trend line across the
batches.
This can be explained by a number of factors, the higher PLGA concentration
having a higher viscosity which in turn will require higher shear forces for
droplet dispersion. If the energy input via the homogeniser remains the same
and is not increased then the resulting MPs will be larger (Viswanathan, 1999,
Hamishehkar, 2009). The resulting size may also be due to the maximum
volume of a sphere that can be solidified as a function of polymer
concentration. It was also concluded by Behrend that the viscosity of the
dispersed phase has a more significant influence droplet size over the
viscosity of the continuous phase provided coalescence is avoid by the
addition of an emulsion stabiliser (Behrend, 2000).
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2% (w/v)
PLGA
20% (w/v)
PLGA
15% (w/v)
PLGA
10% (w/v)
PLGA
5% (w/v)
PLGA
Figure 2.6: Control of MP size
based on PLGA concentration.
The mean diameters were: 2% (w/v)
PLGA 2.4 ± 2.5 µm, 5% (w/v) PLGA
2.5 ± 0.8 µm,10% (w/v) PLGA 9.0 ±
8.9 µm, 15% (w/v) PLGA 13.8 ± 7.4
µm and 20% (w/v) PLGA 21.6 ± 7.4
µm.
All batches manufactured by
W/O/W double emulsion with
homogeniser speed set at 4,000
rpm for the primary emulsion and
9,000 rpm for the secondary
Batches: BN 48, 175, 43,
171 and 39
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Through the data accumulated thus far, the impact of some of the process
variables on MP size distribution was becoming clear. However, the optimum
solvent evaporation time and MP collection method was still not determined.
Data to be discussed in section 2.3.5 will argue that the shorter the solvent
evaporation time, the better the entrapment efficiency of the MPs and
therefore 4 hours was chosen as a standard parameter.
There are two main methods of retrieving and washing MPs prior to freeze
drying, these being centrifugation and filtration. It is important to remove all
traces of the PVA from the surface of the MPs but equally important not to
damage the MPs during the process. Figure 2.7 shows the size distribution of
two batches of MPs manufactured in exactly the same way with the only
difference being the collection method. In this case, filter paper (pore size 2.7
µm) was used and whilst the size distribution profiles were expected to be
similar, it was notable that the batch collected by centrifugation was slightly
smaller. This was probably because the centrifugation method would collect all
of the MPs in the sample whereas some of the smallest MPs may have
passed through the filter paper. However, the two profiles did also not overlap
exactly at the higher end of the size distribution with the centrifugation batch
again presenting smaller MPs. It is uclear why this was and whether the
perceived effect caused by centrifugation is significant. Although the MPs
were manufactured under the same conditions they were not prepared
together and potentially other variables (e.g. PVA batch) may have had a
minor effect on the MPs.
A further improvement to the filtration method to cut down on variability
between batches was to use commercially available filter units that had a 0.2
µm pore size. These would allow to retrieval of almost all of the MPs. However,
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in some cases, if the smallest fraction (< 5 µm) was not required, the MPs
could be allowed to settle for a few minutes leaving the smallest MPs
suspended in the PVA which could then be removed by pipetting prior to the
centrifugation or filtration step. This removal of the smallest MPs would
improve the normal distribution of the size profile.
It appeared upon inspection of the SEM micrographs that neither of the
washing and collection methods damaged the MPs (Figure 2.7B and C). The
MPs in both batches were non porous and spherical. However, if MPs of less
than 20 µm were to be prepared, the centrifugation method of MP collection
was preferable and routinely used as the filtration of the MPs became very
slow. The smallest MPs may have begun to clog the filter which in turn, may
have led to insufficient washing off of the PVA from the MPs which could lead
to agglomeration of the MPs post drying.
.
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Figure 2.7: [A] Size distribution of PLGA 85 15 MPs manufactured by single
emulsion (20% PLGA, 19,000 rpm) and collected by centrifugation ( ) or
filtration ( ). The mean MP size for the centrifuged batch was 12.8 ± 7.8 µm
and for the filtration batch, 14.6 ± 8.3 µm.[B] Scanning electron micrograph of
PLGA MPs collected by filtration (x1,500). [C] Scanning electron micrograph of
PLGA MPs collected by centrifugation (x1,500).
Batches: BN 4 and 11
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The processing method for the manufacture of MPs had been thoroughly
investigated and using the knowledge gained by the above studies, a robust
protocol could be written to highlight which parameters should remain constant
and which parameters that could be altered to affect the size range of the MPs.
The only parameter not to be investigated in these studies was the emulsion
stabiliser (PVA) concentration. Although this parameter was also likely to
affect MP size (Ye, 2010), a 0.3% (w/v) solution was adopted from the start and
used throughout as it was a commonly used concentration.
The MPs would be used to initially to investigate protein release profiles in-
vitro (Chapter 3) and would go on to be used in in-vitro cell assays (Chapter 4)
and ex-vivo models of bone regeneration (Chapter 5). Three distinct size
ranges were chosen to further interrogate the reproducibility of the protocol
and three batches of each size range were made. The size ranges of these
MPs are shown in Figure 2.8 and will be referred to in the text as 1-5 µm, 20-
30 µm and 50-100 µm MPs. The distribution profiles of the three separate
batches within each size range were similar (images of these MPs can be
seen in the next Section in Figure 2.10), but there was statistical significance
between the three different size distributions.
The reproducible fine tuning of MPs sized between 1 and 100 µm can be
achieved by standardising the majority of the manufacturing parameters and
only altering the PLGA concentration and/or the homogeniser speed at the
primary and secondary emulsion. Table 2.1 shows the achievable size ranges
using this processing method and to date no other groups have reported in the
literature such control of MP size without post manufacture processing.
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Figure 2.8 . Size distribution traces for three batches of PLGA 50 50 MPs. The
average size of these MPs was 2.9 ± 1.1 µm (5% PLGA homogeniser setting
4,000/9,000 rpm), 25.3 ± 12.9 µm (20% PLGA homogeniser setting
4,000/9,000 rpm) and 82.8 ± 27.8 µm (20% PLGA homogeniser setting
4,000/2,000 rpm).
Batches: BN 216, 217, 184, 179, 180, 181, 188, 191, 193
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Table 2.1: Complete range of achievable MPs sizes using the W/O/W double
emulsion method of manufacture and Silverson homogeniser
between 1 and 100 µm.
Size
Description
DCM
Volume
(PLGA
% (w/w))
Primary
rpm
Secondary
rpm
Size Achieved:
1- 3 µm 50 ml
(2%)
9000 9000 1.8 ± 0.6 µm
1- 5 µm 20 ml
(5%)
4000 9000 2.5 ± 0.8 µm
5  10 µm 10 ml
(10%)
4000 9000 6.8 ± 5.6 µm
10  20 µm 6.67 ml
(15%)
4000 9000 13.8 ± 7.5 µm
20  30 µm 5 ml
(20%)
4000 9000 26.2 ± 13.5 µm
50  100 µm 5 ml
(20%)
4000 2000 86.6 ± 24.6 µm
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2.3.2 Microparticle morphology
As discussed previously, two methods of MP manufacture were investigated
(S/O/W and W/O/W). As well as well as determining the size distribution, it
was also important to image the MPs to ensure that that they had spherical
morphology ensuring that a stable emulsion had been formed and to
determine whether there were any surface pores on the MPs which could
affect the outcome of future protein release studies.
Figure 2.9 shows the morphology of 50  100 µm MPs manufactured by each
of the two methods at three different magnifications. The W/O/W MPs have
very few surface pores and exhibit a smooth surface. On the other hand, the
S/O/W MPs are more irregularly shaped they have more pores and a rough
surface. The rough surface maybe due to the surface bound microparticles of
lysozyme that were not encapsulated properly and the pores possibly due to
the presence of hydrophyllic PEG used in the micronisation process leaching
out of the MP, this was confirmed by the recent work by Bhatt (Bhatt, 2012).
Also, MPs yielding surface pores were also produced when the copolymer
Poloxamer 407 was added during MP manufacture (Mahboubian, 2010).
However, these detailed features were not highlighted in the literature by
others (Morita, 2000b, Al-Azzam, 2002) and indeed it maybe that the speed of
solvent evaporation or the freeze drying efficiency may have contributed to the
different morphologies (Rosca, 2004, Allison, 2008b). Unfortunately, the
freeze drying process was the least controllable process in the MP
manufacture protocol due to multi-usage of two different freeze driers.
However, wherever possible the same freeze drying conditions were
employed for each batch of MPs manufactured.
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The surface morphology of the S/O/W MPs may have contributed to loss of
protein during the manufacturing process, therefore reducing entrapment
efficiency which will be discussed later in Section 2.3.5. For long term protein
release studies, the non-porous surface of the W/O/W MPs would be more
advantageous to avoid a fast burst release (Allison, 2008a).
Figure 2.10 shows the morphology of the three distinct size ranges defined in
Figure 2.8 at three different magnifications. In each case the MPs were non-
porous, spherical and were expected to be good tools for localised protein
delivery.
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Figure 2.9: Scanning electron micrographs comparing PLGA MPs
manufactured by the W/O/W emulsion method [A, C and E) and the S/O/W
emulsion method [B, D and F]. The W/O/W MPs have a 1% (w/w)HSA/lysozyme
loading and the S/O/W MPs have a 5% (w/w)HSA/lysozyme loading. Scale bars
are as indicated
Images of S/O/W MPs courtesy of Giles Kirby (PhD student, School of
Pharmacy, University of Nottingham)
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Figure 2.10: SEM images of PLGA MPs fabricated from 5% (w/v) [A] and 20%
(w/v) [B] PLGA with homogeniser speeds set at 4,000/9,000 rpm and MPs
fabricated from 20% (w/v) PLGA with homogeniser speed at 4,000/2,000 rpm [C]
at magnifications of x200 (scale bar 100 µm), x600 (scale bar 20 µm) and
x1000 (scale bar 10 µm).
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2.3.3 PLGA Degradation
2.3.3.1 Measurement of pH
An important aspect for using PLGA polymers for drug delivery applications is
their controllable degradation rate. As the polymer degrades, it will begin to
swell opening up micro-pores allowing the entrapped molecules to release
(Dawes, 2010). Degradation of PLGA is by hydrolytic scission of the ester
linkages of the polymer back bone and it is reported that PLGA polymers with
different lactide:glycolide ratios will degrade at different rates with the higher
lactide content slowing the rate due to the pendent (attached to polymer
backbone) methyl group on the lactic acid sterically hindering the attack of
water molecules thus the presence of lactic acid increases the hydrophobicity
of the polymer (Anderson, 1997, Wu, 2001).
If PLGA were to degrade in a closed environment, then there would be a build
up of degradation products (lactic and glycolic acid) which would reduce the
pH of the surrounding media (Liu, 2012). This is a good tool to measure PLGA
in-vitro but it is unlikely to mimic the in-vivo situation as i) the degradation
products are not confined to the site of administration and ii) there are active
metabolic processes within the body to remove and excrete the degradation
products. To compare the degradation of PLGA 50 50 and PLGA 85 15 having
similar molecular weights in PBS, the pH was monitored over 60 days, with
fresh PBS being added at each time point. The data is shown in Figure 2.11
and shows that the pH drop was more rapid for the PLGA 50 50 than the
PLGA 85 15 which only began to drop after 45 days, thus confirming the
literature findings (Wu, 2001). Interestingly, beyond 40 days, the pH in the
PLGA 50 50 test group began to rise. This was probably because from 15
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days onwards, the polymer began to lose mass, the degradation products
were removed with each replacement of PBS until eventually the effect of the
pH drop was being diluted out by the addition of fresh PBS. This hypothesis
could only be confirmed by setting up a mass loss degradation study.
2.3.3.2 Measurement of mass loss
A PLGA degradation study examining mass loss was set up by incubating a
known mass of PLGA 50 50 MPs in PBS at 37oC and at defined time-points,
removing the PBS, drying and reweighing the MPs. A similar study with the
same PLGA was also set up at 45oC. The hypothesis was that this would
accelerate the degradation rate and increase the mass loss. This aspect of
PLGA degradation may have consequences on the use of these MPs as
delivery devices as a faster degrading polymer is more likely release its
contents quicker and potentially allow for control of release through
manipulation of the glass transition temperature.
The results of the PLGA 50 50 mass loss study are shown in Figure 2.12.
Despite a considerable level of error in the results due to the nature of the
experiment, it was still quite evident that mass loss does occur over time as
the polymer degrades and the mass loss is dramatically accelerated at higher
temperatures. The glass transition temperature (Tg) of this polymer was
reported as 49.0oC (measured by DSC) and it is stated that as the Tg is
approached, the degradation rate will increase (Aso, 1994). This data confirms
these findings.
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Figure 2.11: Comparison of pH values over time for PLGA 85 15 Mwt 56 kDa
( ) and PLGA 50 50 Mwt 59 kDa ( ) both formulated with
30% (w/w) PLGA-PEG-PLGA triblock copolymer and incubated at 37
oC in PBS.
The PBS was replaced with fresh at each time-point.
Batches: BN 135, 142, 149 (PLGA 50 50) B140, 147, 154 (PLGA 85 15)
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Figure 2.12: Mass loss of PLGA 50 50 Mwt 56 KDa MPs through degradation
at 37oC ( ) and at 45oC ( ) after incubation at 37oC in PBS. The PBS was
replaced with fresh at each time-point.
Batch: BN 172
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2.3.3.3 Change in MP morphology
A final investigation into the degradation of PLGA MPs was an attempt to
image the MPs over time. PLGA 50 50 was used as it has the quickest
degradation time and in addition a small amount (10% (w/w)) of PLGA-PEG-
PLGA triblock copolymer was added to increase the degradation rate (the
copolymer will be introduced in detail in the following Chapter). This data on
MP degradation was not as clear cut as pH and mass loss studies (Figure
2.13). During the first 9 days of incubation there was no change in the external
morphology of the MPs. This was not unexpected as neither mass loss nor a
pH drop had been detected over this time in other experiments. However, by
day 14 the MPs had begun to fuse with each other rather than degrade as
individual MPs which had been reported by other researchers (Dawes, 2010).
It has also been reported that the macroporosity of individual MPs reduces as
degradation occurs but microporosity increases (Mao, 2007).
The effect seen in Figure 2.13 was probably the result of bulk erosion
occurring. By 20 days some MPs had blended into each other to form
microporous plaques whilst other MPs still maintained their shape. This
continued up to 28 days where most MPs had either become individual flat
discs or had combined together. It was noted that by 28 days the total volume
of the MPs had reduced and by day 36 all of the MPs had amalgamated into
one structure approximately 3 mm in length which upon examination was
pliable. This may have been a residue of the PLGA-PEG-PLGA triblock
copolymer.
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Figure 2.13: Scanning electron micrographs of PLGA 50 50 MPs formulated
with 10% (w/w) PLGA-PEG-PLGA triblock copolymer after incubation at 37
oC in
phosphate buffered saline for [A] 0 days, [B] 9 days, [C] 14 days, [D] 20 days,
[E] 28 days and [F] 36 days. Scale bar 20µm x600 (A-E) and 1 mm x25 (F)
Batch: BN 243
A B
C D
E F
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2.3.4 Optimisation of total protein and lysozyme activity assays
2.3.4.1 The bincinchoninic acid assay
There are a number of different methods to determine total protein content
including, UV absorption spectroscopy (@ 280 nm), dye based assays
(Bradford assay) and copper reduction assays (Lowry). The bincinchoninic
acid assay (BCA) is a well established assay and is also based on copper
reduction but it has a higher tolerance against intereference (Noble, 2009).
Amino groups in proteins will reduce Cu2+ to Cu1+ in an alkaline environment
which in turn will chelate with BCA and give a measurable colour change.
The goal of this work is to be able to detect protein released from PLGA MPs
but as has been demonstrated in the previous section, there is likely to be a
drop in pH in the surrounding release media as the polymer degrades. Thus, it
was important to ascertain whether this drop in pH would affect the sensitivity
of the BCA assay. Also, the protein extraction method (Sah, 1997) uses
sodium hydroxide which would have a high pH which may also affect the
assay. Therefore BCA standard curves were prepared with HSA/lysozyme
standards (ratio 9:1) from 3-100 µg/ml in PBS adjusted to a range of pH
values from 2 to 12.
As can be seen in Figure 2.14 the pH value of the diluent had little or no effect
on the BCA standard curve. This was a surprising result as the assay is
expected to work only in an alkaline environment. It may be that the pH of the
working solution (pH 11.25) was enough to counteract the lower pH of the
diluents. Nevertheless, this result gave confidence that the assay would give
reliable results for both entrapment assays and release assays.
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Figure 2.14: The bicinchoninic acid assay standard curve performed at [A] pH
2, [B] pH 4, [C] pH 6, [D] pH 8, [E] pH 10 and [F] pH 12 to determine the effect
of pH on the assay n=3.
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2.3.4.2 The Micrococcus lysodeikticus assay
The main driver for the use of lysozyme in optimisation studies was the fact
that its biological activity can be measured in-vitro by its action on the
bacterium Micrococcus lysodeikticus. This assay utilises the fact that
lysozyme preferentially hydrolyzes the ȕ-1,4 glycosidic linkages between N-
acetylmuramic acid and N-acetylglucosamine which occur in the bacterial cell
wall structure of Micrococcus lysodeikticus bacteria. The turbid solution of
cells becomes less cloudy as the cells lyse and this can be measured over
time at an absorbance of 450nm.
As for the BCA assay, it was important to determine whether the assay was
affected by pH. Standard curves were set up with HSA/lysozyme standards
(ratio 9:1) at 3-100 µg/ml in PBS adjusted to a range of pH values from 2 to 12.
The lysozyme component would be a tenth of the total protein and so the
standard curves were constructed with a lysozyme concentration of 0.5-10
µg/ml. Figure 2.15 shows that this assay is very sensitive to pH. Either the
lysozyme was becoming denatured, (but this is unlikely for low pH values as it
is reported to be most stable in acidic conditions such as glycine buffer (Jiang,
2002)) or more likely the bacteria are affected by pH and receptor binding in
the cell wall was not possible. It was reported that in acid conditions that
lysozyme still binds to the mucopolysaccharides of the cell wall but no lytic
activity is evident (Gagliardi, 1986).
It was therefore concluded that although total protein can be measured at a
range of pH values with confidence, results from the lysozyme activity assay
will only be of value around neutral pH. Figure 2.16 shows a typical standard
curve for both BCA and Micrococcus lysodeikticus assay in standard PBS
buffer at pH 7.4. For each assay a new standard curve will be constructed.
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Figure 2.15: The Micrococcus lysodeikticus assay standard curve performed
at [A] pH 2, [B] pH 4, [C] pH 6, [D] pH 8, [E] pH 10 and [F] pH 12 to determine
the effect of pH on the assay n=3.
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Figure 2.16: Typical standard curves for [A] bicinchoninic acid assay and [B]
Micrococcus lysodeikticus assay in PBS at pH 7.4 n=3
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2.3.5 Entrapment efficiency of HSA/lysozyme in PLGA MPs
2.3.5.1 Solid in oil in water emulsion
Lysozyme was used in conjunction with human serum albumin (HSA) as a
bulk carrier and stabilising excipient (Morlock, 1996, He, 2011). The addition
of the bulk carrier was to shield the active molecule from the water/oil interface
during MP manufacture. The solid-in-oil-in-water (S/O/W) single emulsion
method of protein entrapment required the lysozyme to be co-lyophillised with
PEG6000 in an aqueous medium (Morita, 2000a). The action of freeze drying
resulted in the protein being micronized in a continuous PEG phase and the
proposed advantage of this method was that the protein can be directly mixed
into the organic polymer phase and only one emulsion step was required,
subjecting the protein to only one water/oil interface.
As well as the addition of bulk carrier and MP manufacture by S/O/W, the
effect of solvent evaporation time on entrapment efficiency was investigated. It
was reduced from 24 hours to 4 hours to minimise protein loss in the PVA
stabilising bath. The results of this investigation are shown in Table 2.2. In
each case the total protein loading was 5% (50 mg into 1 g PLGA 50 50) and it
was micronized with 400 mg PEG6000. Lower masses of PEG6000 were also
used to co-lyophilise the lysozyme and HSA but the entrapment efficiencies
for these were generally below 20%.
Reducing the evaporation time had a clear effect on improving the entrapment
efficiency for all three loading conditions (HSA/lysozyme, HSA alone and
lysozyme alone) but, the values were not comparable. HSA loading alone
provided the best entrapment efficiency with and improvement from 21.8%
after 24 hours evaporation to 56.8% after 4 hours of evaporation. The shorter
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time also improved the entrapment efficiency of the lysozyme alone batch by
91% but still the final value was only 13% meaning the vast majority of the
lysozyme had been lost during the manufacturing process. The HSA/lysozyme
batch after 4 hours of solvent evaporation returned an entrapment efficiency of
21.8% compared to 9.7% after a 24 hour solvent evaporation period.
Despite the clear advantages of reducing the evaporation time, the overall
results for the entrapment efficiency were not encouraging and it would not be
cost effective or efficient to transfer this method of manufacture to the
entrapment of growth factors due to the high losses.
Table 2.2 Effect of solvent evaporation time on the entrapment efficiency
of lysozyme ± human serum albumin in PLGA MPs using the
S/O/W emulsion method
HSA/PEG/Lysozyme Content in 1 g
PLGA 50 50
Evaporation
Time (hrs)
Entrapment
Efficiency (%)(n=3)
49 mg HSA 1 mg Lyso 400 mg PEG6K 24 9.7 ± 1.2
49 mg HSA 1 mg Lyso 400 mg PEG6K 4 21.9 ± 0.7
50 mg HSA 400 mg PEG6K 24 21.8 ± 14.6
50 mg HSA 400 mg PEG6K 4 56.8 ± 14.9
50 mg lyso 400 mg PEG6K 24 6.8 ± 1.0
50 mg lyso 400 mg PEG6K
4 13.0 ± 1.6
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2.3.5.2 Water in oil in water emulsion
Despite the predicted poor entrapment efficiency results expected with the
W/O/W manufacture method, when tested the results were in fact, more
encouraging. Batches of PLGA MPs were manufactured with a range of
HSA/lysozyme loadings ranging from 0.05 to 5% (w/w) and entrapment
efficiency estimations by BCA assay were made for each batch in triplicate.
The was a strong inverse relationship between loading and entrapment
efficiency, as loading went up entrapment efficiency went down but even with
5% (w/w) loading, the W/O/W method out-performed the S/O/W method (Figure
2.17). A similar result was reported in the literature by Trivedi who found that
encapsulation efficiency of Aceclofenac in PLGA significantly increased as the
drug:polymer ratio decreased and the same trend was reported for
doxorubicin in PLGA nanospheres (Trivedi, 2008, Kalaria, 2009). The likely
explanation for these results was that the more drug/protein that was available,
the more that would be likely to be lost during solvent evaporation and this
would be especially pertinent for lysozyme which is hydrophilic and likely to
leach away. A total loading of 1% (w/w) was chosen as a standard loading for
the majority of future studies and the entrapment efficiency of this protein
loading was highly significant when compared to the S/O/W result (Figure
2.17).
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Figure 2.17: Effect of HSA/lysozyme loading on the entrapment efficiency of
PLGA 50 50 MPs (50-100 µm) using the W/O/W emulsion method (4 hour
evaporation time) and a comparison of the entrapment efficiency a 5% (w/w)
protein loading using the S/O/W method of manufacture. (For W/O/W PLGA
Mwt was 56 KDa and for S/O/W PLGA Mwt was 58 KDa)
Batches: BN 101 (SOW) and BN 188-195 (WOW)
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The work performed thus far on this project was to optimise the achievable
size range of manufactured PLGA MPs but, the important studies on
entrapment efficiency were only performed on 50-100 µm sized MPs and so
entrapment efficiency measurements were performed on a range of MP sizes
each loaded with a total of 1% protein (9 mg HSA with 1 mg lysozyme in 1 g of
PLGA 50 50) and manufactured following the W/O/W method. The results are
shown in Figure 2.18. For MPs above 2.5 µm, the entrapment efficiency was
above 50% and increased with MP size. There was a discrepancy with the 20-
30 µm size range in this study but further work with this size range has yielded
MPs with typically 70-80% entrapment efficiency. The smallest MPs had the
lowest loading efficiency and this was attributable to lower PLGA
concentrations being used during manufacture resulting in MPs with thinner
outer shells which would be more prone to hydrolytic attack during the solvent
evaporation process during manufacture. The significance between the
entrapments efficiencies of the 1-5 µm, 20-30 µm and 50-100 µm MPs is
highlighted in Figure 2.18.
It was suggested by Dhakar and Colleagues that the polymer concentration
affects entrapment efficiency in three ways: i) at high concentrations, the
polymer precipitates faster on the surface of the aqueous dispersed phase
preventing diffusion across the phase boundary, ii) the high concentration
increases viscosity and delays diffusion within the polymer droplets and iii) a
high polymer concentration results in larger MPs and loss from the surface is
reduced. Therefore and as confirmed in Figure 2.18, MP size is directly related
to entrapment efficiency (Dhakar, 2010).
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Figure 2.18: The relationship between MP size and entrapment efficiency
using the W/O/W double emulsion method of MP manufacture. 1% (w/w) loading
PLGA 50 50 Mwt 58 KDa. n=3
Batches: BN 49, 175, 173, 171, 179, 39 and 191
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2.4 Conclusions
This Chapter has highlighted the manufacture parameters that affect the size
distribution and entrapment efficiency of biodegradable PLGA MPs. Although
a lot of work has been cited in the literature regarding the use PLGA, no
groups as yet have demonstrated the control over size distribution from 1 to
100 microns as reported in this Chapter. The variable parameters within the
protocol for manufacturing these MPs have been thoroughly tested to produce
a reproducible and robust method for producing the biodegradable MPs.
A range of different values for protein entrapment efficiencies have been
reported in the literature and much of the data in this Chapter agreed with the
trends in published data regarding MP size and drug loading. However, it was
interesting to discover that the W/O/W method of manufacture was preferable
to the S/O/W method despite there being two aqueous interfaces within the
W/O/W method which were expected to be detrimental to encapsulation
efficiency. The reason for this remains unclear but may relate to the addition of
a stabilising excipient or bulk carrier to the bioactive model protein lysozyme.
As yet the retention of biological activity of the protein within the MP was
unknown but the Micrococcus lysodeikticus assay to determine lysozyme
activity had been investigated and operating parameters were defined for
sample testing.
The techniques described in this Chapter for MP manufacture will be used to
make MPs for future studies to determine the typical rate of lysozyme release
over time and further formulation of the MPs will attempt to tailor the release
profiles to different rates which may have the potential for use with different
growth factors.
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Chapter 3: Control of protein delivery from PLGA microparticles by
the novel use of a triblock copolymer to uncouple protein
release from polymer degradation
3.1 Introduction
During bone and cartilage repair, there is a complex cascade of biological
events controlled by growth factor signalling promoting progenitors and
inflammatory cells to migrate and trigger healing processes. Although for
some applications, therapeutic drugs can be delivered at supraphysiologic
concentrations without any serious side effects (for example antibiotics), the
delivery of growth factors must have much tighter control in order to be
effective, mimic in-vivo kinetics and avoid unwanted biological effects. The aim
of this Chapter is to describe the development of a novel microparticulate
delivery system having controlled kinetics of release that are faster than the
degradation of the scaffold. A system that combines control over the rate of
growth factor delivery and provides support for the surrounding and newly
formed tissue will be a considerable achievement in the field of tissue
engineering.
The previous Chapter described the development and optimisation of a
protocol to manufacture PLGA microparticles (MPs) reproducibly in defined
size ranges. In addition, the MPs were successfully loaded with the model
protein lysozyme in conjunction with human serum albumin (HSA) as a bulk
carrier and investigations into the degradation of PLGA were performed. This
Chapter will build on this work by investigating the profile of lysozyme release
from PLGA MPs during in-vitro release assays and attempt different strategies
to control the rate of protein release from the MPs.
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Despite PLGA being cited as a valuable material for drug delivery applications
due to its non-toxic degradation products and having FDA approval for use in
certain medical devices and drug delivery applications, it is well documented
that protein release from PLGA follows a triphasic profile (Cohen, 1991, Jiang,
2002, Ye, 2010). This release profile involves two mechanisms; diffusion and
erosion. Firstly there is a burst release followed by a lag phase and then a
second phase of release. In the early burst and lag phase, protein release is
governed by diffusion through a network of water filled pores and channels.
The burst is caused by the rapid diffusion of surface bound and near surface
entrapped protein and the lag is caused by the inability of entrapped protein to
diffuse out due to being protected by hydrophobic PLGA. The lag phase
continues until erosion of the polymer matrix by hydrolysis occurs releasing
more of the entrapped protein from the structure. The triphasic profile is not
optimum for drug delivery as therapeutic levels may be too high during the
burst and are not be maintained during the lag phase. The release profiles
have been the subject of mathematical modelling (Batycky, 1996) and the size
and porosity of the microspheres are highlighted as playing a key role in drug
release mechanisms (Klose, 2006).
Many strategies have been adopted to improve the release profiles by
reducing the initial burst which can account for a large percentage of protein
loss in the first few hours. Studies have investigated altering MP manufacture
procedures to modify internal morphology (Igartua, 1997, Mao, 2007), altering
the protein molecular weight and/or loading (Sandor, 2001), modifying protein
with additives to improve stability (Kang, 2001, Diwan, 2001) and
comprehensive reviews have been written on these approaches (Yeo, 2004b,
Giteau, 2008). As well as high burst, incomplete release of protein from PLGA
has long been cited as a problem (Rosas, 2001, Giteau, 2008). The
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combination of these two issues means that often the actual amount of
therapeutic protein available for release over the optimum timescale is very
low.
The strategy proposed for this thesis was to incorporate an in-house
manufactured PLGA-PEG-PLGA triblock copolymer into the PLGA at the point
of MP manufacture to modulate the MPs release profiles. Although triblock
copolymers have been used alone as drug delivery devices (Chen, 2005,
Ghahremankhani, 2007), they have not been used incorporated into PLGA
MPs. If MPs could be engineered to release their payload in specified time-
frames ranging from a few days to a number of weeks then, it would give the
flexibility to manufacture MPs loaded with different growth factors so
mimicking the growth factor kinetics required during tissue repair and keep the
delivery localised.
It was hypothesised, that introduction of PLGA-PEG-PLGA triblock copolymer
into MPs would make them more hydrophilic and that this would modify
release from the MP in two ways. Firstly, it would encourage the ingress of
water to wash out the surface and near surface bound protein and secondly,
the ingress of water would accelerate the hydrolytic attack on PLGA and so
increase the degradation rate allowing protein to be released gradually,
through pores and channels, so avoiding the lag phase seen in MPs fabricated
from PLGA alone (White, 2013) .
Before materials can be tested in-vivo they must first be thoroughly assessed
in-vitro for both ethical and financial reasons. Many studies have been
performed to investigate in-vitro release profiles from MPs but as yet no
standard protocol has been determined to give a good in-vitro/ in-vivo
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correlation. Researchers have compared static with dynamic release systems
(Hernandez, 1998), continuous flow systems (Aubert-Pouessel, 2002) and
looked at the importance of maintaining sink conditions (Klose, 2011). But, the
important thing to note is that whatever in-vitro release system is used, it must
be adequately controlled to minimise variables and error so that subsequent
release assay results can be comparable.
Despite real progress being reported in releasing multiple growth factors
simultaneously from a single scaffold to achieve multiple responses in the
surrounding tissue (Raiche, 2004, Sohier, 2006, Suciati, 2006, Jaklenec,
2008), a MP based system with the potential to be delivered by microinjection
has not yet been developed and there is no standard manufacturing
procedures that can be applied to all proteins due to their unique structure,
molecular weight and charge.
A further problem with using MPs as delivery tools is the potential for migration
of the MPs away from the site of delivery. This could potentially lead to
systemic side effects or cause an unwanted inflammatory response (Yoon,
2008, Wu, 2010). Incorporation of a second type of MP, one that is
thermosensitive, could bind the protein loaded MPs in a porous matrix so
avoiding migration and provide stability to the scaffold structure. This would
give support to the surrounding tissue and provide a better environment for
new tissue growth. PLGA and low molecular weight PEG have been blended
together by hot melt techniques and can be milled to form irregular shaped
MPs (Rahman, 2012a). The PEG acts as a plasticiser and by careful
manipulation of the PEG concentration, the MPs can be tailored to become
cohesive at body temperature. These temperature sensitive MPs will form
bridging points between other temperature sensitive MPs as well as with the
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protein loaded MPs forming a single solid structure and thus preventing
migration of growth factor loaded MPs from the site. As the low molecular
weight PEG is not chemically bonded to the PLGA, it can leach away in an
aqueous environment due to its hydrophyllicity and this will cause a rise in
glass transition temperature of the polymer resulting in the bridging points
strengthening and therefore the overall structure becoming stronger (Dhillon,
2011). A schematic depicting the mechanism of setting is shown in Figure 3.1
Figure 3.1 Schematic of in-situ setting mechanism of thermosensitive
MPs and incorporation of a non-temperature sensitive component which could
be either be an osteoconductive ceramic or a growth factor loaded MP
Adapted from (Rahman, 2013)
This project aims to address some of these issues to achieve a
microparticulate delivery system with the potential to apply the technology to
different growth factors to achieve profiles of release over different and
clinically appropriate therapeutic time frames. An additional aim is to provide a
three dimensional porous scaffold to support to the surrounding tissue and
encourage cell proliferation and differentiation. The system would be most
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effective if protein was released in advance of the polymer degradation so that
there was a scaffold still present to host the new tissue growth.
Although the work in this project is aimed primarily at bone regeneration, the
technology once developed, could potentially be applied to the repair of other
damaged tissues such as cartilage, liver or nervous system (Schneider, 2012,
Chistiakov, 2012, Xiong, 2012).
3.2 Materials and Methods
All the laboratory equipment, consumables and chemicals used during the
work for this Chapter can be sourced in Appendix I, tables A1, A2 and A3.
Where MP batch numbers are stated, the details of the manufacturing
parameters can be found in Appendix II.
3.2.1 Preparation and characterisation of PLGA-PEG-PLGA triblock
copolymer
Synthesis of the PLGA-PEG-PLGA triblock copolymer occurred by
ring opening polymerisation of the DL-lactide and glycolide monomers in the
presence of PEG1500 and a stannous octoate (Sn(Oct)2) catalyst under a dry
nitrogen atmosphere using vacuum gas manifold or Schlenk line (Zentner,
2001). Prior to polymerisation, PEG was first dried in the reaction vessel
under vacuum with stirring at 120°C for 3 hours. The temperature was then
raised to 150°C, the monomers were added to the vessel and the reaction
mixture was allowed to equilibrate under a dry nitrogen atmosphere. After 30
minutes, the Sn(Oct)2 was added and the reaction allowed to proceed for a
further 8 hours. The resultant copolymer was dissolved and precipitated in
water in order to remove un-reacted monomers. The triblock copolymer was
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then dried under vacuum to remove residual water and stored frozen until
required. Acknowledgement goes to Giles Kirby (PhD student, School of
Pharmacy, University of Nottingham) for preparing the batches (Kirby, 2011).
The molecular weight and polydispersity index of the copolymer was
determined using gel permeation chromatography (GPC) with differential
refractometer detection. Tetrahydrofuran (THF) was employed as an eluent,
with two columns (30 cm, PolarGel-M) in series calibrated against polystyrene
standards.
Nuclear Magnetic Resonance (NMR) analysis of the copolymer was
undertaken using a Bruker DPX-300 Spectrometer (300 MHz) with
deuterated choloroform (CDCl3) as the solvent. A tetramethylsilane
(TMS) signal was taken as the zero chemical shift. The composition of the
copolymer was determined by 1H NMR by integrating the signals pertaining to
each monomer (Hou, 2008).
Three batches of PLGA-PEG-PLGA triblock copolymer were used in this work
and these were labelled as TBII-B, TBII-C and TBII-F.
Acknowledgement goes to Natasha Birkin (School of Chemistry, University of
Nottingham) for performing the GPC and NMR
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3.2.2 MP manufacture incorporating PLGA-PEG-PLGA triblock
copolymer
PLGA MPs were formed using a water-in-oil-in-water (W/O/W) emulsion
method as previously described in Chapter 2 with lysozyme and human serum
albumin (HSA) being co-encapsulated together. But, in addition to the PLGA
polymer, PLGA-PEG-PLGA triblock copolymer was introduced into the
dichloromethane (DCM). The MP size range chosen for the work on
optimisation of release profiles were in the 50-100 µm range and were
manufactured using the following parameters. An aqueous solution of HSA
and lysozyme (9 mg HSA, 1 mg lysozyme dissolved in 100 µl distilled water)
was added to a solution of PLGA and PLGA-PEG-PLGA in DCM. In each
case a 1 g batch was manufactured and the triblock copolymer was added to
give weight percentages of 0, 10, 20 and 30% (w/w). The phases were
homogenised for two minutes at 4,000 rpm (Silverson L5M) to form the water-in-
oil emulsion. This primary emulsion was transferred to 200 ml 0.3% (w/v) PVA
solution and was homogenised for a second time at 2,000 rpm for a further
two minutes. The resultant double emulsion was stirred at 300 rpm for a
minimum of 4 hours to facilitate DCM evaporation. MPs were then
collected by filtration, washed and lyophilized. Control MPs without protein
(100 µl distilled water) were always manufactured alongside the test MPs.
3.2.3 Manufacture of self assembling thermosensitive scaffolds directly
loaded with lysozyme by hot melt fabrication.
PLGA can be plasticised with low molecular weight PEG (PEG400) by hot
melt blending to lower the glass transition temperature of PLGA. MPs
manufactured with a glass transition temperature around 37oC will form a
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scaffold at body temperature to provide support for the surrounding tissues. A
blend of 93.5% PLGA (w/w) with 6.5% (w/w) PEG400 is ideal for such applications
(Dhillon, 2011) and a schematic of the manufacturing process is shown in
Figure 3.2. Briefly, PLGA (85 15, 56 KDa) was weighed (9.35 g) onto a PTFE
sheet and 0.65 g of PEG400 was added directly. The sheet was transferred to
a hotplate set at 120oC to allow the polymers to melt and the PEG400 was
mixed in thoroughly using a PTFE spatula. The polymer sheet was allowed to
cool, cut into small pieces and milled using a Krups 75 mill. The required size
fraction (usually 100-200 micron) was collected by sieving through woven
mesh sieves. Once collected, the MPs were stored vacuum packed and frozen
until required
To directly melt blend lysozyme into the PLGA/PEG MPs, lysozyme was
ground using a pestle and mortar to try to reduce its particle size. The
PLGA/PEG MPs (4.95 g) were mixed with the ground lysozyme (50 mg) on a
PTFE sheet to give a 1% (w/w) total loading of lysozyme. The mix was
transferred to a hotplate set at 70oC and the blend was allowed to melt before
being thoroughly mixed with a PTFE spatula. MPs were manufactured by
milling as described above.
To form scaffolds, PLGA/PEG/lysozyme particles (100 mg) were weighed and
transferred to the barrel of a 1 ml syringe. The bore end of the syringe had
been cut off and the plunger used to gently compress the particles against a
gloved thumb. Syringes containing particles were prepared in triplicate. The
syringes containing scaffolds were placed vertically into a 50 ml tube that
contained dampened blue roll to keep the atmosphere moist. The scaffolds
were sintered for 2 hours at 37oC then, removed from the syringe barrels and
dried overnight in a freeze drier.
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3.2.4 Determination of glass transition temperature by rheology
Rheology is the study of deformation and flow of materials and can be used to
determine the glass transition temperature of polymers. A Physica MCR 301
rheometer fitted with 25 mm parallel plate geometry and an environmental
hood was used to determine the rheological properties of PLGA MPs and
PLGA MPs formulated with PLGA-PEG-PLGA triblock copolymer. Oscillatory
measurements at a constant gap distance (0.5 mm) and a controlled strain
(0.1%) were conducted under nitrogen gas flow to determine the change in the
material with temperature as the dependant variable.
Each sample of MPs manufactured from PLGA 50 50 and PLGA 85 15 having
either 0,10 or 30% (w/w) PLGA-PEG-PLGA triblock copolymer loading were in
turn loaded onto the rheometers Peltier plate and the environmental hood was
lowered. Data was collected every 30 seconds with constant strain amplitude
of 0.1% and a frequency of 1 Hz applied over a temperature ramp of 20oC to
70oC. Graphs of phase angle (į), storage modulus (G) and loss modulus (G)
were plotted against temperature and the point at which the storage and loss
modulus intercepted was deemed to be the glass transition temperature of the
material.
3.2.5 Degradation of PLGA ± triblock copolymer through mass loss
In order to assess the effect of PLGA-PEG-PLGA triblock copolymer on the
degradation rate of PLGA, mass loss was measured over time following the
method previously described in Section 2.2.7.2. The MPs were prepared with
0%, 10% and 30% (w/w) and a defined mass (20 mg) of the MPs was incubated
at either 37oC or 45oC (for accelerated degradation) in PBS. At defined time-
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points, the MPs were dried and re-weighed before being re-suspended back in
PBS. Traces of MP mass against time were prepared.
3.2.6 Protein release studies
3.2.6.1 Release of HSA/lysozyme from PLGA MPs
Release studies were set up by weighing a known mass of blank MPs and
protein loaded MPs (e.g. 25 mg, 50 mg or 100 mg depending on the MP size)
into labelled tubes (either 15 ml or 1.6 ml centrifuge tubes) in triplicate for each
batch. Phosphate buffered saline (PBS) was then added (e.g. 1 ml, 1.5 ml or 3
ml) and the lids were secured. The tubes were then gently rocked on a 3-D
shaker at 5 rpm in a humidified incubator set at 37oC.
At defined time-points, the tubes were removed from the rocker. For MPs >50
µm, the tubes were placed upright and left for at least 30 minutes for the MPs
to settle at the bottom of the tube. For smaller MPs, the tubes were
centrifuged at 3000 rpm (MSE, Mistral 1000) for 3 minutes to sediment the
MPs. The supernatants were collected using either a plastic Pasteur pipette or
Gilson pipette and were stored frozen until required. Fresh PBS to the same
volume was returned to the tubes which were re-sealed and re-incubated on
the rocker until the next collection time-point. The frozen supernatant samples
could be tested in the BCA assay for total protein (Section 2.2.8.1) using PBS
as the diluent.
At the end of the study, after the last collection point, the tubes were dried on
a freeze drier and any remaining particles/protein were dissolved out in
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DMSO/SDS/NaOH solution and a BCA protein assay performed (Section
2.2.8.1 ). The cumulative protein released was calculated as a percentage of
the total protein measured (cumulative total released plus total remaining in
tubes) for each time-point.
cumulative release of protein cumulative %age
at each time-point (µg) X 100 = released at each
cumulative release + protein in tube time-point
at end of study (µg) at end of study (µg)
A schematic of the main two studies set up is shown in Figure 3.3
3.2.6.2 Release of lysozyme from PLGA/PEG scaffolds
The PLGA/PEG/lysozyme scaffolds manufactured in Section 3.2.3 were
placed in the wells of a 24 well plate and 2 ml of PBS added to each. As a
control three PLGA/PEG particulate scaffolds without lysozyme were also
placed in the plate which was placed on a 3D rocker set at 5 rpm. At specified
time-points, the PBS was collected from each well and replaced with fresh.
The collected sample was tested for total protein (BCA) and lysozyme activity
(M. lysodekticus) and cumulative release curves were constructed.
The scaffolds were imaged under SEM and a sample of the
PLGA/PEG/lysozyme MPs were tested to determine their entrapment
efficiency.
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3.2.7 Detection of lysozyme activity: Micrococcus lysodekticus
The Micrococcus lysodekticus assay was used to measure lysozyme activity
in the supernatants as described in Section 2.2.9.
3.2.8 Statistical analysis
Where error bars are presented on figures, they were calculated from the
standard deviation of the mean with a minimum replicate number of three. For
cumulative release profiles, cumulative error bars were calculated by squaring
the standard deviation at each time-point, adding the values cumulatively then
calculating the square root of the cumulative value for standard deviation at
each time point.
Values for protein concentration or protein activity were calculated from either
the polynomial equation or the straight line equation of the appropriate
standard curve as stated.
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3.3 Results and Discussion
3.3.1 Characterisation of PLGA-PEG-PLGA triblock copolymer
The studies performed to demonstrate release profiles from biodegradable
MPs throughout this project necessitated the use of three different PLGA-
PEG-PLGA triblock copolymer batches (TBII-B, TBII-C and TBII-F).
Unfortunately, the nature of the manufacturing technique rendered it difficult to
produce polymers with exactly the same parameters. Molecular weight and
molecular weight distribution of the copolymers was evaluated for each batch
using gel permeation chromatography (GPC) and H1NMR analysis was also
performed to characterise the material. The results of these analyses are
shown in Appendix IV and acknowledgement goes to Natasha Birkin, School
of Chemistry, University of Nottingham for performing the characterisation.
The quantitative data obtained from the analysis of the copolymers is
summarized in Table 3.1.
Despite the polydispersity indices being similar, the overall molecular weights
varied from just under 4000 to just over 5000 Da. This discrepancy in
molecular weights could influence the effect that the triblock copolymer would
exert on protein release from MPs. Hence, it was important that the same
triblock copolymer batch was used in comparative studies to ensure the effect
seen is not due to different triblock batches. The three triblock copolymer
batches were manufactured at different stages during the three year proect
and thus a direct comparative study was not performed. However, there was
evidence that MPs made incorporating the lower molecular weight triblock
copolymer released their cargo quicker than those manufactured with the
higher molecular weight triblock copolymer. Preferred storage conditions
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(frozen and vacuum packed) would help avoid degradation and the batches
were dispensed into aliquots to avoid repeated freeze thaw cycles.
Table 3.1 Table of PLGA-PEG-PLGA triblock copolymer parameters
Triblock copolymer
batch
Molecular Weight
(Da)
Poly Dispersity Index
PLGA-PEG-PEG TBII-B 5202 1.56
PLGA-PEG-PEG TBII-C 4590 1.60
PLGA-PEG-PEG TBII-F 3960 1.53
3.3.2 The effect of PLGA-PEG-PLGA triblock copolymer on the
viscoelastic properties of PLGA.
The viscoelastic property of a polymer can be determined by dynamic
mechanical thermal analysis and is measured by applying a sinusoidal force
(stress) and determining the resulting displacement (strain). Rheology is the
study of deformation and flow of a material. If the material was perfectly elastic,
the stress and strain would be in perfect phase. If it was purely viscous there
would be a 90 degree phase lag. A viscoelastic material will result in phase lag
in between 0 and 90 degrees which can be determined by a rheometer and is
represented by the following equations.
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Stress: ı = ı0VLQWȦį
Strain: İ = İ0VLQWȦ
Where
ȦLVWKHIUHTXHQF\RIVWUDLQRVFLOODWLRQ
t is the time
į is the lag phase between stress and strain
The shear storage or elastic modulus (G) represents the deformation energy
stored and the shear loss or viscous modulus (G) represents the deformation
energy dissipated as heat.
Storage modulus: G = ı0 cosį
İ0
Loss modulus: G = ı0 sinį
İ0
Phase angle (tan delta): tanį = G
G
The rheometer can therefore be used to determine the viscoelastic properties
of PLGA and the effect of adding PLGA-PEG-PLGA triblock copolymer.
The rheology of the PLGA-PEG-PLGA block copolymers with polylactic acid
MPs incorporated in the copolymer has been investigated (Hou, 2008) but, to
date there is no published work on rheological analysis of PLGA MPs that
have been formulated with triblock copolymer during the fabrication process.
As a polymer goes through its glass transition, the storage modulus will
decrease significantly and the loss modulus will reach a maximum. Using data
from the rheometer set at a constant strain amplitude of 0.1% and a frequency
of 1 Hz applied over a temperature ramp of 20oC to 70oC, graphs of phase
angle (tanį), storage modulus (G) and loss modulus (G) can be plotted
against temperature (Santovena, 2004). Transition from a glassy state to a
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rubbery state does not occur instantaneously at one temperature, but in order
to define a glass transition temperature or Tg, the point where G equals G
was taken as this is also defined as the gelation point (Weng, 2007). This
value usually relates closely to the peak in phase angle (tan į) which is
another value quoted but this often overestimates the Tg. The glass transition
temperatures reported in the certificate of analysis for the two polymers used
are 49oC for PLA 50 50 (Mwt 56 KDa) and 50.3oC for PLGA 85 15 (Mwt 52
KDa). These values were recorded by differential scanning calorimetry (DSC)
rather than rheological analysis.
The data in Figures 3.4 and 3.5 show the dynamic mechanical thermal
analysis traces for MPs made from PLGA 50 50 and PLGA 85 15 both alone
and with the incorporation of 10% (w/w) and 30% (w/w) PLGA-PEG-PLGA triblock
copolymer. The addition of PLGA-PEG-PLGA triblock copolymer had a direct
and dose responsive effect on the Tg of both PLGA polymers. Regarding the
PLGA 50 50, the polymer with no PLGA-PEG-PLGA had a glass transition
temperature of 45.7oC which was reduced down to 33.6oC on the addition of
30% (w/w) PLGA-PEG-PLGA. The 10% (w/w) loading gave an intermediate Tg
(Figure 3.4). The same analysis was performed on PLGA 85 15 fabricated
with 10% and 30% (w/w)PLGA-PEG-PLGA triblock copolymer and this data is
shown in Figure 3.5. Again the copolymer affected the glass transition
temperature but the values were higher. The starting Tg was 57.8 oC reducing
down to 52.7oC (10% (w/w)) followed by 45.6
oC (30% (w/w)).
The reason for this is that the PLGA-PEG-PLGA is acting as a plasticiser on
the higher molecular weight PLGA. It interweaves between the tightly packed
entangled polymer chains taking up space and acts like a lubricant enabling
the chains to move more readily making the PLGA become more flexible. It
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has been reported that the glass transition temperature of PLGA decreases
with a decrease in lactide content and these results uphold these findings
(Passerini, 2001).
The potential advantage of this for protein release is that as shown in the
previous Chapter (Figure 2.12), polymer degradation occurs quicker as
temperature increases. Increased degradation will result in faster protein
release. If the polymeric matrix of the MP can be altered to have a lower Tg,
then it should be possible to achieve faster degradation and therefore faster
protein release at lower temperature such as body temperature.
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Figure 3.4: Rheological traces of [A] PLGA 50 50 Mwt 56 KDa and MPs
formulated with [B] 10% and [C] 30% w/w PLGA-PEG-PLGA triblock
copolymer. Storage modulus (blue), loss modulus (red) and phase angle
(green). [D] Glass transition temperature of the polymers. Copolymer batch
TBII-C was used
Batches: BN 231, 235 and PLGA 50 50
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Figure 3.5 Rheological traces of PLGA 85 15 Mwt 52 KDa formulated with [A]
0%, [B] 10% and [C] 30% w/w PLGA-PEG-PLGA triblock copolymer. Storage
modulus (blue), loss modulus (red) and phase angle (green). [D] Glass
transition temperature of the polymers. Copolymer batch TBII-B was used
Batches: BN 128, 130 and 132
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3.3.3 The effect of PLGA-PEG-PLGA triblock copolymer on the
degradation rate of PLGA.
This project has established that the degradation rate of PLGA MPs is related
to temperature with a higher temperature causing faster degradation. Also, the
addition of a triblock copolymer lowered the glass transition temperature. It
can therefore be hypothesised that the incorporation of PLGA-PEG-PLGA
triblock copolymer may increase the overall degradation rate and that this will
impact on future studies of protein release. This was tested by manufacturing
PLGA 50 50 MPs with 0, 10, 20 and 30% (w/w) triblock copolymer (TBII-C) and
performing a mass loss study over 50 days at two different temperatures. The
results are shown in Figure 3.6 where data is recorded at 37oC and at 45oC.
Although the addition of triblock copolymer appeared to increase the PLGA
degradation rate, there was not a great deal of difference between the
formulations as due to the nature of the experiment, the error was relatively
high. At 45oC the degradation was much faster in all groups with no obvious
differentiation between the triblock concentrations but the MPs without triblock
degraded the slowest.
It was now feasible that MPs loaded with a model protein could be
manufactured with different degradation rates and therefore display different
release rates. Although the degradation rate is likely to play a key role in
protein release from these MPs, the increased hydrophilic nature of these MPs
is also expected to play a positive role in accelerating the release above the
degradation rate. In which case the PLGA MPs would still be able to provide
structure after the protein had been released.
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Figure 3.6: Mass loss of PLGA50 50 Mwt 56 KDa through degradation at [A]
37 oC and [B] 45 oC. Mcroparticles formulated with 0% (purple), 10% (blue),
20% (green) and 30% (orange) (w/w) PLGA-PEG-PLGA triblock copolymer and
incubated in PBS. The MPs were dried before weighing at each time-point.
Copolymer batch TBII-C was used
Batches: BN 172, 230, 232, and 234
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3.3.4 HSA/Lysozyme release from PLGA MPs
3.3.4.1 Effect of PLGA-PEG-PLGA triblock copolymer content on protein
release from MPs fabricated with PLGA 50 50 and PLGA 85 15
A release study was set up to determine both the effect of PLGA-PEG-PLGA
triblock copolymer and the lactide: glycolide ratio on the release of
HSA/lysozyme from PLGA MPs. The schematic depicting the organisation of
the study is shown in Figure 3.3A. All MPs were fabricated following the
standard protocol described in the previous Chapter using 20% (w/v) PLGA with
a 1% (w/w) loading of HSA/lysozyme (9 mg and 1 mg) with a primary
homogenisation speed of 4,000 rpm and a secondary homogenisation speed
of 2,000 rpm.
All batches of MPs were imaged by scanning electron microscopy and were
sized by laser diffraction. Figure 3.7 shows the morphology of these MPs.
Some of the MPs had surface pores but this phenomemon did not relate to
either the copolymer concentration or the lactide: glycolide ratio. Indeed, the
most porous MPs were evident in the batches that contained no triblock
copolymer (e.g PLGA 85 15 0% (w/w) triblock copolymer). However, not all MPs
exhibited pores and generally, the outer surface of the MPs was smooth.
These surface pores may relate to pockets of entrapped protein that were very
close to the MP surface which were lost during the solvent evaporation
process resulting in a small pore. The creation of these pores is therefore a
side effect of the emulsion process and may not be easily controlled but will be
monitored for trends in the data. Conceivably, the burst release from MPs with
surface pores may be reduced due to surface protein already being lost during
the manufacturing process. However, in practice, using the PLGA 85 15 with
no triblock copolymer as an example, the converse appeared to be true
Chapter 3
121
(Figure 3.10 open circle) with a burst release of just over 30% from this
formulation. No further protein release was detected from this formulation for
the next 30 days indicating that the remaining protein remained entrapped
within the polymer matrix. This formulation was allowed to release up to 70
days and a second phase of release occurred after 47 days (data not shown).
The unusually large burst release from this formulation remained an anomaly
as the formulation was not repeated in future studies due to its clinically
irrelevant release profile.
This issue of burst release has been investigated by many groups with
different strategies being adopted in an attempt to control it. Studies have
investigated altering MP manufacture procedures to modify internal
morphology (Igartua, 1997, Fu, 2003, Mao, 2007), altering the protein
molecular weight and/or loading (Sandor, 2001), modifying protein with
additives or using a bulk carrier to improve stability (Kang, 2001, Diwan, 2001)
or modifying the PLGA with the addition of a hydrophilic component (Cleek,
1997, Yeo, 2004b). However, for some applications a high initial dose is not
always a disadvantage as long as the level of the burst is reproducible.
A relatively straightforward answer to the issue of burst release may be to
subject the MPs to a washing step to remove any surface bound material prior
to the start of a release assay. A short study to monitor the burst over 24
hours for small PLGA 50 50 MPs in the 10-20 µm range indicated that 80% of
the total burst occurred in the first hour, a further 7% in the next 2 hours
followed by a further 6% in the next 4 hours leaving only 7% being released
between 7 and 24 hours. A short wash may therefore be useful in controlling
the burst, but it was decided not to incorporate it into the current protocol.
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Figure 3.7: Effect on morphology of the incorporation of PLGA-PEG-PLGA
triblock copolymer into PLGA microspheres. PLGA 50 50 [A, C and E] was
compared with PLGA 85 15 [B, D and F]. PLGA-PEG-PLGA was incorporated
into the PLGA at 0% [A and B], 10% [C and D) or 30% (w/w) [E and F] of the
total mass. All microspheres were loaded with 1% HSA/lysozyme. Copolymer
batch TBII-B was used.
Batches: BN 129,131,133, 138, 139 and 142
A
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B
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Another consideration was the effect of PLGA-PEG-PLGA triblock copolymer
on the size and entrapment efficiency of the MPs. The addition of copolymer
did slightly reduce the average MP size and this data is shown in Table 3.2.
The average MP size for PLGA 85 15 was approximately 20% greater than
that of the PLGA 50 50 MPs without copolymer and both reduced in size with
the addition of copolymer. The smallest MPs were 64.57 ± 15.87 µm (PLGA
50 50 30% (w/w) triblock) and the largest were 95.20 ± 31.90 µm (PLGA 85 15 0%
(w/w) triblock).
Potentially, the size differences were caused by a combination of factors.
Firstly, the increased content of the triblock copolymer resulted in a reduction
in the overall content of PLGA and it was shown in Chapter 2 that total PLGA
concentration plays a pivotal role in MP size. Secondly, the addition of a
hydrophyllic component would alter the dynamics of emulsion formation
resulting in smaller MPs and thirdly the difference between the size of the
PLGA 50 50 and PLGA 85 15 could have been because they have slightly
different molecular weights and inherent viscosities. Although the average MP
size shows up the differences in the batches, the normal distribution is
generally 30 % of the mean and so all of the size profiles overlap considerably
(data not shown). The reduction in size due to the addition of triblock
copolymer may lead to faster protein release due to the release assays being
set up based on MP mass (Dawes, 2009). A higher number of small MPs
would be present in a comparable mass of larger MPs resulting in larger
surface area from which the protein could be released.
The entrapment efficiency results are shown in Table 3.3. The lowest values
are shown in formulations without added triblock copolymer which may be
tenuously linked in with the morphology as these tended to have the most
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surface pores. However, all of the entrapment efficiency values were within
the range 64.6 and 94.1% which was acceptable for the release studies.
Table 3.2 Average size distribution of PLGA MPs formulated with PLGA-
PEG-PLGA triblock copolymer (TBII-B)
PLGA 50 50 Mwt 59
kDa
PLGA 85 15 Mwt56
kDa
0% (w/w)
PLGA-PEG-PLGA
77.51 ± 26.19 µm 95.20 ± 31.90 µm
10% (w/w)
PLGA-PEG-PLGA
70.75 ± 20.46 µm 94.01 ± 27.60 µm
30% (w/w)
PLGA-PEG-PLGA
64.57 ± 15.87 µm 87.71 ± 24.43 µm
Table 3.3 Entrapment efficiency of PLGA MPs formulated with PLGA-
PEG-PLGA triblock copolymer (TBII-B)
PLGA 50 50 Mwt 59
kDa
PLGA 85 15 Mwt56
kDa
0% (w/w)
PLGA-PEG-PLGA
64.6 % 73.7 %
10% (w/w)
PLGA-PEG-PLGA
71.8 % 95.1 %
30% (w/w)
PLGA-PEG-PLGA
74.9 % 81.7 %
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The MPs characterised in this Section were set up in a dynamic release study
(gently rocking) with regular sampling points. The collected supernatants were
tested for total protein using the bicinchoninic acid (BCA) assay. The
cumulative release from the PLGA 50 50 MPs are shown in Figure 3.8 where
there is a clear differentiation of the release profiles. All of the protein was
released from the 30% (w/w) triblock copolymer batch within 3 days. It could not
be related directly to degradation because the release was so quick. Data in
Figure 3.6 showed that this formulation lost approximately 50% of its mass
after 20 days. Instead, it was thought that the presence of such a high
hydrophilic content in the MPs caused swelling, opened up any pores and
produced a hydrogel-like structure so facilitating protein release
(Ghahremankhani, 2007). However, once all the protein had released, the
MPs were still intact which could provide a scaffold for tissue support.
The MPs containing 10% (w/w) triblock demonstrated a much more sustained
release over the 30 day period with approximately 30-40% of the protein still
available in the MPs for release. This sustained release of protein over one
month was very encouraging as it overcame the triphasic release (seen in
Figure 3.8) from MPs with no triblock copolymer added where a lag phase of
little or no release was evident between days 2 and 11. This release from the
10% (w/w) triblock MPs appeared to be more related to polymer degradation as
this lower percentage of triblock would cause a slower rate of water ingress
which would still affect the hydrolytic degradation of the MPs but at a slower
rate allowing the protein to release gradually throughout what would otherwise
be the lag phase.
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Figure 3.8: Cumulative release of HSA/lysozyme (1% loading) from PLGA 50
50 Mwt 59 KDa MPs (50-100 µm) formulated with 30% ( ), 10% ( ) or 0% ( )
w/w PLGA-PEG-PLGA triblock copolymer (TBII-B)
Batches: BN 123, 125 and 127
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Figure 3.8 showed the effect of incorporated PLGA-PEG-PLGA triblock
copolymer on the protein release profile from PLGA 50 50 MPs. Figure 3.9
shows the effect of lactide:glycolide ratio on release in conjunction with triblock
copolymer. Figure 3.9A shows the comparative release profiles of 30 % (w/w)
triblock copolymer incorporated into PLGA 50 50 and PLGA 85 15, whilst
Figure 3.9B shows the 10% (w/w) triblock comparison. In both cases the PLGA
50 50 MPs release faster than their PLGA 85 15 counterparts. PLGA 85 15
has a much slower degradation rate (months rather than weeks) due to its
higher lactide content. The presence of methyl side groups in lactic acid
makes it more hydrophobic than the glycolic acid and hence lactic acid rich
PLGA copolymers are less hydrophilic, absorb less water and subsequently
degrade more slowly which explains why the release is slower than that from
PLGA 50 50 (Makadia, 2011). However, the addition of 30 % (w/w) triblock
copolymer resulted in a practically zero order release for the first week of the
study which meant that the release was again decoupled from the polymer
degradation rate.
The addition of 10% (w/w) triblock copolymer to PLGA 85 15 resulted in a
delayed release profile (Figure 3.9B). There was very little burst release
(possibly due to this batch of MPs having the most surface pores) and no
release until after two weeks. Normally, this polymer would not start to
degrade in-vitro until after 6 weeks on test (data not shown) and so the
triblock was therefore still having an effect on the release rate.
All these combinations of triblock copolymer concentration and
lactide:glycolide ratios has produced an interesting set of distinct release
profiles which are shown together in Figure 3.10 with the error bars removed
for clarity (White, 2013).
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Figure 3.9: [A] Comparison of cumulative protein release from PLGA 50 50
Mwt 59 KDa ( ) and PLGA 85 15 Mwt 56 KDa ( ) MPs (50-100 µm) loaded
with 1% HSA/lysozyme and formulated with 30% (w/w) PLGA/PEG/PLGA
triblock copolymer. [B] Comparison of cumulative protein release from PLGA
50 50 Mwt 59 KDa ( ) and PLGA 85 15 Mwt 56 KDa ( ) loaded with 1%
HSA/lysozyme and formulated with 10% (w/w) PLGA/PEG/PLGA triblock
copolymer (TBII-B)
Batches: BN 125, 131, 127, 133.
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Figure 3.10 Summary of release profiles achieved in study 1 showing the
effect of PLGA-PEG-PLGA concentration and Lactide:glycolide ratio. Closed
symbols represent PLGA 50 50 and open symbols represent PLGA 85 15 with
square being 30%, triangle being 10% and circle being 0% (w/w) PLGA-PEG-
PLGA triblock copolymer (TBII-B)
Batches: BN 123, 125, 127, 131 and 133
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These release profiles give a very good insight into how the incorporation of
a hydrophilic copolymer will affect the protein release from PLGA MPs.
However, the issue of incomplete release by the end of the 30 day period
has not yet been addressed. For PLGA 85 15 MPs this is likely to be due to
their longer degradation time and as shown in Figure 3.10 for each
formulation the total percentage released is lower in the PLGA 85 15
formulations. However, it cannot be ignored that the PLGA 50 50
formulations with little or no modification with PLGA-PEG-PLGA triblock
copolymer have also not released all of their cargo. Figure 4.6 showed that
for these formulations nearly 75% of the total mass would have been lost
and this was indeed observed in the release vessels.
The issue of incomplete release maybe due to a number of factors such as
the properties of the release medium, the sampling method or the adsorption
of the released protein either back on the PLGA matrix or the inside of the
release vessel, protein aggregation or protein denaturation (Giteau, 2008,
Tran, 2012). Different strategies have been applied to further understand and
improve release profiles. The use of continuous flow systems (Aubert-
Pouessel, 2002) negates the build up of degradation products and is more
likely to replicate the in-vivo environment. However, previous experience
showed that this method had its own problems in maintaining flow rates and
subsequently led to highly variable results. Static and dynamic systems have
been compared with dynamic systems such gentle rocking, stirring or shaking
increasing the release rate but not altering the release profile (Hernandez,
1998). The effect of release medium will also influence the release rate adding
a surfactant has been shown to increase the protein rate (Paillard-Giteau,
2010) and it is reported that lowering the pH by for example using glycine
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buffer at pH 2.5 will improve lysozyme stability and avoid aggregation (Giteau,
2008). Clearly, however, this would not be a physiologically relevant model.
It is important that any system used to investigate drug release is repeated in
exactly the same way for subsequent tests for the data to be comparable. A
small, seemingly insignificant alteration of the protocol (for example, a small
change in the volume of release medium or an alteration in the rocking speed)
will undoubtedly change the dynamics of the process and potentially lead to a
different release profiles being obtained. Although the in-vitro release profiles
cannot be guaranteed to be a fully accurate prediction of what will happen in-
vivo, they are a good starting point, especially if they are robustly performed. It
was therefore important for this project that the release profiles had low inter
and intra batch variability which is the subject of the next Section.
3.3.4.2 Reproducibility of release profiles
A further release study was initiated to further investigate the effect of PLGA-
PEG-PLGA triblock copolymer on the release profiles of HSA/lysozyme from
PLGA MPs. The schematic depicting the organisation of this study is shown in
Figure 3.3B. In this case a 20 % (w/w) loading of triblock copolymer within PLGA
50 50 was investigated along with a 1:1 combination of MPs with both a 10%
(w/w) and a 30% (w/w) loading to determine whether an intermediate trace
between the 10 and 30% profiles seen in figure 3.9 could be achieved. The
first study recorded the release of triplicate samples from one batch of MPs.
The second study was used as an opportunity to investigate the reproducibility
of the profiles both within batches and across batches. Therefore for each
formulation three separate batches of MPs were made and tested in triplicate.
Chapter 3
132
The MP sizes were comparable to those achieved in the first study with the
mean MPs sizes ranging from 54 µm to 90 µm depending on the copolymer
concentration. The entrapment efficiencies ranged from 63% to 90% across
the batches which also compared well to the first study. The results are shown
in Figure 3.11 where the separate batches are highlighted by different colours.
It was encouraging to see that the release profiles were similar both within
batch triplicates and between batch triplicates. This gave confidence in the
developed protocols and the effect of the PLGA-PEG-PLGA triblock
copolymer on release.
To investigate the reproducibility of the profiles further, these results were
compared retrospectively to the profiles (for the appropriate formulations)
achieved in the first release study and these are shown in Figure 3.12. In
general, the profiles matched up well especially for the highest concentration
of PLGA-PEG-PLGA triblock copolymer (30 % (w/w)) within PLGA 50 50. The
other formulations, 30 % (w/w) in PLGA 85 15 and 10 % (w/w) in PLGA 50 50 as
well as PLGA 50 50 alone showed slightly more variation between the studies
with the release from the second study being consistently lower. Although
these studies were performed using the same batch of PLGA-PEG-PLGA
triblock copolymer (TBII-B), they were nearly three months apart and it may be
that storage may have degraded the triblock slightly. Nevertheless, the
protocols to manufacture protein loaded MPs and tailor the rate of model
protein release from them were very reproducible both within batches,
between batches (Figure 3.11) and moderately reproducible over time (Figure
3.12). Such robust testing of release profiles has not been cited in the
literature.
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Figure 3.11: Reproducibility of cumulative release profiles. [A] Release from
PLGA 50 50 Mwt 59 KDa MPs (50-100 µm) formulated with 10% (w/w) PLGA-
PEG-PLGA triblock copolymer (n=9). [B] Release from PLGA 50 50 Mwt 59
KDa MPs (50-100 µm) formulated with 20% (w/w) PLGA-PEG-PLGA triblock
copolymer (n=8). [C] Release from PLGA 50 50 Mwt 59 KDa MPs (50-100 µm)
formulated with 30% (w/w) PLGA-PEG-PLGA triblock copolymer (n=7). [D]
Release from PLGA 85 15 Mwt 56 KDa MPs (50-100 µm) formulated with 30%
(w/w) PLGA-PEG-PLGA triblock copolymer (n=9).Copolymer batch TBII-B was
used. Separate colours highlight triplicate traces of separate batches.
Batches: BN 135, 136, 138, 140 142, 143, 145, 147, 149, 150, 152 and 154.
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Figure 3.12 Comparison of total protein release from study 1 (closed symbols)
and study 2 (open symbols) [A] PLGA 50 50 Mwt 59 KDa MPs (50-100 µm)
with 0% (w/w) PLGA-PEG-PLGA triblock copolymer . [B] PLGA 50 50 Mwt 59
KDa MPs (50-100 µm) with 10% (w/w) PLGA-PEG-PLGA triblock copolymer [C]
PLGA 50 50 Mwt 59 KDa MPs (50-100 µm) with 30% (w/w) PLGA-PEG-PLGA
triblock copolymer [D] PLGA 85 15 Mwt 56 KDa MPs (50-100 µm) 30% (w/w)
PLGA-PEG-PLGA triblock copolymer. Copolymer batch TBII-B as used in both
studies.
Batches: BN 123, 125, 127, 133, 139, 146, 153, 138, 145, 152, 135, 142, 149,
140, 147 and 154
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Data in Figure 3.13 again shows the release profiles from the PLGA 50 50
MPs containing 30 % and 10 % (w/w) triblock copolymer shown in Figure 3.11
but in addition, the individual release profiles are also shown for a combination
of both MP types mixed together at a 1:1 ratio before the start of the release
assay. This result showed, as hypothesised, the release profile for the
combination batch was in between the two other release profiles. So, the
overall total protein release was dependent on some slow and some fast
releasing MPs. The burst over the first 3 days was high (caused by the 30 %
(w/w) triblock MPs) and then release was slow (caused by the 10 % (w/w) triblock
MPs). The variation between the individual traces of the combination group
was greater than the variation of the other two groups but this was not
surprising due to their being two different MP types present.
This data gave real encouragement that a cocktail of different MPs could be
delivered containing different growth factors and would release their cargo at
different rates within an overall sustained release profile. The great advantage
of this would be that for example, angiogenic growth factors could be delivered
quickly to develop vasculature followed by a slow more sustained release of
osteogenic or chondrogenic factors to regenerate bone (Jeon, 2008, Strobel,
2011). Other researchers have tried different methods to achieve temporal
control over release rate from biomaterials. Systems based on controlling
gelatin cross-linking in multi-layered devices have been successful in
delivering bone morphogenetic protein -2 (BMP-2) and insulin like growth
factor-1 (IGF-1) to cells to affect their differentiation (Raiche, 2004) and more
recently, PLGA microsphere scaffolds have been used to deliver IGF-1 and
transforming growth factor ȕ (TGF-ȕ) sequentially by suppressing the burst
release in some MP batches and not in others followed by fusing the MPs
together with DCM vapour (Janklene 2008).
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The advantage of the system presented in this project is the injectable nature
of the MPs. Their potential, without any copolymer modification but co-
delivered with cells (from umbilical cord blood), was shown to promote
neovascularisation in ischemic peripheral artery disease when combinations of
vascular endothelial growth factor, hepatocyte growth factor and Angiopoietin-
1 were delivered (Saif, 2010). It would therefore be hoped that having the
ability to tailor the release rate using the PLGA-PEG-PLGA copolymer and
potentially deliver growth factors at different rates along with cell delivery
would improve tissue regeneration when applied to in-vivo studies.
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Figure 3.13: Individual cumulative protein release profiles from PLGA 50 50
Mwt 59 KDa MPs formulated with either 10 % (w/w) PLGA-PEG-PLGA (green)
or 30 % (w/w) PLGA-PEG-PLGA (purple). In addition a release profiles were
obtained by mixing the above two MP types in a 1:1 ratio (orange) Copolymer
batch TBII-B was used
Batches: BN 135, 138, 142, 145, 149, 152, 160, 161 and 162
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3.3.4.3 The influence of MP size on protein release profile.
All the data shown in this Chapter thus far has involved the use of 50-100 µm
MPs. Smaller MPs can be made as demonstrated in Chapter 2 and may be
more applicable to certain applications where for example, injection is required
through a fine bore needle. Therefore, smaller MPs manufactured with a
comparable HSA/lysozyme loading were compared against the 50-100 µm
MPs to determine the effect on release. It was hypothesised that smaller MPs
would release faster due to the increased surface to volume ratio and the
result was very clear that this was apparent (Figure 3.14). This gives the
potential for a further method to control release and achieve multiple growth
factor delivery as rather than using a high triblock copolymer concentration,
small MPs could be manufactured instead.
However, this may not be the best option, as there are drawbacks. The
smallest MPs have lower entrapment efficiencies (Chapter 2) meaning much
of the active molecule will be lost during their manufacture. Also, the overall
porosity of a scaffold is an important parameter in promoting cell growth and
differentiation, small MPs may take up free space between larger MPs and
reduce the porosity. However, the 2 µm MP size range has been identified as
the optimal size for some in-vivo applications (Sandor, 2002) and many
groups use PLGA nanoparticles but generally not for orthopaedic applications
(Budhian, 2008, Muthu, 2009)
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Figure 3.14: Cumulative protein release from different sizes of PLGA 50 50
Mwt 59 KDa MPs loaded with 1% (w/w) HSA/lysozyme with no PLGA-PEG-
PLGA triblock modification. MPs shown are 151.3 ± 60.7µm ( ), 13.84 ±
7.48µm ( ) and 2.58 ± 0.81 µm ( ) n=3
Batches: BN 123, 171 and 175
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3.3.5 Lysozyme release from thermosensitive PLGA/PEG scaffolds
This Chapter has discussed in detail the controlled release of model protein
with bulk carrier (HSA/lysozyme) from MPs manufactured from PLGA. These
MPs have the advantage of being injectable but, will not spontaneously form a
supportive structure and therefore as a side project, direct incorporation of
lysozyme (without HSA) into thermosensitive PLGA/PEG MPs was
investigated. PLGA 85 15 plasticised with low molecular weight PEG (400 Da)
were milled into rough irregular shaped MPs. These MPs were mixed with
lysozyme and melted at temperatures that were not destructive to the protein
then re-milled to produce lysozyme containing thermosensitive MPs that could
be used make a three dimensional porous scaffold.
Scaffolds fabricated in this way were used in a release study and the profile of
release is shown in Figure 3.15. The release had a significant burst followed
by slow release, but it was still detectable at 60 days and only 50% of the total
loading had been released. Therefore, there was still a considerable amount
of lysozyme retained within the scaffold structure available for release. Figure
3.15 also shows a representative macro image and the actual SEM image of
the scaffold structure prior to the release assay (Figure 3.15 B and C) where
the individual MPs and the pores between them can be clearly seen. By the
end of the study, the scaffold was still intact and the outer surface of the
scaffold had developed a skin probably due to the constant contact with the
release media (Figure 3.15 D) causing degradation at the surface and it was
evident that the MPs had melted into each other. This may not be the case in-
vivo as the scaffold is likely to interdigitate with the host bone (Rahman,
2012a). The interior structure of the scaffolds remained very porous, although
individual MPs could no longer be seen. The intact scaffolds had considerable
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compressive strength, when manually compressed. However, the strength
was not quantified using a texture analyser.
For long term delivery of growth factors with structural support, this method
may have an application especially as no bulk carrier protein was needed,
entrapment efficiency was high (85%) and as will be discussed later, the
lysozyme remained active. These thermosensitive MPs could be used in-
conjunction with the growth factor loaded spherical MPs to gain the benefits of
both systems namely, controlled release and structural support in an injectable
format.
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Figure 3.15 [A] Total protein release of lysozyme from thermo-sensitive
PLGA/PEG scaffold. [B] A typical PLGA/PEG scaffold [C] SEM showing
surface of PLGA/PEG scaffold prior to start of study [D] SEM showing surface
of PLGA/PEG scaffold after 56 days in PBS [E] SEM showing the interior of a
PLGA/PEG scaffold after 56 days in PBS.
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3.3.6 Detection of lysozyme activity in release supernatants
The key to a successful delivery system is whether the bioactive molecule
retains its activity throughout the MP manufacture and release procedures.
The advantage of using lysozyme was that its activity can be monitored by its
ability to lyse the bacterium Micrococcus lysodeikticus.
The release profiles shown in this Chapter have been constructed by
measurements of total protein and as the lysozyme content was always 10%
of the total with HSA being the remainder, the expected activity could be
predicted by simply dividing the total protein by a factor of ten. The predicted
level of activity was then compared to the actual measured lysozyme activity.
The data at each collection time-point of predicted versus actual lysozyme
activity for the MPs used in release study 1 (Figure 3.3A) are shown in Figure
3.16. Only up to day 13 is shown as beyond this the build up of degradation
products lowered the pH in some samples and compromised the bioassay.
Although activity was detected in most of the release supernatants, the
correlation was not always consistent with the anticipated values and was
often higher than expected.
Both the total protein assay and the activity assay have their own levels of
inherent error and may not be directly comparable. On the other hand, the
assumption that the lysozyme and the HSA release from the MPs at the same
rate may not be true. The smaller lysozyme molecules may release faster from
the polymeric matrix than the larger HSA molecules (Sandor, 2001, Zilberman,
2008). However, the positive activity results were indicative that lysozyme was
not being denatured during the manufacture and release process regardless
of the quantified value.
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The lysozyme released from the thermosensitive scaffolds shown in Figure
3.15 was also tested for activity and the results are shown in Figure 3.17. Here,
the correlation between the predicted and actual lysozyme activity was much
stronger and despite release after the initial burst being low, it was detectable
in both the assay systems. Lysozyme could be detected in this system up to
day 28 because the degradation rate of PLGA 85 15 is slower than that of
PLGA 50 50. The improved correlation may be due to the absence of a carrier
protein which was not required in the melt blend encapsulation process as
neither organic solvent nor water/oil interfaces were required in the protocol.
However, later results will argue that the presence of the carrier protein does
not stearically inhibit BMP-2 activity (Chapter 4). The thermosensitive scaffold
system is an additional tool for the delivery of certain bioactive molecules that
can withstand mild elevation of temperature and it has the advantage of
providing considerable structural support for the newly formed tissue.
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Figure 3.16: Activity of lysozyme released from 50-100 µm MPs formulated
with [A] PLGA 50 50 0% (w/w) PLGA-PEG-PLGA, [C] PLGA 50 50 10% (w/w)
PLGA-PEG-PLGA [E] PLGA 50 50 30% (w/w) PLGA-PEG-PLGA. [B] PLGA 85
15 0% (w/w) PLGA-PEG-PLGA [D] PLGA 85 15 10% (w/w) PLGA-PEG-PLGA and
[F] PLGA 85 15 30% (w/w) PLGA-PEG-PLGA. The black bars are predicted
values and the white bars are actual lysozyme activity by M. lysodeikticus
assay. The copolymer batch was TBII-B
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3.3.7 Lowering total protein loading improves short term release
profiles from sub 30 micron PLGA microparticles
The technology developed in this Chapter has proved to be repeatable and
reliable but transferring the technology to smaller sized MPs may be
problematic due to the very high burst release of around 70% seen from 2.5
µm MPs (Figure 3.14). The total protein loading was reduced, the hypothesis
being that a lower mass of protein may embed more efficiently within the MP
and so be more protected from the release medium and therefore the burst
release may be reduced.
Figure 3.18A shows the release over 5 days from three batches of 1-5 µm
MPs each with a different total protein loading. The 0.5% (w/w) and 1% (w/w)
loadings gave a very high burst (approximately 70-80%) and a similar profile
as seen before (Figure 3.14). However, the 0.1% (w/w) loading did result in only
a 25% burst which was consistent with that achieved with 50-100 µm MPs. It
was reasonable to suggest that reducing the protein content enabled the
PLGA to entrap the protein more effectively. However the entrapment
efficiencies of these MPs were disappointing. The 1% (w/w) loading had a 21.2%
EE only to be improved to 28.0 % for the 0.5% (w/w) loading and 27.8% for the
0.1% (w/w) loading. Therefore the applications for this size of MP may be
considerably limited.
Figure 3.18B shows the release profile over 5 days from 20-30 µm MPs. The
burst was not as high as that from the 1-5 µm MPs with the 1% (w/w) loading
being slightly higher than the 0.5% (w/w) loading. Unfortunately, release from
the 0.1% (w/w) loaded MPs was undetectable and so this was repeated using
100 mg mass into 3 ml PBS. Although not directly comparable, this still
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showed a lower burst of just 10%. The entrapment efficiency values for these
MPs was improved over the 1-5 µm MPs and ranged from 51.4 to 58.5%. All
of the profiles showed little or no release over the next 4 days which was not
unexpected as with no PLGA-PEG-PLGA copolymer modification, a lag phase
would have been expected. To improve the traces and avoid the lag phase,
the addition of PLGA-PEG-PLGA triblock copolymer could be considered for
the 20-30 µm MP size range.
It could therefore be concluded that the smallest size of MP that could
potentially be manipulated to tailor release would be those in the 20-30 µm
size range and future work was planned to use this size range to deliver
recombinant human BMP-2. This work is the subject of the next Chapter.
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Figure 3.18. Cumulative total protein release profiles from [A] 1-5 µm PLGA 50
50 MPs and [B] 20-30 µm PLGA MPs. Three total protein loadings were tested
1% ( ), 0.5% ( ) and 0.1% ( ) n=3
Batches: BN 179, 180, 181, 183, 184 and 185
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3.4 Conclusions
The work in this Chapter has described the development of a new PLGA
based microparticulate delivery system having the capability to reproducibly
control the local release of the model protein lysozyme. The MPs were
spherical and had few or no surface pores. The inclusion of a hydrophilic
PLGA-PEG-PLGA triblock copolymer in the manufacture process altered the
sub-optimal triphasic release kinetics such that they were decoupled from
polymer degradation. The incorporated triblock concentration was directly
related to the rate of protein released from the MPs and this was also
demonstrated to be linked to glass transition temperature and the degradation
rate of the PLGA MPs. The release rate from PLGA 85 15 and PLGA 50 50
could be tailored using the copolymer but the former always demonstrated a
slower rate of release. The release profiles were shown to have both intra and
inter batch reproducibility which would give confidence in using the system for
growth factor release studies.
As well as copolymer concentration and lactide:glycolide ratio of the PLGA,
the size of the manufactured MPs also affected release rate with the smallest
MPs releasing their protein at the fastest rate. However, the entrapment
efficiency was reduced in sub 20 micron MPs but, this could be partially
overcome by reducing the overall protein loading in the MPs. A further study
showed that release profiles could also be modified by mixing PLGA MPs of
two different formulations and this provided another route, not previously
reported, for controlling release kinetics.
Preliminary data showed the feasibility of introducing a porous hardened
scaffold to support of the surrounding tissue and to prevent MP migration
away from the site of delivery. The addition of these MPs would not affect the
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injectability of the system and would harden in-situ to provide a three
dimensional structure for tissue development.
Despite some discrepancies in the data, it was demonstrated that lysozyme
remained active throughout the process of MP manufacture and after release
from the MP into PBS. The correlation between lysozyme activity and
predicted activity was best when the release was from thermosensitive
scaffolds where no bulk carrier protein was used and no solvents were used
in the manufacture process.
Some of the formulations developed within this project are potentially
promising candidates for delivery of growth factors. The 10 % (w/w)PLGA-PEG-
PLGA with 50 50 PLGA that demonstrated sustained release over four weeks
would be most relevant for bone morphogenetic protein -2 (BMP-2) delivery,
whilst the 30% (w/w)PLGA-PEG-PLGA with 85 15 PLGA formulation and the
30% (w/w)PLGA-PEG-PLGA with 50 50 PLGA formulation achieved complete
release after 10 and 4 days respectively and these two formulations would
be more appropriated for angiogenic growth factors such as platelet derived
growth factor (PDGF) and vascular endothelial growth factor (VEGF) when
50-100 µm MPs are used.
The following Chapters will focus on bone morphogenetic protein -2 and its in-
vitro and ex-vivo effects on early osteogenesis. The tailored release technology
will be translated to 20-30 µm MPs to achieve the required release to create a
biological response.
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Chapter 4: Tailored release of biologically active rhBMP-2 from
biodegradable microparticles
4.1 Introduction
Bone morphogenetic proteins (BMPs) are growth factors that are members of
the transforming growth factor-beta (TGF ȕ) superfamily. Based on their
structural features and amino acid sequence, the 35 mammalian members are
subdivided into i) TGF-betas, ii) activins/inhibins, iii) BMPs/growth and
differentiation factors (GDFs) as well as iv) a more distantly related group of
glial derived neurotrophic factor (GDNF) family of ligands. The main
components of the TGF ȕ superfamily and how they are related are shown in
Figure 4.1. The cytokines/growth factors with outstanding importance in
control of wound healing and repair and affect both osteogenesis and
chondrogenesis are TGF ȕ, BMP-2, BMP-4 and BMP-7 and are highlighted
red in Figure 4.1 (Weiskirchen, 2009).
However, BMP-2 is the most widely used growth factor to stimulate
osteogenesis (Boden, 2005). It induces osteoblast differentiation via SMAD
proteins which are intracellular proteins that transduce extracellular signals
from ligand binding at the cell membrane to the nucleus where they activate
gene transcription. A number of transcription factors Runx2/CbfĮ1, Osx, Dlx5
and Msx2 work synergistically to regulate the gene expression of downstream
proteins to induce osteoblasts and therefore they play a prominent role in
skeletal development. See Figure 1.8 (Wu, 2008).
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Figure 4.1 The main signalling molecules in the TGF ȕ super family
(Weiskirchen, 2009)
BMPs have been extensively studied (Reddi, 1998, Lieberman, 2002) and
rhBMP-2 (InfuseTM, Medtronic Sofamor Danek Inc.) and rhBMP-7 (OP-1TM ,
Stryker Biotech) were approved by regulatory bodies and marketed for the
treatment of non-union bone defects, open tibial fractures and spinal fusion (De
Biase, 2005, Swiontkowski, 2006, Hsu, 2008). However, delivery of BMPs is
complicated by their short biological half lives, localized action and rapid
clearance (Bessa, 2008). Attempts to improve the plasma half life of therapeutic
proteins have been made with some success (Werle, 2006, Kontermann, 2011),
but often to counteract the half life problem, high concentrations have tended to
be used clinically. This resulted in some reported side effects mainly caused by
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poorly controlled doses leading to overgrowth and uncontrolled bone formation,
soft tissue swelling, pain, bladder retention, male infertility, osteolysis and
more recently a risk of cancer when high doses were used (Zara, 2011,
Carragee, 2011, Helgeson, 2011, Perri, 2007, Devine, 2012).
These implications emphasized the need for strategies to improve the efficacy
and safety of recombinant growth factor delivery systems. Gradual sustained
delivery of rhBMP-2 over a number of weeks could therefore harness the
undoubted benefits of the molecule for bone regeneration but also mitigate
the high doses and corresponding health and cost implications of
supraphysiologic concentrations (Cahill, 2009). Encapsulation of the growth
factor within a hydrophobic polymer microparticle (MP) will protect it from
proteolytic enzymes at the target site and if formulated correctly, will allow its
gradual release from the MP into the local area. This would be likely to
improve the safety and reduce the side effects of growth factor delivery.
During fracture healing, BMP-2 expression is highest at the early stages to
initiate and direct migration of progenitor cells for the formation of new bone,
which is critical to the proper healing of damaged tissue (Bostrom, 1998,
Kloen, 2003, Tsiridis, 2007). But, the delivery should then be sustained for a
number of weeks to complete the repair process (Jeon, 2008). The optimum
therapeutic dose of BMP-2 for bone regeneration is not well defined. Many
animal studies have been performed, for example, evaluation by micro
computed tomography showed that bone growth could be measured as a
response to 30  240 ng/mm of BMP-2 in 5mm rat calvarial defects when
grafted in conjunction with PLGA (Cowan, 2007). In contrast, much higher
doses were used in a rat femoral segmental defect model where doses of 1-20
µg were assessed within a collagen sponge and 12 µg was declared optimum
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for this model (Angle, 2012). Earlier work claimed that 0.93 µg of BMP-2
combined with PLGA could repair rat segmental defects (Lee, 1994). It is often
difficult to compare results between studies due to dissimilar experimental
conditions. In humans, as already alluded to, the concentration of endogenous
BMPs (ng) is much lower than the amounts used clinically (µg). Improved
delivery devices should allow lower, more clinically relevant doses to be
administered, thus reducing the unwanted side effects.
The activity of BMPs can be determined in-vitro by their effect on certain cell
types to alter their differentiation pathway. In particular, rhBMP-2 will inhibit the
differentiation pathway of a C2C12 myoblast cell line into myotubes and drive
the differentiation of the cells into an osteoblast lineage and involves cross talk
with the wnt3a signalling pathway (Katagiri, 1994, Nakashima, 2005). C2C12
cells exposed to rhBMP-2 will therefore express alkaline phosphatase (ALP)
activity with the levels of activity being directly proportional to rhBMP-2
concentration (Kim, 2004).
Cultures of primary osteoblasts and osteoblast cell lines will form a calcified
extracellular matrix in the presence of osteogenic media although the mineral
deposition can either form a nodular or diffuse pattern. Cells derived from the
calvaria are heterogeneous in nature with a small percentage being
osteoblasts and these are more likely to form distinct nodules in-vitro due to
localisation of the colonies (Declercq, 2005). It has been shown by von Kossa
staining that the presence of rhBMP-2 increases the mineral deposition from
human mesenchymal stem cells (huMSCs) (Johnson, 2009).
To go some way to achieving an improved delivery device for rhBMP-2, the
PLGA MP manufacture and formulation technology as well as the controlled
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release profiles determined in the first two results Chapters of this thesis will
be translated to the release of rhBMP-2. Specifically, release assays will be
set up to i) compare the release of HSA/lysozyme and HSA/rhBMP-2, ii)
investigate the effect of PLGA-PEG-PLGA triblock copolymer on the release
using model protein from 20  30 µm MPs, iii) determine the scalability of the
release system and iv) investigate release of rhBMP-2 from PLGA/PEG
thermosensitive scaffolds. To detect the presence of released rhBMP-2 and to
ensure that it remains biologically active, it will be assessed by enzyme linked
immunosorbent assay (ELISA) as well as an in-vitro model of early
osteogenesis. It will also be tested for its effect on mineralisation by primary
osteoblasts as a late marker of osteogenesis.
4.2 Materials and Methods
All the laboratory equipment, consumables and chemicals used during the
work for this Chapter can be sourced in Appendix I, tables A1, A2 and A3.
Where MP batch numbers are stated, the details of the manufacturing
parameters can be found in Appendix II.
4.2.1 Reconstitution of rhBMP-2, addition of HSA and storage
rhBMP-2 was supplied by Professor Walter Sebald (University of Wurzburg,
Germany) in 5 mg lyophilised aliquots (Ruppert, 1996). It was reconstituted in
500 µl of 0.1 % (w/v) human serum albumin. It was then distributed into 5 x 100
µl aliquots each containing 1 mg of rhBMP-2. One of the aliquots was further
diluted with 900 µl of 0.1% (w/v) HSA and dispensed into 100 aliquots, each
aliquot containing 100 µg of rhBMP-2. A further aliquot was diluted with 400 µl
of 0.1% (w/v) HSA and dispensed into 100 aliquots, each aliquot containing 500
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µg of rhBMP-2. The reconstituted samples were stored frozen until use. Two
batches of rhBMP-2 were used during the work for this project (Sept 10 and
Feb 11).
The addition of HSA as a bulk carrier for MP production was performed very
carefully by adding either a further 9 mg of HSA directly to the 100 µl aliquot
containing 1 mg of rhBMP-2, a further 9.5 mg HSA to the 100 µl containing
500 µg rhBMP-2 or 9.9 mg to the aliquot containing 100 µg rhBMP-2. This
gave 10 mg of total protein suitable for a 1% (w/w) loading into 1 g of PLGA.
Other rhBMP-2 loadings used for this work were 0.5 mg rhBMP-2 with 9.5 mg
HSA and 0.1 mg rhBMP-2 with 9.9 mg HSA.
4.2.2 Manufacture of HSA/rhBMP-2 loaded PLGA MPs formulated with
PLGA-PEG-PLGA triblock copolymer
PLGA MPs formulated with PLGA-PEG-PLGA triblock copolymer were
fabricated the using the method previously defined in Chapter 2, Section
2.2.4.2 to prepare MPs in the 20 -30 µm or 50-100 µm size range. For
controlled release batches, PLGA-PEG-PLGA triblock copolymer was added
at either 10% (w/w) or 30% (w/w) in a total of 1g. The HSA/rhBMP-2 MPs were
loaded with a total of 1% (w/w) comprising of three different rhBMP-2
concentrations using the solutions prepared in the previous Section. Control
MPs were manufactured by using 100ȝl of distilled water in the primary
emulsion.
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4.2.3 Incorporation of rhBMP-2 loaded MPs into PLGA/PEG
thermosensitive scaffolds
A 1% (w/v) solution of high viscosity carboxymethylcellulose (CMC) was made
by overnight magnetic stirring of 1 g of CMC in 100 ml of distilled water.
Thermosensitive PLGA/PEG MPs manufactured by hot melt blending were
sieved to achieve a <100 µm fraction. These MPs were mixed at a ratio of 1:1
(50 mg: 50 mg) with PLGA MPs (20-30 µm) loaded with HSA/rhBMP-2 (1% (w/w)
loading 9.5 mg with 0.5 mg in 1 g PLGA). The high viscosity CMC (800 µl) was
added to the mix of MPs to form a thick paste. The paste was transferred into
a custom made PTFE 6x12 mm cylindrical mould and gently tampered down.
The mould containing MPs was put in a sealable bag to maintain humidity and
placed in a 37oC incubator for 30 minutes after which time the scaffold could
be released from the mould for use. Acknowledgement goes to the Medical
Engineering Unit at Nottingham University for manufacturing the moulds.
4.2.4 Release assays
4.2.4.1 Indirect release assays (supernatant collection)
Release assays were set up with two different masses of MPs (25 mg in 1.5
ml PBS and 50 mg in 3 ml PBS at pH 7.4). The tubes were gently rocked on a
3D shaker at 5 rpm in a humidified incubator at 37°C. At defined time intervals,
the tubes were centrifuged at 3,000 rpm (MSE, Mistral 1000) for 5 minutes
and the supernatant was removed and stored frozen. The MPs were
resuspended in the same volume of fresh PBS and re-incubated.
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In a separate study,thermosensitive PLGA/PEG scaffolds with incorporated
rhBMP-2 loaded MPs were placed in 1 ml of PBS in a Bijou bottle to measure
the release profile. The collected supernatants from all assays were stored
frozen before being thawed and assayed for total protein content using the
micro BCA assay kit as well as in an appropriate bioassay or ELISA for
rhBMP-2.
4.2.4.2 Direct release assays (co-culture)
To gauge the direct in-vitro response of rhBMP-2 loaded MPs and to ensure
there were no adverse effects caused by the MPs on the cells co-culture
release assays were set up. On day zero, 30 mg of HSA/rhBMP-2 loaded MPs
(1% loading 9.5 mg HSA with 0.5 mg rhBMP-2) were weighed along with 6 mg
of MPs without protein loading. These were in the 20-30 µm size range. The
loaded MPs were suspended into 15 ml PBS and 1 ml dispensed into 15
microcentrifuge tubes. The blank MPs were suspended into 3 ml PBS and
dispensed into 3 microcentrifuge tubes. Each tube contained 2mg of MPs and
were placed on a 3-D rocker at 37oC for the release study. At each time-point
(1, 3, 6, 9 and 12 days) all tubes were centrifuged and supernatant carefully
removed and discarded. Three of the tubes containing loaded MPs were
retained and freeze dried overnight. Fresh PBS was added to the remaining
tubes and they were re-incubated on the rocker. This was repeated at each
time-point with the blank tubes being collected at day 12. This resulted in a
collection of MPs that had been exposed to PBS for 0-1, 1-3, 3-6, 6-9 and 9-
12 days and could be used in direct co-culture studies with C2C12 cell to see
if they were able to elicit a pNPP response in the cells. The design of this
experiment is shown schematically in Figure 2.2.
Figure 4.2 Schem
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4.2.5 Detection of rhBMP-2 in release supernatants by immunoassay
(ELISA)
The commercially available rhBMP-2 ELISA kit (Quantikine) was used to
determine the levels of released rhBMP-2 in supernatants. Briefly, a
monoclonal antibody specific for rhBMP-2 was provided pre-coated onto a
micro-plate. Standards and samples were transferred to the wells and any
rhBMP-2 present was bound by the immobilized antibody. The plates were
washed and an enzyme-linked monoclonal antibody specific for rhBMP-2 was
added to the wells. Following a further wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added and a colour developed in
proportion to the amount of rhBMP-2 bound in the initial step. Once the
reaction was stopped, the colour change could be detected at 450 nm. The
detection levels for the Manufacturers standards was 62.5  4000 pg/ml but
the detection of the rhBMP-2 used in these studies (combined with HSA)
required the standard curve in the ng/ml range (5  100 ng/ml).
4.2.6 Culture of C2C12 myoblasts and immortalised human
mesenchymal stem cells
Both mouse C3H C2C12 muscle myoblasts (ATCC, CRL-1772) and
immortalised human mesenchymal stem cells (kindly donated by Dr Hassan
Rashidi, School of Pharmacy, University of Nottingham) were cultured in a
complete tissue culture media consisting of Dulbeccos Modified Eagles
Medium (DMEM), 10% (v/v) foetal calf serum (FCS), 1% (w/v) antibiotic solution
(consisting of 10,000 units/ml of penicillin and 100mg/ml of streptomycin
sulphate) and 2mM L-glutamine. The cultures were maintained at 37°C, 5%
CO2 in air in a humidified atmosphere in T75cm2 flasks. The cells were sub
Chapter 4
162
cultured when judged to be 80-90% confluent. The media was aspirated and
cultures were rinsed with approximately 10 ml of PBS. The cells were then
treated with a small volume (approximately 3ml) of trypsin/EDTA (0.5 g/L
trypsin, 0.2 g/L EDTA) for no more than 5 minutes at room temperature. Once
the cells had detached from the flask surface, a further 10 ml of complete
media was added and the total contents transferred to a 15ml centrifuge tube.
The suspension was centrifuged for 5 minutes at 1,000rpm (Sigma, 2-16K).
Media was then aspirated, and the pellets were usually re-suspended in 4 ml
and sub-cultured at a typical ratio of 1:4 in 10 ml of complete media. Sub-
culturing was required every 2 to 3 days for the C2C12 cells and every 3 to 4
days for the immortalised MSCs.
4.2.7 Measurement of rhBMP-2 activity in release supernatants by
alkaline phosphatase expression in C2C12 cells and immortalised
human mesenchymal stem cells
Alkaline phosphatase (ALP) is expressed as an early marker of osteogenic
differentiation and when osteogenesis is induced using rhBMP-2, the levels of
ALP are proportional to the BMP-2 concentration. Activity of rhBMP-2 in
release supernatants was measured in-vitro by monitoring the level of ALP
expression by C2C12 myoblast cells in the presence of rhBMP-2 (Katagiri,
1994).
The C2C12 cells (no greater than passage 12) were suspended at a
concentration of 10,000 cells per ml in DMEM supplemented with 10% (v/v)FCS
and 1x antibiotic/antimycotic solution. The cell suspension (100 µl with 1000
cells) was added to a 96 well plate and incubated in a humidified environment
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at 37oC 5% CO2 overnight. The media was then replaced with either 100 µl of
rhBMP-2 in complete DMEM at a concentration range of 100-1000 ng/ml to
generate a standard curve or 100µl of the release supernatants in PBS. A
further 100 µl of DMEM was added to the supernatants and 100 µl of PBS was
added to the standards to give a final total volume of 200 µl in all wells. The
expression of ALP after 5 days of culture was measured using a SigmaFAST
pNPP kit. Media was aspirated from the wells and the cells carefully washed
with 100 µl PBS. The pNPP solution, made to manufacturers guidelines, was
added (100µl) to the wells and any de-phosphorylated pNPP which was
indicative of rhBMP-2 activity, could be detected at an absorbance of 405 nm
after 1 hour of incubation at room temperature (protected from light).
In addition to using C2C12 cells, an immortalised human mesenchymal stem
cell line was also used to measure rhBMP-2 activity using the same method
as described above.
4.2.8 Co-culture of HSA/rhBMP-2 loaded MPs with C2C12 cells as a
method for detecting rhBMP-2 activity and measuring rhBMP-2
release
The activity of released rhBMP-2 was determined by directly co-culturing
C2C12 cells with HSA/rhBMP-2 loaded MPs (9.5mg HSA/0.5 mg rhBMP-2 in 1
g of PLGA). C2C12 cells were suspended at 3,000 cells per ml in complete
DMEM and 1 ml was plated into each well of a 12 well plate. After 24 hours
incubation, the media was replaced with media containing serially diluted
suspensions of different masses (2, 1, 0.5, 0.25 and 0.125 mg) of
HSA/rhBMP-2 loaded MPs or HSA/rhBMP-2 loaded MPs which had been
stored during the release assay as described above in Section 4.2.4.2. The
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cultures were left for 5 days before being imaged and assayed using the
SigmaFAST pNPP kit.
In an alternative experiment, a range of cell concentrations (3,000, 1,500 and
750 per ml) were tested with a fixed 2 mg mass of HSA/rhBMP-2 loaded MPs.
.
4.2.9 Von Kossa staining for detection of mineralisation in-vitro
The method of staining for calcium deposition is the von Kossa method
(Bancroft, 1992). It highlights deposits of calcium salt by staining cells or
tissue sections with a solution of silver nitrate. Silver is deposited by replacing
the calcium which is reduced by strong light. The calcium deposits are then
visualized as metallic silver (Declercq, 2005).
Mouse primary calvarial cells (mPCCs) were kindly isolated and donated by
Adam Taylor and Laura Sidney (PhD students, School of Pharmacy,
University of Nottingham). The calvaria were dissected from CD1 neonates
(supplied by the Biomedical Services Unit, Nottingham University) and
digested using a solution of 1.4 mg/ml collagenase type IA and 0.5 mg/ml
trypsin II S. Cells released during the first 2 populations (10 minutes each
digestion) were discarded and the population of cells from the next 3
digestions were plated in tissue culture flasks at a density of 6.6 x 103
cells/cm2. Cells were cultured in ĮMEM containing 10% FCS and 2mM L-
Glutamine and 100 U/ml penicillin/100 ȝg/ml streptomycin.
The mPCCs were exposed to HSA/rhBMP-2 loaded MPs (9 mg HSA/1 mg
rhBMP-2) for 28 days in direct co-culture by placing 4 mg of MPs (PLGA 50 50
10% (w/w) TBII-F, 50-100 micron) into the wells of a six well plate containing
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100,000 cells per well . After incubation in a humidified atmosphere at 37oC,
the cells were fixed in 10% (v/v) paraformaldehyde for 30 minutes. A 1% (w/v)
silver nitrate solution in distilled water was added to the cells and subjected to
UV light for 60 minutes. The cells were then rinsed in distilled water and
treated with 5% (w/v) sodium thiosulphate solution in distilled water for 5
minutes to remove any unreacted silver. The cells were then rinsed in distilled
water and imaged. Calcium nodules appear dark brown/black.
4.2.10 Imaging of cells, cells with microparticles and scaffolds
Cultured cells were imaged using a Nikon Eclipse TS100 microscope at a
magnification of x10 and polymer scaffolds were imaged by scanning electron
microscopy (JSM 6060LV).
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4.3 Results and Discussion
4.3.1 Comparison of model protein and growth factor release
All of the work performed on controlled release in the previous Chapters
involved the use of the model protein lysozyme in conjunction with human
serum albumin (HSA) as a bulk carrier protein and the release was measured
from 50-100 µm sized MPs. The future direction of the project was to
investigate the embryonic chick femur as a model for bone regeneration and
this necessitated a smaller MP size to be studied. The size range chosen was
20-30 µm because this size of MP can be manufactured with the same PLGA
concentration (20 % w/v) as the 50-100 µm with the smaller size being
achieved by an increased homogeniser speed. It was expected that tailoring of
protein release kinetics using PLGA-PEG-PLGA would still be feasible with
this smaller MP size especially as previous results showed there was a lag
phase after the burst when the MPs had not been modified with PLGA-PEG-
PLGA triblock copolymer (Chapter 3 Figure 3.18B).
The starting point was to compare rhBMP-2 release with that of the model
protein lysozyme from the established 50-100 µm size range before looking at
the smaller size range to ensure that the technology was transferable from
model to growth factor. A batch of 50-100 µm PLGA 50 50 MPs were loaded
with HSA/rhBMP-2 (9mg HSA with 1mg rhBMP-2) and were tested in a
dynamic release assay and retrospectively compared with HSA/lysozyme data
(Figure 4.3A). Both types of MP had been formulated with 10% (w/w)PLG-PEG-
PLGA triblock copolymer.
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Two batches of PLGA 50 50 20-30 µm also formulated with 10%(w/w) PLGA-
PEG-PLGA triblock copolymer were manufactured one containing
HSA/lysozyme (9 mg HSA with1 mg lysozyme) and one containing
HSA/rhBMP-2 (9.9 mg HSA with 0.1 mg rhBMP-2) and these were also both
put on a dynamic release assay. The profiles are shown in Figure 4.3B.
The release profiles for the larger MPs showed a small burst release and
further sustained release over time. The profiles of the model protein and the
growth factor did not overlay exactly but the study was retrospective which
may account for the differences. Aloso, two different triblock copolymer
batches were used (TBII-B and TBII-F). However, both formulations had
released similar total amounts of protein over the 30 day period. The smaller
MPs were fabricated with the same triblock copolymer (TBII-F) and show a
better correlation between the traces but the burst release was higher than
that seen with 50100 µm MPs. This was not unexpected as previous results
showed that the smallest MPs had the highest short term release (Chapter 3,
Figure 3.14). These data gave confidence that HSA/rhBMP-2 release from 20-
30 µm MPs could be detected and quantified especially over the first 10 days.
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Figure 4.3. Total protein release profiles from [A] 100 mg of 50 -100 µm MPs
and [B] 50 mg of 20  30 µm MPs comparing HSA/rhBMP2 ( ) and
HSA/lysozyme ( ) PLGA 50 50 MPs formulated with10% (w/w) PLGA-PEG-
PLGA triblock copolymer n=3
Batches: BN 344, 125, 313 and 314
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4.3.2 Effect of PLGA-PEG-PLGA triblock copolymer and MP mass on
the rate of protein release from PLGA MPs
The release from two different masses (25 mg and 50 mg) of MPs loaded with
HSA/rhBMP-2 (0.1 mg rhBMP-2 with 9.9 mg HSA) was expressed as either
cumulative protein release in µg (Figure 4.4A and 4.4B) which indicated the
actual amount of protein delivered and as cumulative percentage release
(Figure 4.4C and 4.4D) which showed the overall shape of the release profiles.
The ratio of MP mass to release volume was kept the same for both masses.
The data is shown for MPs fabricated with 10 % and 30% (w/w) PLGA-PEG-
PLGA triblock copolymer and sized at 20-30 µm. Increasing the triblock
copolymer accelerated the release and the data showed that release positively
correlates with MP mass (Figure 4.4A compared to Figure 4.4B).
Over 90% of the protein load was released in the first 20 days from the 30%
(w/w) PLGA-PEG-PLGA copolymer following a diminishing release profile,
whereas only approaching 60% of the total protein was released from the 10%
(w/w) PLGA-PEG-PLGA copolymer formulation over 30 days following a
sustained release profile after the burst. The addition of PLGA-PEG-PLGA
copolymer had therefore resulted in two distinctly different release profiles
from these small MPs.
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Figure 4.4. Cumulative total protein release from HSA/rhBMP-2 loaded 20 -30
µm PLGA 50 50 MPs formulated with 10% (w/w) ( ) or 30% (w/w) ( )
PLGA-PEG-PEG triblock copolymer. Cumulative release is shown for two
release conditions; 25 mg in 1.5 ml PBS [A, C] or 50 mg in 3 ml PBS [B, D].
Data is expressed as cumulative µg released [A and B] or cumulative
percentage release [C and D]. n=3
Batches: BN 243 and 245
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The average daily release from these MPs is shown in Table 4.1 where the
estimated rhBMP-2 component of the total protein value is shown (one
hundredth of the total protein) and expressed in nanograms (ng). It would be
expected that many of the values shown in Table 4.1 would fall in the
therapeutic range in bone regeneration applications suggested to be 1-30 nM
for cell signalling (Umulis, 2009). But, the values are much lower than those
used clinically and as discussed earlier in the introduction, the optimum
therapeutic dose of BMP-2 for bone regeneration is not well defined.
When these supernatants were tested with C2C12 cells for ALP activity
(Chapter 3), only the supernatant containing the highest concentration showed
a minimal response in the assay and all of the other samples tested showed
no positive response (data not shown). There may have been a number of
reasons for this problem. The in-vitro assay was simply not sensitive enough
to record rhBMP-2 activity lower than 200 ng/ml. This may have been
compounded by the carrier protein (HSA) hindering the activity of rhBMP-2 at
low concentrations, although, this was unlikely as the rhBMP-2 standard curve
was prepared with an appropriated concentration of HSA. The more likely
explanation may be that the release supernatants were stored frozen and
thawed before use and this could have lead to a minor disruption of the protein
structure with a direct effect on its binding capacity and activity. In particular,
the PBS release medium may have had some effect on the protein structure.
To mitigate some of these issues, rhBMP-2 standard curves were prepared
with and without the HSA carrier, MPs with a higher rhBMP-2 loading were
also manufactured and direct co-culture of MPs and C2C12 was investigated.
The results will be discussed later in this Chapter (Section 4.3.4).
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Table 4.1 Estimated average daily release of rhBMP-2 (ng) calculated
from the total protein release curves shown in Figure 5.4
Days
25 mg
PLGA 50 50
10% TB
50 mg
PLGA 50 50
10% TB
25 mg
PLGA 50 50
30% TB
50 mg
PLGA 50 50
30% TB
0-2 95.1 196.5 101.15 220.15
2-5 6.34 27.47 85.28 265.76
5-9 3.17 38.04 35.7 116.02
9-20 3.63 20.74 19.47 43.81
20-30 9.51 9.51 0.238 2.38
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4.3.3 Incorporation of HSA/rhBMP-2 loaded PLGA MPs into
thermosensitive scaffolds and the effect on protein release rate
It was discussed earlier in Chapter 3 that by plasticising PLGA 85 15 with 6.5 %
(w/w) PEG400 the glass transition temperature could be reduced. Once milled,
PLGA/6.5PEG MPs were mixed into an aqueous carrier and gently packed
into a mould at 37oC, then they would firstly become cohesive, forming
bridging points between MPs and then overtime, they would harden as the low
molecular weight PEG leached away.
This was used as a basis to measure release of lysozyme that had been
directly incorporated into the hot melt. However, many bioactive molecules
would not withstand temperatures over 40 oC and so it was decided to
incorporate growth factor loaded (HSA/rhBMP-2) MPs into the PLGA/6.5PEG
MP scaffold by dry mixing the two types of MP in a 1:1 ratio, mixing with 0.5%
CMC (to act as a lubricant for injection and as an aqueous carrier to
encourage PEG leaching) and incubating at 37oC. As the rhBMP-2 MPs were
sized at 20-30 µm, the PLGA/6.5PEG MPs selected were sub 100 µm.
Approximately 50% of the total protein released from the scaffold over the first
two weeks (Figure 4.5A). Although the burst release in the first 24 hours was
around 25% this was not dissimilar, indeed somewhat lower, than the burst
achieved from HSA/rhBMP-2 MPs alone. Figure 4.5B shows a comparison of
release from HSA/rhBMP-2 MPs alone and the same MPs incorporated in a
scaffold. The release from the scaffold tailed off after 1 week but with 50% of
the protein still within the matrix it would be expected to continue to release
slowly as the scaffold degraded, but this was not investigated further. The
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PLGA 85 15 used in the thermosensitive formulation has a much longer
degradation time than the PLGA 50 50 used to make the loaded MPs.
To illustrate the setting and scaffold formation of these MPs, Figure 4.5C-E
shows the combination of larger MPs (PLGA/6.5PEG MPs with HSA/rhBMP-2
MPs) and their morphology after sintering at 37oC. Figure 4.5E clearly shows
that the thermosensitive MPs have melted in to each other giving structure,
whilst the growth factor loaded MPs remain spherical, not being affected at
37oC. The overall structure of the scaffold remains porous.
These scaffolds at the end of the study had considerable strength and it was
difficult to crush them manually. Unpublished data (Cox, In writing) reported
typical compressive strength values for PLGA/6.5PEG scaffolds of between 2
and 6 MPa after just 24 hours of incubation at 37oC. It is expected that the
scaffolds would release their cargo in a controlled manner depending on the
formulation of the incorporated rhBMP-2 loaded MPs. The release profile may
have been improved if larger 50-100 µm spherical MPs were used but the
rationale was to use smaller MPs in this study. Different ratios of the two MP
types could be tested to gain the optimum combination of release and strength.
However, in this instance, only one copolymer concentration one MP size and
one MP mixing ratio was tested as a proof of concept for this scaffold.
The advantage of adding thermosensitive MPs is that the system will remain
injectable (depending on MP size and carrier) but will strengthen in-situ
providing support to the surrounding tissue and prevent growth factor loaded
MPs migrating and will therefore keep the protein delivery vehicle local and
minimise side effects.
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Figure 4.5 [A] Release from 50 mg HSA/bmp-2 loaded PLGA 50 50 (Mwt 56
kDa) MPs incorporated in a PLGA (85 15 Mwt 56kDa)/6.5% (w/w)PEG (Mwt 400
Da) scaffold (solid line) [B] comparison with release from 50 mg HSA/bmp-2
loaded microprticles alone (dashed line) [C] representative image of
PLGA/PEG MPs manufactured by hot melt blending and milling prior to
sintering.[D] representative image of PLGA MPs manufactured by double
emulsion [E] scaffold showing sintered PLGA/PEG MPs and incorporated MPs.
Scale bar 100 µm. Image [E] courtesy of Dan Gill (MSc student 2011)
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4.3.4 Detection of rhBMP-2 and rhBMP-2 activity in release
supernatants
4.3.4.1 rhBMP-2 detection: Enzyme linked immunosorbent assay (ELISA)
The initial step to detect rhBMP-2 in the release supernatants was to test them
in a commercially available ELISA. The total protein release profile from these
MPs is shown in Figure 4.6A. However, at the advised concentration (62.5 -
4000 pg/ml) the batch of rhBMP-2 (Sept10) used was not detectable. This
may have related to the epitope on the antibody supplied with the ELISA kit
not being identical to the binding site on the rhBMP-2 used leading to a lower
affinity in the immunoassay. The ELISA kit rhBMP-2 was generated through
mammalian cell expression (Chinese Hamster Ovarian) whilst the rhBMP-2
used was expressed in bacterial cells (Esherichia coli). The different
manufacturing methods may have impacted on the recognition of the growth
factor by the ELISA. To counteract this issue, higher rhBMP-2 concentrations
were tested (5-100 ng/ml) and these generated an approriate standard curve
(4.6B) in the range required to detect rhBMP-2 in the collected supernatants.
Indeed, there was some detectable rhBMP-2 in the release supernatants but
the concentration was lower than had been expected in some samples and so
this assay was not appropriate for further studies (Figure 4.6C).
However, this was the first indication that rhBMP-2 had been successfully
released from the MPs. Although the ELISA could be optimised for detection
of growth factors in release media, the technique can only quantify the
presence of the molecule and is not a measure of its
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Figure 4.6: Detection of rh-BMP-2 by ELISA in supernatants collected after
release from PLGA 50 50 Mwt 56 KDa MPs formulated with 30% (w/w)PLGA-
PEG-PLGA copolymer loaded with 1% (w/w) HSA/rhBMP-2 over 40 days. [A] is
the total protein cumulative release curve.[B] is the ELISA standard curve.[C]
is the expected rhBMP-2 concentration calculated from the total protein value
(black bars) and the actual concentration determined by ELISA (white bars).
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4.3.4.2 rhBMP-2 activity: Alkaline phosphatase assay
ALP is expressed as an early marker of osteogenic differentiation and when
osteogenesis is induced using rhBMP-2, the levels of ALP are proportional to
the BMP-2 concentration and is mediated by the induction of a wnt autocrine
loop (Rawadi, 2003). Preliminary studies using ALP expression as a marker
for rhBMP-2 activity in release supernatants were only positive for the burst
release from the first 24 hours of release (data not shown). To improve the
chance of success of the ALP bioassay, a new batch of MPs was
manufactured in the 20-30 µm size range. These and were loaded with a
higher concentration of rhBMP-2, but within the same total loading of 1% (w/w)
(9.5 mg HSA, 0.5 mg rhBMP-2 in 1 g of PLGA modified with 10% (w/w)TBII-F).
Prior to testing any release supernatants, the feasibility of the assay to detect
rhBMP-2 and the sensitivity of the assay was determined. As a preliminary
study, rhBMP-2 at concentrations ranging from 50 - 1,000 ng/ml was cultured
with C2C12 cells and HSA was added to the standards to mimic the carrier
loading in the MPs. By day 5, there was a distinct change in the morphology of
the cells. Figure 4.7A shows that C2C12 cells without rhBMP-2 become
spindle-like and line up to begin the formation of myotubes. As the rhBMP-2
concentration increases, the morphology changes and the cells become more
rounded or cobblestone in shape. This change in morphology is also reflected
by an increase in the ALP expression which displays a good linear response
between 200 and 750 ng/ml (Figure 4.7B).
Unfortunately, it was not sensitive to below 200 ng/ml which meant that in its
current form, most of the rhBMP-2 in the supernatants from the release
assays performed thus far (Table 4.1) would not be detectable, especially as
Chapter 4
179
the samples had been stored in PBS and would need further dilution in culture
medium for the in-vitro assay. An attempt to address this was to combine and
concentrate the HSA/rhBMP-2 in the supernatants from a number of days
release by using 9 kDa molecular weight filter cut off centrifuge tubes. These
samples would then be re-suspended in complete culture medium (DMEM, 10%
(v/v) FCS, penicillin/streptomycin) for cell culture assays. But, this approach was
not successful with little or no detection of rhBMP-2 activity in the
supernatants (data not shown). It was thought that the MP manufacture and/or
release process or the process of concentrating the releasate had denatured
the protein or more likely, the levels in the supernatants were still below the
sensitivity of the assay.
Different parameters of the C2C12 assay were investigated (for example cell
number and culture plate size) to try to optimise the assay and variability
within the assay was improved by removing the cell lysis step. In a further
attempt to determine rhBMP-2 activity in the release supernatants, the
HSA/rhBMP-2 loaded MPs (9.9 mg HSA with 0.1 mg rhBMP-2) were allowed
to release their protein directly into tissue culture media (50 mg MPs in 1.5 ml
DMEM + 10% (v/v) FCS and penicillin/streptomycin). This media was then fed
directly into the pNPP assay. This gave an indication of rhBMP-2 biological
activity in the release supernatants (unlike the ELISA that only detected the
presence of rhBMP-2) but the levels of detection were very low and
considering the sensitivity of the assay and only the first day of release could
be considered to be on the BMP-2 standard curve. However, this study
showed that potentially, BMP-2 remained biologically active during the
process of particle manufacture and release, but further improvement of the
techniques were required.
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A breakthrough in the detection of activity in release supernatants was
achieved by using a new batch of MPs that had been manufactured with a
fivefold higher loading of rhBMP-2 (9.5mg HSA with 0.5 mg rhBMP-2). The
MPs demonstrated a sustained release rate after burst release similar to that
seen before (Figure 4.3B) with approximately 80% of the total being released
in 30 days (Figure 4.8A). The rhBMP-2 released from the MPs in this study
were able to influence the differentiation of C2C12 cells as illustrated by the
ALP expression in these cells up to 13 days (Figure 4.8B). However, the levels
were up to ten times lower than what would have been predicted by the BCA
total protein assay. There was no detection of rhBMP-2 activity beyond 13
days despite release still being detected by the total protein assay (Figure
4.8A) which may be due to assay sensitivity or the effect of the PLGA
degradation products.
The pH of each of the supernatants was recorded and it was shown that the
pH started to drop after 6 days (Figure 4.8A inset) which was earlier than seen
before (Chapter 2). The reason for this may be twofold, firstly, these MPs were
smaller, had thinner exterior shells so would therefore degrade faster and
secondly the collection time-points are further apart so that there is more
likelihood of a build up of degradation products in the supernatant.
Although the work to detect rhBMP-2 activity after release from MPs had gone
some way to validating the delivery system, further work investigated different
strategies to detect active rhBMP-2 from the controlled release system. Two
different approaches were therefore attempted to improve the detection, firstly,
an immortalised human mesenchymal stem cell line was used instead of
C2C12 cells and secondly, co-culture of MPs with C2C12 cells was performed.
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4.3.5 ALP expression by immortalised human mesenchymal stem cells.
Human mesenchymal stem cells (huMSC) isolated from bone marrow have a
low proliferative ability and cannot survive many passages. A population of
huMSCs were kindly immortalised by Dr Hassan Rashidi by retrovirus-
mediated gene transfer following the procedure published by Okamoto in 2002
(Okamoto, 2002). A combination of human telomerase reverse transcriptase
with human papillomavirus E6 and E7 successfully immortalised the huMSCs
without affecting their potential for adipogenic, osteogenic and chondrogenic
differentiation (Rashidi, 2012).
Dilutions of HSA/rhBMP-2 (9.5 mg with 0.5 mg) were prepared with the
rhBMP-2 component concentration ranging from 6.25  1000 ng/ml and these
were tested against both C2C12 cells and the immortalised huMSC cells.
The full range of HSA/rhBMP-2 concentrations for both cell types is shown in
Figure 4.9A. With concentrations of rhBMP-2 above 100 ng/ml, C2C12 cells
were seen to differentiate down the osteoblast lineage. The huMSC response
reached a plateau above 50 ng/ml and was dose responsive with rhBMP-2
below 50 ng/ml (Figure 4.9B), although variation and background values were
both high. These cells were therefore expressing ALP without the presence of
rhBMP-2 which would make using the assay routinely difficult as the actual
absorbance levels, once the background was subtracted, would be very low.
Use of these cells was therefore terminated and the work continued by
focussing on direct co-culture of MPs and C2C12 cells.
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Figure 4.9: rhBMP-2 activity measured by alkaline phosphatase expression in
immortalised human MSCs cells ( ) compared to C2C12 cells ( ). [A] is the
response up to 1000 ng/ml and [B] is the response up to 50 ng/ml
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4.3.6 Direct effect of rhBMP-2 loaded MPs on C2C12 cells
It was shown in Figure 4.7 that C2C12 cells presented a myoblast morphology
after 5 days of culture (Figure 4.7A 0 ng/ml rhBMP-2). The addition of blank
PLGA 50 50 MPs did not adversely affect the cells (Figure 4.10A) and the
cells proliferated amongst and around the MPs with no obvious cytotoxic
effects after 5 days of culture. When HSA/rhBMP-2 (9.5mg with 0.5mg) loaded
MPs were cultured directly with C2C12 cells there was a notable change in the
cell morphology (Figure 4.10B) that was similar to the effect seen by rhBMP-2
alone on the cells (Figure 4.7A), these cells also presented a positive
response for ALP expression (Figure 4.10C).
These results proved that rhBMP-2 released from PLGA MPs could elicit a
biological response on the surrounding cells. To confirm further that the
response was directly related to the rhBMP-2 concentration, a number of
different masses of rhBMP-2 loaded MPs were cultured with a fixed number of
C2C12 cells. Using 2 mg of MPs and below, there was an excellent correlation
with MP mass and rhBMP-2 concentration as determined by ALP expression
(Figure 4.11). As an additional study, 2 mg of rhBMP-2 loaded MPs were
cultured with a range of cell concentrations and data illustrated that the ALP
response was related to cell number (Figure 4.12).
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Figure 4.11 Effect of mass of HSA/rhBMP-2 loaded PLGA 50 50 10% (w/w)
PLGA-PEG-PLGA MPs on alkaline phosphatase expression in C2C12 cells
(n=4)
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Figure 4.12 Effect of C2C12 cell number when cultured with 2 mg of
HSA/rhBMP-2 loaded PLGA 50 50 10% (w/w) PLGA-PEG-PLGA MPs (n=4)
Batch: BN337
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The rhBMP-2 loaded MPs had now been shown to elicit a biological response
when co-cultured with C2C12 cells but the concentration of released rhBMP-2
had not been quantified as the conventional assay was only sensitive at >100
ng/ml and the supernatants from 2 mg of MPs would be below detection limits.
However, by knowing the initial loading (9.5mg HSA with 0.5mg rhBMP-2 per
g PLGA), the entrapment efficiency of the batch (51.47 ± 4.38%) and the
release curve of these MPs (4.8A), it could be estimated that the 2 mg of MPs
would have released approximately 50 ng of rhBMP-2 per day after the initial
burst. It was encouraging that these levels were potentially sufficient to have a
biological effect as it correlated with some of the published data (Cowan, 2007,
Umulis, 2009). However, as discussed earlier, the optimal clinical
concentration is not well defined. The advantage of the microparticulate
delivery system is that the growth factor delivery cannot only be tailored by
formulation of the MPs but also by the mass of the MPs administered.
4.3.7 Sustained rhBMP-2 release determined by direct co-culture of
HSA/rhBMP-2 loaded MPs with C2C12 cells
The direct co-culture of HSA/rhBMP-2 loaded MPs with C2C12 cells showed
that rhBMP-2 was being released from the MP and was able to drive the
differentiation of the cells towards an osteogenic lineage. But, the MPs would
have already released 20-30% of their load in the first 24 hours and it may be
just the effect of this burst released protein that was causing the cells to
differentiate.
To show that rhBMP-2 remaining entrapped in the MPs after the initial burst
was still being released in sufficient quantities to exert a biological effect on
the C2C12 cells, a release study was set up as described in Section 4.2.4.2
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with a schematic shown in Figure 4.2. Individual samples of HSA/rhBMP-2
loaded MPs were exposed to PBS for different times before being recovered,
dried and used in a direct culture C2C12 ALP assay. Figure 4.13 shows the
morphology of C2C12 cells after 5 days of culture with HSA/rhBMP-2 MPs that
had pre-released some of their payload. After 12 days of release prior to
incubating the MPs with the cells, the MPs still caused a biological response in
the cells (demonstrated by a change in morphology), despite approximately 60%
of their protein load (estimated from release curve Figure 4.8A) having already
been released.
To consolidate the morphological changes seen the ALP assay was
performed on the C2C12 cells. The ALP response, as measured by
absorbance at 405 nm, was substantial for the rhBMP-2 loaded MPs
compared to the blank MPs up to day 9. The response then tailed off between
days 9 and 12 which was consistent with a typical diminishing release profile.
The raw data is shown in Table 4.2. Unfortunately it was not possible to
quantify these values due to conventional standard curves only being
sensitive >200 ng/ml.
The MPs were now proven to encapsulate and release rhBMP-2 in a
controlled manner and could be used in further studies into mineralisation and
bone repair forming the basis of the work in Chapter 5.
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Table 4.2 Alkaline phosphatase expression (determined by absorbance at
405 nm) by C2C12 cells after incubation with HSA/rhBMP-2
MPs that had pre-released their protein load into PBS for
different time periods.
Number of
days MPs
exposed to
PBS
50 mg
PLGA 50 50 10% PLGA-PEG-
PLGA TBII-F
(9.5 mg HSA 0.5 mg BMP-2)
Absorbance measured at 405nm
0
0.308 ± 0.05
1
0.266 ± 0.051
3
0.214 ± 0.034
6
0.312 ± 0.127
9
0.314 ± 0.030
12
0.181 ± 0.082
Blank MPs 0.089 ± 0.006
4.3.8 Von Kossa staining for calcium deposits
To further confirm that the HSA/rhBMP-2 loaded MPs could induce
ostegenesis by releasing bioactive rhBMP-2, a 21 day direct culture study was
performed using mouse primary calvarial cells (mPCCs). The HSA/rhBMP-2
(PLGA 50 50/ 30% w/w TBII-F 50 -100 µm) loaded MPs were dispensed
amongst the adhered cells and remained throughout the 21 day culture period
in basal media. Due to the longer culture period for this assay, it was decided
to use 50-100 µm MPs to avoid the expected build up of degradation products
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from the 20-30 µm which may have adversely affected the viability of the cells.
Figure 4.14 shows the von Kossa staining achieved. The opaque MPs are
clearly visible as well as their effect on the surrounding cells.
Acknowledgement goes to Dr Lisa White (School of Pharmacy, University of
Nottingham) for providing the data.
The mPCCs cultured with blank (no HSA/rhBMP-2) MPs showed a weak
diffuse staining with no nodular formation when compared to the HSA/rhBMP-
2 loaded MPs which gave a good strong staining with the presence of nodules.
The cells with no MPs showed no staining for calcium deposits. The data
suggests that the presence of PLGA MPs caused a low level osteoinductive
effect and other researchers have investigated PLGA alone for its osteogenic
potential on human mesenchymal stem cells (Kruger, 2011). However, the
response is greatly enhanced by the release of rhBMP-2 from the PLGA MPs.
The nodular deposition of calcium by primary calvarial cells has been reported
before and is thought that the heterogeneous nature of the primary calvarial
cell population localises the calcification (Declercq, 2005). Due to the large
number of MPs in the culture, it was difficult to define whether the calcification
was localised around individual MPs or whether it was due to the overall level
of rhBMP-2 released. But, it was clear that calcium deposits were evident and
this result gave further evidence as to the osteogenic potential of these MPs.
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Figure 4.14 Von Kossa staining for calcium deposits by mouse primary
calvarial cells after 21 days of culture with [A] no MPs, [B] blank PLGA 50 50
30% (w/w) TBII-F 50 -100 µm MPs and [C] HSA/rhBMP-2 loaded (9 mg HSA/1
mg rhBMP-2 in 1 g) PLGA 50 50 30% (w/w) TBII-F 50 -100 µm MPs.
Scale bar 100 µm. Images courtesy of Dr Lisa White BN 346
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4.4 Conclusions
This Chapter has focussed on transferring the controlled release technology
for a model protein developed in Chapters 2 and 3 to the release of rhBMP-2.
A smaller MP size was used (20-30 µm as opposed to 50-100 µm) and despite
the burst release being higher for these MPs, release could still be controlled
by using PLGA-PEG-PLGA triblock copolymer within the polymer formulation.
The addition of thermosensitive PLGA/PEG MPs to the rhBMP-2 releasing
MPs will still allow the delivery device to be injectable, but will enable the
scaffold to harden in-situ thus giving support to the surrounding tissue and
providing a scaffold for new tissue growth whilst localising growth factor
delivery to the injection site. Results showed that the release of growth factor
after the initial burst is likely to be sustained over a period of months rather
than days as the MPs are trapped in a solid structure which degrades slowly.
Detection of active rhBMP-2 after release from MPs was paramount to the
delivery device being successful and this proved to be a considerable
challenge. The C2C12 cells provided a good tool to detect rhBMP-2 activity
but it was only sensitive >100 ng/ml for the rhBMP-2 used. The expected
levels of rhBMP-2 in the release supernatants were lower than this detection
and so MPs with higher rhBMP-2 content were manufactured and these gave
more encouraging results. Using co-culture techniques, the rhBMP-2 released
from the MPs were shown to be active against C2C12 cells in low masses and
therefore low concentrations of rhBMP-2. Longer term effects were
demonstrated by positive staining for calcium deposits showing that the MPs
had caused mineralisation occur. These rhBMP-2/HSA MPs could now be
progressed to use in an ex-vivo model of bone repair which is the subject of
the following Chapter.
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Chapter 5: The development of an ex-ovo chick femur as a model to
investigate the effects of rhBMP-2 loaded microparticles on
bone regeneration and repair
5.1 Introduction
During the development of pharmaceutical products and medical devices
including drug delivery systems, a reliable ex-vivo model to screen candidate
materials and formulations prior to embarking on large scale pre-clinical
models would be advantageous. This is particularly relevant for models of
skeletal repair as in-vivo models tend to involve large, skeletally mature
animals such as sheep meaning only a relatively small animal numbers are
usually possible in a study. We have utilised the chick embryo to investigate
bone growth and repair as supply is plentiful and cost effective (Rashidi, 2009).
The embryonic development of the chick is well documented with the seminal
work being performed by Hamburger and Hamilton who described the forty six
chronological stages of chick development over the 21 day gestation period
and more recent work using ultrasound imaging and micro computed
tomography to monitor development has been used (Hamburger, 1951,
Schellpfeffer, 2007, Kanczler, 2012). A pictorial guide to in-ovo chick
development is shown in Figure 5.1.
Although the chick embryo is a good candidate as a tool to study the effects of
growth factors on development, one potential problem is that growth can be
affected by a number of variables such as incubation temperature, delay
between laying and incubation and breed of hen (Oviedo-Rondon, 2008). In
particular, the skeletal development can be affected by temperature having a
positive correlation (Brookes, 1972) and so incubation time, humidity and
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temperature control must be taken into careful consideration when planning
studies.
When chick femurs are dissected from day 13 embryos and cultured in-vitro
for 10 to 15 days, they produce new osteoid from skeletal stem cells present in
the perichondrium (Roach, 1996). Therefore, organ culture of small whole
bones may provide a niche for studies of scaffolds and/or growth factors with
or without cells. Tissue culture of the bones at the air/liquid interface is the
preferred method as the higher oxygen concentration is more likely to favour
osteogenic differentiation (Roach, 1997). This method of culture will be
described in this thesis as organotypic culture.
If the femur is removed after 11 days of incubation at 37oC and is cultured
organotypically for a further 10 days, it continues to develop in-vitro. The first 2
days have been described as the adaptation period characterised by release
of intracellular enzymes, followed by a period of steady growth during which
skeletal cells proliferate and secrete bone and cartilage matrix (Roach, 1990).
Although the bones grow, they do not follow normal endochondral ossification
because there is no vasculature present. The chorioallantoic membrane (CAM)
model has been used as an ex-vivo model to test the angiogenic properties of
a tissue or explants and has been used to culture bones and investigate
fracture healing (Takahashi, 1991, Roach, 1998) and has been described as a
preferred model due to the lack of vasculature in in-vitro culture (Kachi, 2008)
but the CAM assay is not in the scope of the current work. The disadvantage
of the CAM assay is that it gives very variable results, is techniquely difficult to
perform and the results are open to different interpretation.
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Endochondral ossification involves a series of precisely controlled events
leading to a cartilaginous template being converted to a highly organised bone
structure. The cellular and molecular events leading to cartilage and bone
formation have been thoroughly studied (von der Mark, 1977, Cancedda, 2000)
and involve mesenchymal stem cells proliferating and differentiating into
chondroblasts, which secrete a cartilagenous matrix and progressively
become embedded chondrocytes. The chondrocytes undergo hypertrophy and
the matrix is calcified as oxygen, nutrients and cellular wastes can no longer
diffuse through the matrix. The chondrocytes degenerate and leave behind a
scaffolding of calcified cartilage. Blood vessels invade and both
osteoprogenitor and hemopoietic cells enter the cartilage model. The
hemopoietic cells will form bone marrow and bone matrix is laid down on
scaffolding of calcified cartilage by osteoblasts. The sequential aspect of this
process is highlighted by the distinct zones from the epiphysis to the diaphysis,
these being resting chondrocytes, proliferative chondrocytes, hypertrophic
chondrocytes and the calcified zone and positional cues are important (Caplan,
1983). The changes in chondrocyte behaviour are tightly regulated by both
systemic factors and locally secreted factors, which act on receptors to effect
intracellular signalling and activation of chondrocyte-selective transcription
factors (Mackie, 2008).
Due to its potential to remodel, bone has inherent regenerative capacity and
therefore any animal model must ensure that the defects created are of critical
size and will not heal spontaneously. It is of utmost importance that any
animals used have reached skeletal maturity and that the model should mimic
the clinical situation as closely as possible which is why large animals are
usually used for preclinical studies (Buma, 2004). However, these studies
have high cost implications and the embryonic chick femur can potentially be
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used to bridge the gap between in-vitro and large animal in-vivo studies. The
whole bone organotypic culture has not been widely used but was compared
directly with chorioallantoic membrane culture was shown to grow well in-vitro
(Kachi, 2008) and has been used more recently to investigate the effect of
parathyroid hormone and parathyroid related hormone on bone formation
(Smith, 2012).
The aim of this Chapter is to develop an ex-vivo model of defect bone repair
which can be used to screen a number of delivery devices containing scaffolds,
cells and growth factors to give a higher chance of success in future animal
studies. The preliminary work is to observe the normal growth of the chick
femur and compare it with organotypic growth using histological techniques.
The cultured bones can be fixed, wax embedded, sectioned then stained with
alcian blue which will stain cartilage matrix and picrosirius red stain along with
phosphomolybdic acid as a mordant which will stain collagen highlighting the
ossified areas of the bone and thus the bone development.
The project will then aim to create defects in the embryonic bone and fill them
with BMP-2 growth factor loaded microparticles (MPs) developed in the early
phase of this project. Any effects of the MPs on the tissue will be determined
by histological techniques. This ex-ovo culture method to investigate critical
defect repair is novel and the development of the technique is the subject of
this thesis chapter.
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Figure 5.1 Normal chick development during the gestational period.
Taken from www.cob-vantress.com
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5.2 Materials and Methods
All the laboratory equipment, consumables and chemicals used during the
work for this Chapter can be sourced in Appendix I, tables A1, A2 and A3.
Where MP batch numbers are stated, the details of the manufacturing
parameters can be found in the Appendix II. The reagents for tissue
processing and histological staining are shown in Appendix III
5.2.1 Dissection of embryonic chick femurs
Fertile hen eggs (Henry Stewart, Dekalb white) were placed in a 37oC
humidified incubator on the day of arrival. If incubation needed to be delayed,
the eggs were stored in a fridge set at 10-18oC (any colder would compromise
the viability of the embryos). After incubation (usually 11 days) the embryos
were sacrificed and the femur bones were dissected out by isolating the leg
and carefully rolling on a piece of sterile filter paper to remove the musculature.
Once dissected, the bones were placed in pairs in PBS to keep them hydrated
prior to use. The procedure for dissection out the bones is shown in Figure 5.2
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5.2.2 Creating critical sized defects in the diaphysis and epiphysis
5.2.2.1Wedge defects
A freshly dissected day 11 femur was placed in a Petri dish under a
stereomicroscope and held carefully with fine forceps. A wedge of bone collar
was carefully cut out of the diaphysis using a fine scalpel blade. Images of
these defects are shown in Figure 5.7.
5.2.2.2 Drill defects
A Day 11 femur was placed on a piece of sterile filter paper under a
stereomicroscope and carefully rolled to dry it. Fine forceps were used to
carefully hold the bone in place with minimal pressure, whilst a 300 µm drill bit
was manually used to create a defect by rotating the drill between the fingers
with gentle pressure on the bone to create a hole. The drill bit was then
removed leaving behind the defect. These drill defects were made in both the
diaphysis and epiphysis and images are shown in Figures 5.7 - 5.9.
5.2.2.3 Non-union defects
In order to create a non-union defect model, a freshly dissected day 11 chick
femur was simply cut cleanly with a sharp scalpel blade and the two pieces
were cultured at set distances apart on Millicell inserts. Images of these
defects are shown in Figure 5.10.
1 mm
0.5 mm
0.3 mm
0.1 mm
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5.2.3 Filling the defects with HSA/rhBMP loaded microparticles
5.2.3.1 Defect filling using femtoject injector
The PLGA MPs to be loaded were suspended in a small volume of PBS to
give a concentrated solution (actual mass/volume not recorded). A pulled
glass capillary was attached to the Femtojet injector and the MPs drawn up
under capillary pressure. The capillary was placed in the defect hole in the
bone and the injection was set to deliver in 0.1 seconds under approximately
90 Pa of pressure using the foot pedal.
5.2.3.2 Defect filling using microspatulas
A small dry mass of MPs to be loaded into the defect were used. A bone, with
defect, was dried thoroughly on filter paper and placed under a
steromicroscope with the gentle support of fine forceps. The 100 µm
microspatula was dipped in the MPs and the attached MPs were transferred to
the defect. If necessary, more MPs were added until the hole was filled and a
larger spatula was used to gently tamper down the MPs. This process requires
a moderate degree of technical skill to avoid further damage to the bone by
handling. Generally, diaphyseal defects were easier to fill than epiphyseal
defects due to the harder composition of the diaphysis.
5.2.4 Filling non-union defects with huMSCs in alginate
The alginate was prepared aseptically by dissolving 1.5 g of alginate in 100 ml
PBS and the resulting solution was left under UV light for 30 minutes.
Immortalised hMSCs were added into 1 ml of the aligate solution (1.5×106 per
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ml) and were mixed by gentle trituration. The alginate/cell solution was added
dropwise into a calcium chloride solution (100 mM) to act as a cross linker.
The calcium chloride solution was later replaced with complete culture medium.
Chick bones were isolated as described earlier and cut in middle to form a non
union defect. The alginate/cell construct was placed between two parts. The
bones were cultured organotypically for 10 days (described below) before
being fixed with 4% (w/v) PFA overnight and processed for histology.
5.2.5 Organotypic culture of chick femurs
The femurs, after treatment, were carefully placed onto the membrane of a
Millicell insert which was subsequently placed into the well of a 6 well non
treated tissue culture plate (Kanczler, 2012). 1 ml of alpha minimal essential
medium (ĮMEM) supplemented with penicillin/streptomycin and ascorbic acid
was added into the well underneath the filter. The media must only be
supplemented with ascorbic acid (50µM) just before use and so a small
volume should be prepared as required. The media was carefully removed by
aspiration and replaced with fresh on a daily basis throughout the ten day
culture period in a humified atmosphere at 37oC. This method is advantageous
for non-union defects and for bones where MPs would be likely to disperse if
submerged in media.
5.2.6 Tissue processing, embedding and sectioning
After the ten day culture period, the bones were carefully removed from the
Millicell insert and if necessary, imaged. The bones were transferred to
labelled wax embedding cassettes. An automated tissue processor was used
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to dehydrate and infiltrate the samples in wax. Details of the reagents and
incubation times used are in Appendix III.
On completion of the program, the cassettes were transferred to a wax
embedder and the sample orientated in the desired plane before embedding in
wax. Sections (10 µm) were cut using a Microtome, stretched on a water bath
at 60oC and mounted on Superfrost plus microscope slides which were
dried on a hot plate at 50oC overnight.
5.2.7 Histology staining: picrosirius red and alcian blue
The sections were first de-waxed in histoclear and rehydrated through a series
of increasing ethanol concentrations. Cell nuclei were stained with Weigerts
haematoxylin and following treatment with acid/alcohol to reduce the pH, the
sections were stained with alcian blue to stain the cartilagenous matrix. After
thorough washing in tap water the slides were treated with phosphomolybdic
acid followed by picrosirius red to stain collagen deposition. Finally the sides
were dehydrated through a series of decreasing ethanol concentrations and
coverslips applied with DPX mounting medium. After drying, the slides were
imaged using brightfield microscopy. The details for the preparation of the
reagents and the ethanol concentration used are shown in Appendix III
5.3 Results and Discussion
5.3.1 Normal chick femur growth
The gestation period of a chick is 21 days and the rate of skeletal
development beyond eight days is remarkably rapid. In order to recreate an
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ex-vivo developmental niche for the study of bone growth and development
and repair it was important to standardise the in-ovo incubation time. Figure
5.3 is an image of a chick embryo at 12 days of incubation showing how
advanced the development is with the legs and wings clearly formed.
Figure 5.3 A close-up image of a chick embryo after 12 days of in-ovo
incubation at 37oC.
Taken from http://php.med.unsw.edu.au/embryology
To investigate the natural growth rate of the chick femur during
embryogenesis, eggs were removed from incubation daily from day 8 to day
15 and the femurs were carefully dissected from the embryo. After imaging,
they were processed in preparation for histological analysis and stained with
picro-sirius red and alcian blue to highlight the osteogenic and chondrogenic
areas within the bone.
Chapter 5
208
Figure 5.4 shows the scale of growth and thickening of these bones over this
development period by endochondral ossification. At day 8 they are very
fragile and approximately 3 mm in length. By day 15, they are approaching 10
mm in length and much stronger. Dissection from the surrounding musculature
was more difficult. The increasing vascularisation during development can be
seen by the reddening of the diaphysis over time.
Figure 5.5 shows sections of these bones after picro-sirius red/alcian blue
staining. The process of the conversion of cartilage to bone by endochondral
ossification is described in more detail Section 1.3 of Chapter 1. Briefly,
primary ossification occurs in the diaphysis and bone collar forms followed by
cavity formation and vascularisation. As blood vessels, osteoclasts, and
osteocytes continue to invade, the medullary cavity is formed and the
diaphysis continues to lengthen during embryonic development. The histology
shown in Figure 5.5 confirms the progression of this process and the efficacy
of the staining procedure. The day eight femur was practically all cartilage and
consequently stained blue. By day ten, primary ossification had begun in the
diaphysis and was shown by the picro-sirius red staining. As time progressed,
the picro-sirius red staining became more extensive and progressed towards
the epiphysis. By day fifteen, only the epiphysis was still cartilaginous and the
diaphysis had a recognised cancellous bone structure. If bones had been
dissected at later gestation times, secondary ossification centres in the
epiphysis would have completed the transformation of cartilage to bone
leaving just articular cartilage at epiphyseal plates to allow to continued growth
of the bird after hatching.
Chapter 5
209
This work on using the developing chick femur as a model to research bone
repair and regeneration is of a collaborative nature with a number of other
groups working on different aspects of the model. It was important to
standardise the in-ovo incubation and it was agreed that day 11 would be
suitable for the majority of studies. The relatively the early stage of
endochondral ossification gives optimum opportunity and scope to i) re-create
the natural in-ovo development outside the egg by culturing the bones, ii) alter
the natural development by looking at the effects of rhBMP-2 and iii) use the
bone as a model for critical defect repair.
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5.3.2 Chick femur growth during organotypic culture
The chick femurs dissected from the day 11 embryos were in most cases
treated in pairs. For example, either one femur would be treated with growth
factor releasing MPs whilst the other would be treated with blank MPs and
then they would be both cultured organotypically, or one femur would be fixed
whilst its pair would be cultured.
To demonstrate the growth of the embryonic bones in tissue culture, one
femur was fixed in 4%(w/v) paraformaldehyde immediately after dissection
whilst its pair was cultured for 10 days on a Millicell insert with daily changes
of culture medium supplemented with ascorbic acid. Figure 5.6A shows the
extent of the bone growth over the ten day period. The non-cultured femur
was approximately 6 mm in length whilst the cultured paired femur was
approximately 10 mm in length. Although this is significant growth, it is more
like the in-ovo growth seen from day 11 to day 14 rather than mimicking the
gestation as the chick would normally hatch on day 21. However, this growth
in culture gives a good opportunity and scope to study the developmental
process. Day 11 chick femurs were also cultured submerged in the media
throughout the 10 day culture period. These femurs also grew well (data not
shown) but this method was not preferred as any addition of MPs to the
exterior surfaces of the bones would be lost in the media.
A potential drawback with this work is the delicate nature of the bones and
very careful handling that is needed to avoid damage to the bone. Figure 5.6B
shows another pair of femurs, again, one was fixed upon dissection and the
other was cultured. It is clear that the bone in culture has not grown normally
in-vitro. The diaphysis looks narrower and the epiphyses appear bigger than
expected. This was probably the result of mishandling the bone whilst setting
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up the culture thus disturbing the normal growth processes. The manual
dexterity required to handle the bones is a procedure which improved with
practice. But, it is very important that anomalies in bone morphology that may
have been caused by handling are not mistaken for a response caused by
experimentation with growth factors.
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5.3.3 Critical sized defects in chick femur
The aim was to use the embryonic chick femur as a model to investigate the
potential of BMP-2 loaded MPs to influence the surrounding developing tissue.
MPs could be either injected directly into the femur in a minimally invasive
manner, or defects could be made and the MPs used to fill them. The latter
seemed a more appropriate method to research the regeneration and repair.
There is no literature available on the use of chick femur defects and a
number of different techniques were attempted.
5.3.3.1Wedge defects
Before the ability of growth factor loaded MPs to affect bone repair could be
tested, reproducible critical sized defects in the bone needed to be established.
The first attempt was, under a stereomicroscope, to use a fine scalpel blade to
cut a wedge out of the diaphysis. Two different methods were attempted,
firstly, to take out and remove a completely diaphyseal wedge (Figure 5.7A)
and secondly, to cut a wedge but leave some of the bone collar intact (Figure
5.7B). The reason for this was to potentially use the flap of bone collar to hold
the MPs in place after administration. The difficulty in using this method as a
model was the inability to cut reproducible wedges as well as the damage
caused by forceps whilst handling the bone. Despite handling the bones
becoming less damaging with practice, it was decided not to use a scalpel to
make the defect as the size and shape could not be guaranteed from bone to
bone.
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5.3.3.2 Drill defects
The wedge defect model was not chosen for study due to the size and shape
of the defect not being reproducible. Precision micron sized drills were
sourced and used to manually create holes in the bones. The advantage to
the drill was that the diameter of the hole would always be the same and with
careful rotation of the drill, the material inside the hole could be removed. This
was a very skilful process requiring dexterity to create defects without causing
further damage to the bone. Unpublished work (Hassan Rashidi) showed that
the chick femur could self heal defects under 200 micron in size whereas a
300 micron defect did not repair over the ten day culture period.
The 300 micron drill bit was therefore used as the standard to create the
defects for use in bone repair studies. Figure 5.8 shows the drill being used on
a day 11 femur. The precision of this drill meant that if required, multiple
defects could be made on a single femur. Figure 5.9 shows a drilled
diaphyseal defect and picro-sirius red/alcian blue staining after ten days of
organotypic culture post defect of the same femur. An intact femur is shown
for comparison and the staining clearly shows the extent of the ossification at
this level of development. It is clear that the defect has not healed. Instead, it
seems that the cells of the bone collar may have migrated into the defect to
form a thin layer of bone inside sealing off the defect. This observation was
not seen in all defects created during the course of this work but possible
migration of cells during the creation of the defect and during tissue culture will
be discussed later.
The advantage of using the drill was that defects could also be created in the
epiphyses. This chondrogenic area of the bone could play a key role in the
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study of rhBMP-2 release especially if the cells could be driven prematurely
down an osteogenic path by the action of released rhBMP-2. The problem
with creating epiphyseal defects was that the tissue is very soft and it was i)
easy to cause unintentional damage and ii) difficult to see the defect once it
had been created due to the tissue appearing to fill back into the hole. A
successful epiphyseal defect is shown in Figure 5.10. The bone was carefully
blotted dry to aid visualisation of the defect. The histology shown in Figure
5.10D is not of the same bone but representative slide. Good histological
sections of the epiphyseal defect were not often easy to achieve mainly due to
the orientation of the bone embedded in the wax. The section shown in Figure
5.10D still appears to have some tissue in the defect but it has not stained.
The epiphysis has a number of different zones where cells are in different
stages of development. Some are in a resting phase whilst some are
proliferative. It was not possible to accurately predict when the defect was
made what cell types were being disturbed which may have led to some of the
biological variability in the model.
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5.3.3.3 Non-union defects
Fractures that do not heal over several months are described as non-union.
There can be a number of causes such as excessive motion at the fracture
site, invasion of muscular tissue, too much distance between the fractured
ends, infection, inadequate blood supply or bone diseases. Although the drill
defects mentioned earlier would go some way to modelling this, bones were
cut and cultured apart to more closely model non-union.
Figure 5.11 shows that the femur has little capacity to re-grow in culture over
ten days when the two ends were set at over 1 mm apart. This is confirmed by
the Alcian blue/picro-sirius red staining of the sections shown in Figure 5.12.
The histology confirms the clean cut across the diaphysis with no discernable
growth of the bone within the diaphysis. However, at 1 mm apart there may be
evidence of some growth into the gap in one bone over ten days as shown by
the light images in Figure 5.11 but unfortunately, the sectioning and staining of
this femur was not successful. Despite little or no growth along the diaphysis,
the epiphyses of the cut bones seemed to have continued to grow normally
over the culture period.
Cutting the bone further along the diaphysis where there were more likely to
be proliferating cells may have provided a different result regarding grow-back,
but using the diaphysis cut in the middle potentially provided a good model to
model the non-union fracture. Strategies for bridging the gap between the two
pieces of bone will be discussed later (Section 5.3.4.3).
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Figure 5.11: Non union defect model at [A] day 1 and [B] day 10 of
organotypic culture. Bones were cleanly cut and placed on the membrane
apart. The single femur highlighted in a circle shows some evidence of bone
re-growth
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5.3.4 Filling the defects with microparticles
Once sufficient a defect had been created, the challenge was to fill it with
rhBMP-2 loaded MPs. An micro-injector system was available for use as well
as microspatulas. Both methods were assessed in the performance of these
studies.
5.3.4.1 Injection method
The Femtojet injector had been used in a separate project to deposit growth
factor loaded MPs into the developing chick femur to cause minimal damage
to the surrounding tissue. In this case, fine pulled capillaries often used in
embryology and in-vitro fertilisation techniques, were used for injection. This
injection technique was adapted by using a wider bore capillary to fill the
femoral defects and non growth factor loaded PLGA MPs were used for
preliminary studies.
Two problems became apparent with using the injector. The MPs had to be
administrated in solution (PBS) and this was loaded by capillary action. Quite
often, too few MPs were taken up into the capillary with the PBS being
preferably loaded. Once sufficient MPs had been loaded (visually judged, no
quantification) they were ejected into the defect. The problems were that in
some cases, surface tension caused the volume injected to remain on the
surface of the bone with few MPs entering the defect (Figure 5.13A) and in
other cases, the injected MPs spilled out of the defect completely (Figure
5.13B). It was thought that the reason for these problems was the force of the
injection and the fact that no surrounding tissue was holding the MPs in place
which would not be the case if a minimally invasive injection technique was
being used. Being able to successfully administer MPs into the defect,
preferably a know
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5.3.4.2 Microspatula method
The issues surrounding the injection method of MP administration prompted
the use of microspatulas to fill the day 11 chick femoral defects. The first
attempts to apply a thick paste of MPs in a small volume of PBS to diaphyseal
and epiphyseal defects showed limited success. Figure 5.14A is a
stereomicroscope image showing a pair of femurs after 0 and 10 days of
culture with blank MPs administrated by spatula. The MPs are in the defect
and on the surface of the bone but not localised enough to warrant good
delivery of growth factors.
To improve the administration technique, dry MPs were used. It was
discovered that dry MPs would adhere to a 100 micron spatula. The bone and
defect area were thoroughly dried by rolling on filter paper and the MPs on the
spatula were transferred to the defect. Remaining moisture within the defect
would attract the MPs into the defect and this was a much more effective way
of filling the defect. Figure 5.14B shows a close-up light microscope image of
MPs successfully transferred into the diaphyseal defect.
Once the methods to create and fill critical sized defects in day 11 chick
embryonic femurs had been established, they could be applied to growth
factor loaded MPs and any effects on bone repair established through
morphology changes and histology.
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Figure 5.14 Microparticles applied to the bone defects by microspatula. [A]
shows the microparticles applied as a paste to a pair of femurs. One was
cultured for 10 days. Grid is 2 mm [B] shows an improved method using dry
microparticles to localise them in the defect. Circle shows area of defect.
BN 332
300 µm
1 mm
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Using hexane rather than the more commonly used xylene in the preparation
of the femurs for sectioning meant that PLGA MPs in the main, could survive
the tissue processing without being dissolved and therefore could be
visualised within the defects after sectioning.
A good level of filling in diaphyseal defects using the microspatula was usually
observed although results could be quite variable. Figure 5.15 shows multiple
cross sections up through a drill defect. The images A to D depict the bottom
to the top of the defect. The defect does appear to enlarge as the surface is
approached. This may be due to the drill not being removed cleanly from the
hole or what seems to be the case in Figure 5.15D, the section was taken very
near to the bone surface (hence the very thick bone collar) and MPs were
dispersed on the surface.
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Figure 5.15 Cross sections through drill defect filled with blank PLGA
microparticles using a micrspatula showing the presence of microparticle
throughout the defect. [A] is the base of the defect with [B], [C] and [D]
showing sections toward the surface of the defect. Scale bar 100 µm
BN 332
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5.3.4.3 Filling the non-union defect
Bridging the gap in the non-union defect model is difficult to do due to there
being nothing to hold the MPs in place during organotypic culture. A
combination of growth factor loaded MPs with the temperature sensitive
(PLGA/PEG400) MPs presented as being a solution to the problem but
preliminary studies were not successful. Although work was not continued with
this model in combination with temperature sensitive scaffolds, there is much
scope for future work potentially with pre-formed scaffolds containing
mesenchymal stem cells and growth factors made specifically with dimensions
to bridge the two cut bones.
Another strategy to bridge the gap was performed by a Dr Hassan Rashidi
who kindly permitted the use of some of his results. An alginate gel was
prepared and seeded with immortalised human mesenchymal stem cells
(MSC) (as used for rhBMP-2 detection studies in Chapter 4). The alginate was
used as an inert component to hold the cells in place between the two bone
pieces so that any response was due to the cells. Figure 5.16A shows the gel
containing MSCs in contact with both ends of the bone despite leakage of the
gel from the site. The bone was cultured on a Millicell insert for the standard
10 days and prepared for alcian blue/picrosirius red staining which is shown in
Figure 5.16B.
This result showed the MSCs still in place around the ends of the bone and
there appears to be a layer of bone formed at the edge of the cut on both
sides of the bone. If this micrograph is compared to those in Figure 5.12 then
the difference becomes clear. The cells may therefore be playing a positive
role on bone growth.
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5.3.5 Potential pitfalls in histological analysis
Artefacts can be commonplace in histological images and as such they must
always be viewed with caution and interpreted carefully. The embedding of
these small bones into wax was often problematic and ensuring a level plane
was difficult. The chick femurs are not a simple uniform shape, the condyles
protrude at each end of the bone and the angle at which they are sectioned
can give different, sometimes anomalous results. Figure 5.17 attempts to
depict the issues faced with sectioning with just a simple tube shape. If
identical sections are taken from identical shapes, the results can be
drastically different from each other simply because of the orientation of the
shapes. For the femurs often horizontal sections would make the epiphysis
appear detached from the diaphysis simply because they were not on the
horizontal plane. Another issue to be wary of was thickened bone collars due
to near surface sectioning. It is important to take many sections from one bone,
thoroughly inspect the sections and draw conclusions carefully.
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Vertical Slice Horizontal Slice
Figure 5.17 Representation shwing how identical shapes can give different
results due to their orientation when being sectioned in exactly the same way
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5.3.6 Effect of HSA/rhBMP-2 loaded microparticles on chick femur
growth and repair
After 11 days of incubation, primary ossification was well underway in the
embryonic chick femur and the diaphysis had a mineralised bony structure.
Once the technique was optimised, filling diaphyseal defects was relatively
easy due to the hole having a structure that could support the MPs. Figure
5.18 shows both blank MPS (Figure 5.18A) and MPs loaded with HSA/rhBMP-
2 (Figure 5.18B) successfully loaded into diaphyseal defects. The sections are
at an approximate 90 degree different plane to the sections shown in Figure
5.17. In this case the defect is cut through vertically rather than horizontally.
In both examples in Figure 5.18, the defect is clearly defined, the MPs are
visible and the defect is completely filled albeit with some overspill at the bone
surface. In both examples, the tissue surrounding the defect is not necrotic
and indeed in some places, the MPs appear integrated with the tissue.
However, there does not appear to be any discernable effect of the rhBMP-2
released from the MPs on the tissue, the two micrographs look very similar.
This is not a surprising result as although rhBMP-2 is a potent inducer of
osteogenesis, the diaphysis has already undegone the ossification process.
These diaphyseal studies provide proof of concept that PLGA MPs can be
used to fill a critical sized defect. It may be possible to deliver MPs loaded with
potent chondrogenic growth factors into these diaphyseal defets to see a
response. It is more sensible to deliver rhBMP-2 MPs to the epiphyseal
regions of the bone to determine an osteogenic effect
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Although the epiphyseal defects were more likely to show effects caused by
rhBMP-2, they were more difficult to create and fill. This was due to their
cartilaginous nature, making it difficult to microscopically manipulate the
spatula containing the MPs into the defect without causing further damage.
Figure 5.19A shows a vertical section through an epiphyseal defect loaded
with blank PLGA MPs. Only a few MPs are visible (highlighted by arrows) but
the outline of the defect is clear. Despite a faint red staining, around the edge
of the defect, there is no apparent effect of the MPs. It is feasible that the red
staining may be due to osteogenic cells from the thin bone collar being pushed
into the defect by the drill. On many control slides of blank MPs, there was
evidence of positive picrosirius red staining (collagen) either surrounding the
defect or at the base of the defect. However, the effects were generally very
weak when compared to the rhBMP-2 positive MPs.
Figure 5.19B shows a vertical section through an epiphyseal defect loaded
with rhBMP-2 MPs. This was the first of a few very interesting results. Despite
the defect not being clearly defined, there was a distinct increase in picrosirius
red staining around the rhBMP-2 MPs that were clearly visible and artefacts in
sectioning were ruled out. The morphology changes of the chondrocytes at the
base of the defect may have been an indicator of tissue damage or more likely
a response to the released rhBMP-2 as similar morphological changes can be
seen in the surrounding chondrocytes in Figure 5.20.
By carrying out repeats tests on a number of femurs it became credible that
the rhBMP-2 entrapped with the PLGA MPs was releasing after administration
to the defect and the the released rhBMP-2 was affecting the surrounding
chondrocytes encouraging them to begin to express collagen. It must be
mentioned that not all femurs gave positive results but the issues mainly
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surrounded problems with embedding, sectioning and visualising the defects
and MPs adequately, especially after the difficulties in loading he MPs into the
defects.
Figure 5.20 gave the clearest indication of these MPs affecting the
surrounding tissue. The image shows a horizontal section through an
epiphyseal defect and quite clearly there was an affect of the MPs on the local
tissue. This was exceedingly encouraging to see the PLGA MPs re-directing
the differentiation of the surrounding cells. The alcian blue/picrosirius red
staining is a clear indicator of chondrogenic and osteogenic areas in the bone
but for further evidence of the effect of the MPs immunostaining would be a
useful tool. This will be discussed in Chapter 6 under future work.
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Figure 5.20 The epiphyseal region of an 11 day ex-ovo chick femur following
10 days of organotypic culture in basal media. A 300 µm drill defect was made
prior to culture and filled with rhBMP-2 loaded PLGA microparticles (1% (w/w)
total loading 9.5 mg HSA/0.5 mg rhBMP-2). Femurs were processed and
stained with alcian blue (glycosaminoglycans in cartilage) and picrosirius red
(collagen in bone). Position of microparticles highlighted through cross section
of defect are highlighted ( ) showing localised picrosirius red staining around
the microparticles.
BN 337
100 µm
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5.4 Conclusions
The developing chick embryo has been used as an ex-vivo model to
investigate the effects of rhBMP-2 loaded MPs on the repair of bone. The rate
of osteogenesis within the chick femur is relatively quick with the total
gestational period being 21 days. Choosing the mid-point of day 11 gave
femurs undergoing primary ossification and was optimal for studies with MPs.
As with many ex-vivo biological systems, this model had issues with variability
from study to study but these could be improved through training and practice
to improve the level of skill required.
Defects in the bones could be reproducibly made using a micro-drill bit, but
filling the defects could only be successfully achieved using micro-spatulas as
micro-injection techniques proved unsuccessful. For non-union defects, the
rhBMP-2 loaded MPs could be delivered in an alginate gel. However, the
diffusion rate of the rhBMP-2 into alginate is unknown and work to investigate
the release into the alginate would have to be performed. Preliminary work
with immortalised mesenchymal stem cells showed the potential of using the
alginate gel as a scaffold and there may be further potential to use the
PLGA/PEG thermosensitive scaffold to bridge the gap.
Importantly, the same batches of HSA/rhBMP-2 MPs that were used in in-vitro
assays of early osteogenesis (Chapter 4) were also used for the investigations
into bone repair (BN 331 and BN 337).
The data in this Chapter showed that these MPs could be loaded into a critical
sized defect and exerted an osteogenic effect on the cartilage rich areas of the
bone. These results were encouraging and give confidence that these MPs
could be used in other models of bone development (e.g. direct injection of
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MPs into the epiphysis with minimal damage to surrounding tissue) and
indeed some positive data has been produced (Rashidi, unpublished).
Now the protocols for MPs production and tailoring of release profiles are in
place, the future work would be to produce MPs with different growth factors
and establish whether synergistic effects of growth factors on bone repair are
possible. Eventually these biodegradable MPs could be candidates as bone
void fillers in large animal critically sized defect studies.
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Chapter 6: Summary and future direction
The work in this thesis was performed to begin to address some of the
limitations currently preventing optimal performance of protein therapies, by
combining tissue engineering strategies for designing biocompatible scaffolds
with drug delivery strategies for localised growth factor release. The project
was focussed on therapies relating to bone repair applications but could be
applied to other areas of regenerative medicine.
The aim was to develop a microparticulate system to achieve localised
delivery of biologically active proteins with control over their rate of release in
a three dimensional structure. The ideal biomaterial needed to meet a range of
requirements that included being biodegradable, osteoconductive, integrative,
mechanically compatible with native bone and ideally osteoinductive. The
synthetic polymer PLGA was the chosen as the biomaterial for use as it has
been used extensively for research into controlled release as it can be tailored
to degrade at different rates and it has a good track record for safety. The
versatility of PLGA allows the fabrication of devices with a wide range of
mechanical, degradation and drug release properties.
In Chapter 2, the emulsion techniques cited in the literature for microparticle
manufacture were developed and improved to enable the reproducible
manufacture of PLGA microparticles loaded with the model protein lysozyme.
The water-in-oil-in water technique was the preferred method over the solid-in-
oil-in-water technique due to the superior entrapment efficiency results
achieved. The higher the entrapment efficiency meant there was less wastage
of the bioactive molecule during the manufacture process leading to a
commercially more cost effective product.
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The use of a homogeniser with control at low speeds, meant batches of PLGA
microparticles could be reproducibly made in distinct size ranges within 1 to
100 µm and so had the versatility for different potential applications. The
microparticle manufacture technique was thoroughly interrogated to
understand the impact of the variables within the emulsion technique on size,
morphology and entrapment efficiency.
Entrapment efficiency was directly proportional to microparticle size. Values of
over 50% were usually achieved for microparticles over 10 µm in size up to 90%
for microparticles sized around 100 µm. Entrapment efficiency was inversely
proportional to total protein loading and a 1% (w/w) total loading was chosen as
optimal. Human serum albumin was use as a bulk carrier protein to potentially
protect the lysozyme from the water-oil interface and to allow the level of
lysozyme to be altered within a constant total protein loading.
The degradation rate of PLGA with was investigated by measuring its pH and
mass loss over time as well as the long term effect on the morphology of the
microparticles. The findings agreed with published work and showed that
PLGA 85 15 degraded slower than PLGA 50 50 and the degradation rate was
temperature sensitive.
Chapter 3 concerned controlling the rate of protein release from PLGA
microparticles by the addition of a PLGA-PEG-PLGA triblock copolymer at the
point of microparticle manufacture. The triblock copolymer acted as a
plasticiser and changed the viscoelastic properties of PLGA by reducing the
glass transition temperature which in turn affected the release rate of the
entrapped protein.
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The hydrophilic nature of the PLG-PEG-PLGA copolymer increased water
ingress into the PLGA microparticles and increased the hydrolytic degradation,
allowing the entrapped protein to be released in a gradual manner, thus
overcoming the lag phase normally associated with release from PLGA
delivery systems. The higher concentrations of the copolymer accelerated the
protein release over and above the rate of polymer degradation leaving a
three dimensional structure in place to support ongoing tissue growth. The
mechanical properties of the scaffold could be improved by using
thermosensitive PLGA microparticles plasticised with low molecular weight
PEG which form bridging points between the microparticles that harden as the
PEG leaches away.
The model protein used was lysozyme as its biological activity could be
detected by its action on the bacterial cell wall of Micrococcus lysodeikticus.
Positive lysozyme activity in the release supernatants indicated that the
protein had retained its conformation throughout the manufacture of the
microparticles and after subsequent release. The correlation between
released lysozyme and its activity was improved when the lysozyme was
directly melt blended into plasticised PLGA microparticles.
Once the optimisation assays were complete, the technology was transferred
to the growth factor rhBMP-2 and a single polymer formulation (PLGA 50 50
with 10% (w/w) triblock copolymer) and microparticle size (20-30 µm) was
chosen to give a sustained release over a one month period. If these
microparticles were mixed with thermosensitive PLGA/PEG microparticles,
then an in-situ scaffold could be formed to localise the release. The formation
of the scaffold, immobilised the microparticles, prevented unwanted migration
and slowed the release of rhBMP-2.
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Cumulative release curves based on total protein were used to predict the
expected level of rhBMP-2 in the release supernatants. The expression of
alkaline phosphatase in C2C12 myoblast cells was used as a tool to detect
rhBMP-2 activity in the release supernatants. However, the assay was not
sensitive enough to detect the rhBMP-2 in the samples.
An alternative was to co-culture C2C12 cells directly with HSA/rhBMP-2
loaded microparticles and detect the effect of released rhBMP2 on the
morphology and ALP expression of the cells. The response was directly
proportional to microparticle mass. In addition, the response could still be
detected by microparticles that had pre-released a proportion of rhBMP-2 prior
to testing against C2C12 cells. This showed that the release of active rhBMP-
2 was sustained for over 12 days. The same rhBMP-2 loaded microparticles
also caused deposition of calcium by murine primary calvarial cells after 21
days of culture as determined by von Kossa staining. These results gave
confidence that the released rhBMP-2 had retained its structure and remained
active after release from the microparticles.
Finally, the rhBMP-2 loaded microparticles were used in an ex-vivo study of
bone repair using the chick embryonic femur as the model. The femurs were
dissected at day 11 of gestation and grown organotypically for 10 days in-vitro.
Once normal growth was established, defects were made in the bones and
filled with rhBMP-2 loaded microparticles. The effect of the microparticles was
determined by histological analysis. The microparticles caused the
chondrogenic cells of the epiphysis to stain positive for collagen which was an
indication that the cells were being driven locally through ossification and that
the microparticles were having a biological effect on the tissue.
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The work presented in this thesis has laid down the technology for further
research into the effect of a range of different growth factors. The immediate
future work to confirm the results of the histological staining would be to
perform immunostaining on the sections for collagen I. In-situ hybridisation
techniques could be performed to determine the success of the cell signalling
and gene transcription within the cells.
Different polymer formulations could be selected to manufacture
microparticles with different release characteristics for delivery of growth
factors with different kinetics. A similar progression of research could be
performed for each key growth factor until a specially formulated cocktail of
microparticles could be delivered in a large animal critical sized femoral defect
model for optimal tissue repair. The addition of thermosensitive microparticles
would localise the microparticles and give mechanical support to the structure.
Sterilisation of the material is an important factor in the development of a new
medical device. There are a number of sterilisation techniques including
gamma, electron beam and ultraviolet irradiation as well as ethylene oxide
treatment and these may affect the material especially with regard to chain
scission and a reduction in molecular weight. Studies to understand the
change in material characterstics and and effect on release profiles would
need to be performed post sterilisation prior to the material entering in-vivo
studies.
The techniques developed during the course of work for this thesis would
enable the fabrication of growth factor loaded microparticles that could be
applied to a range of regenerative medicine applications and are an exciting
tool to have in the Tissue Engineers tool box.
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Appendix I: Equipment, consumables and materials
The equipment, consumables and materials used to perform all of the studies
described in this thesis are detailed in Tables A1 (equipment), A2
(consumables) and A3 (chemicals/reagents) along with manufacturer, model
number, supplier and primary use.
Table A1 Laboratory equipment inventory
Equipment
Manufacturer/
Model Number
Supplier Use
3D rocker Gyrotwister
Fisher Scientific UK,
Ltd
Release assay
Automatic tissue
processor
Leica TP1020
Leica Microsystems
(UK) Ltd
Tissue prep
Balance
Mettler Toledo
AB-5
Fisher Scientific UK,
Ltd
General
Centrifuge
MSE
Mistral 1000
Scientific Laboratory
Supplies Ltd
General
Centrifuge Sigma 2-16K
Scientific Laboratory
Supplies Ltd
Cell culture
Safety cabinet Class II Biomat 2
Thermo Electron
Corporation
Cell culture
Freeze drier Edwards Modulyo D IMA Edwards, UK
MP
Preparation
Freezer
LabCold Fisher Scientific UK,
Ltd
Storage
Fume hood
Mach-Aire Classic
FC
Mach-Aire Ltd
MP
Preparation
GPC PL-GPC-120 Polymer labs MP Mwt
High shear mixer Silverson L5M
Silverson machines,
UK
MP
Preparation
Hotplate
Yellow line MST
Basic C
Fisher Scientific UK,
Ltd
General
Incubator Sanyo MCO-17A1C
Scientific Laboratory
Supplies Ltd
Cell culture
Injector Eppendorf Femtojet VWR International Defect filling
Magnetic stirrer -
multiway
Variomag
Thermo Scientific,
Uk
MP
preparation
Magnetic stirrer -
single
IKA Big squid
Fisher Scientific UK,
Ltd
General
Microcentrifuge
Spectrafuge 24D
Labnet Inc
Scientific Laboratory
Supplies Ltd
Release assay
Microscope Nikon EclipseTS100 Nikon Imaging cells
Microtome Leica RM2165
Leica Microsystems
(UK) Ltd
Sectioning
Mill Krups 75 Amazon.co.uk
MP
preparation
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Equipment
Manufacturer/
Model Number
Supplier Use
Orbital shaker IKA MTS 4
Scientific Laboratory
Supplies Ltd
General
Oven Binder
Scientific Laboratory
Supplies Ltd
General
Particle sizer Coulter LS230 Beckman Coulter,UK MP sizing
pH meter
Mettle Toledo
Seven easy
Scientific Laboratory
Supplies Ltd
pH readings
Plate reader Tecan Infinate M200 Tecan UK Ltd, UK Assay reading
Refrigerator LabCold
Fisher Scientific UK,
Ltd
Storage
Refrigerator for eggs Liebherr Profiline Leibherr GB Ltd Eggs storage
Rheometer Physica MCR 301 Anton Paar, UK
Tg
determination
Scanning electron
microscope
JSM 6060LV Jeol, UK MP imaging
Sputter coater SCD 030
Balzars,
Lichtenstein
MP gold
coating
Steromicroscope Leica M216F
Leica Microsystems
(UK) Ltd
Bone imaging
Camera Qimaging Q17837
Vacuum packer Orvid VM03
Scientific Laboratory
Supplies Ltd
General
Vacuum pump
Charles Austin
B100 SEC
Scientific Laboratory
Supplies Ltd
General
Vortex mixer Stuart Scientific SA8
Scientific Laboratory
Supplies Ltd
General
Wax embedder Leica EG1160
Leica Microsystems
(UK) Ltd
Embedding
Woven mesh sieves 100, 200 micron
Scientific Laboratory
Supplies Ltd
Sieving
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Table A2 Consumables inventory
Consumables
Specification/
Catalogue Number
Supplier Use
Beakers 20 -500 ml
Fisher Scientific
UK, Ltd, UK
General
Bijou bottles (7 ml) CON 7524
Scientific
Laboratory
Supplies Ltd
General
Centrifuge tubes
(15/50 ml)
15 ml 188261
50 ml 227270
Greiner Bio One
Release
assays
Filter paper (Grade 1) Z240095
Scientific
Laboratory
Supplies Ltd
Femur
dissection
Filter units (0.2 µm) FIL6570
Scientific
Laboratory
Supplies Ltd
MP
preparation
Fine forceps Dumont Size 5
Scientific
Laboratory
Supplies Ltd
Femur
dissection
Glass followers (50 mm) FB55626
Fisher Scientific
UK, Ltd, UK
MP
preparation
Glass scintillation vials VGA-050-300P
Fisher Scientific
UK, Ltd, UK
MP
preparation
Laboratory blue roll CMC 790-011L
Fisher Scientific
UK, Ltd, UK
General/MP
prep
Micro drill bit (300 µm) Guhring 300 µm Cromwell Femur defect
Micro spatulas (0.1-1
mm)
FB70365
Fisher Scientific
UK, Ltd, UK
Filling defect
Microcentrifuge tubes
(1.6 ml)
72.690 Sarstedt Ltd
Release
assays
Millicell inserts
Millipore
FDR-541-020X
Fisher Scientific
UK, Ltd, UK
Femur culture
Multichannel pipette
(20-200 µl)
F14401
Scientific
Laboratory
Supplies Ltd
BCA assays
Parafilm SEL0400030P
Fisher Scientific
UK, Ltd, UK
General
Pasettes (3 ml) FB55348
Scientific
Laboratory
Supplies Ltd
Release
assays
Pipette filler FB69000
Fisher Scientific
UK, Ltd, UK
General
Pipette tips (all sizes) FR1200/1250/1015 Alpha Laboratories General
Pipettes (20-200, 100-
1000 µl)
S1122-18301/8810C Starlab (UK) Ltd General
Pipettes glass (5 ml) 12314388
Fisher Scientific
UK, Ltd, UK
DCM pipetting
Pipettes plastic (5, 10
ml)
TVK-671-
040Q/050N
Fisher Scientific
UK, Ltd, UK
General
PTFE scaffold moulds
Mechanical engineering unit. University of
Nottingham
Scaffold
preparation
PTFE screw cap jar FB58832
Fisher Scientific
UK, Ltd, UK
MP
preparation
PTFE sheet Bako-glide Amazon UK
MP
preparation
Pulled capillaries
Supplied by Human Development Unit.
University of Nottingham
Micro-injection
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Consumables
Specification/
Catalogue Number
Supplier Use
Scalpel SCA-310-150A
Fisher Scientific
UK, Ltd, UK
Chick
dissection
Sealable bags BAG 1018/20/26/28
Scientific
Laboratory
Supplies Ltd
General
storage
Syringes SZR 150-041H
Fisher Scientific
UK, Ltd, UK
General
Tissue culture flasks Nunc178905/178883
Fisher Scientific
UK, Ltd, UK
Cell culture
Tissue culture plates Nunc 96/24/6 well
Fisher Scientific
UK, Ltd, UK
Cell assays
Wax embedding
cassettes and base
moulds
380308E  base
14039441100 -
cassette
Leica
Microsystems
Wax
embedding
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Table A3 Chemical/reagents inventory
Chemical/ Reagent
Specification/
Catalogue Number
Supplier Use
Acetone A/0560/17
Fisher Scientific
UK, Ltd, UK
General
Alcian blue 8G 400460100 Acros Organics Staining
Alpha MEM BE12-169F
Sigma-Aldrich,
UK
Femur culture
Antibiotic antimycotic
solution
A5955  100 ml
Sigma-Aldrich,
UK
Cell culture
Ascorbic acid A4403
Sigma-Aldrich,
UK
Femur culture
Bicinchoninic assay kit Pierce 23235
Fisher Scientific
UK, Ltd, UK
Protein assay
BMP-2 ELISA kit DBP-200
R and D Systems
Europe Ltd, UK
BMP-2
detection
rhBMP-2
Professor Walter Sebald (University of
Wurzburg, Germany
Growth factor
Collagenase type 1A C5894
Sigma-Aldrich,
UK
mPCC
isolation
Dichloromethane D/1856/17
Fisher Scientific
UK, Ltd, UK
MP preparation
Dimethylsulphoxide D-5879
Sigma-Aldrich,
UK
Protein assay
Distilled water In-house supply General
DL Lactide 9026
Lancaster
Synthesis
TB Preparation
DMEM VX42430025
Sigma-Aldrich,
UK
Cell culture
DPX mountant D/5319/05
Fisher Scientific
UK, Ltd, UK
Slide
preparation
Ethanol E/0650DF/17
Fisher Scientific
UK, Ltd, UK
Histology
FCS Cell culture
Fertile eggs Dekalb White
Henry Stewart
(Medegg)
Embryo
development
L-Glutamine G7513
Sigma-Aldrich,
UK
mPCC
isolation
Glycolide Purasorb G
Purac,
Netherlands
TB preparation
Hexane H/0406/17
Fisher Scientific
UK, Ltd, UK
Histology
Histoclear 717969-1
Scientific
Laboratory
Supplies Ltd
Histology
Human serum albumin A9511
Sigma-Aldrich,
UK
MP preparation
Industrial methylated
spirits
M/4400/17
Fisher Scientific
UK, Ltd, UK
Cleaning
general
Liquid nitrogen Cryospeed
BOC Industrial
gases
Snap freezing
MPs
Lysozyme L-6876
Sigma-Aldrich,
UK
Model protein
Micrococcus
lysodekticus
M-3770
Sigma-Aldrich,
UK
Lysozyme
activity
Paraformaldehyde 158127
Sigma-Aldrich,
UK
Tissue fixing
Appendices
271
Chemical/ Reagent
Specification/
Catalogue Number
Supplier Use
Penicillin/Streptomycin
Invitrogen
VX15070063
Fisher Scientific
UK, Ltd, UK
Femur culture
Phosphate buffered
saline
BPE9739-1
Fisher Scientific
UK, Ltd, UK
Release assay
Phosphmolybdic acid 221856
Sigma-Aldrich,
UK
Histology
Poly (DL lactic-co-
glycolic) acid 50 50
LX00279-133
Mw 59 kDa IV 0.45 dL/g
LX00195-63
Mw 62kDa IV 0.46 dL/g
LX00414-125
Mw 56 KDa IV 0.44 dL/g
Evonik
Industries,
Birmingham,
Al, USA
MP preparation
Poly (DL lactic-co-
glycolic) acid 85 15
LP421
Mw 53 kDa IV 0.40 dL/g
LX00195-135
Mw 56 KDa IV 0.43 dL/g
LP546
Mw 52 KDa IV 0.40 dL/g
LP671
Mw 50 KDa IV 0.40 dL/g
Poly vinyl alcohol (87-
89% hydrolysed)
363170
Sigma-Aldrich,
UK
MP preparation
Polyethylene glycol 400 PEG400 Clariant SE, UK MP preparation
Polyethylene glycol
1500
81210
Sigma-Aldrich,
UK
TB preparation
Polyethylene glycol
6000
81260
Sigma-Aldrich,
UK
Micronisation
SigmaFast pNPP kit N-2770
Sigma-Aldrich,
UK
ALP activity
Silver nitrate S-6506
Sigma-Aldrich,
UK
Von Kossa
Sirius red 365548
Sigma-Aldrich,
UK
Staining
Sodium
carboxymethylcellulose
C4888
Sigma-Aldrich,
UK
Scaffold
preparation
Sodium dodecyl
sulphate
L-3771
Sigma-Aldrich,
UK
Protein assay
Sodium hydroxide 467176
Sigma-Aldrich,
UK
Protein assay
Stannous octoate/Tin
(II) 2-ethylhexanoate
S-3252
Sigma-Aldrich,
UK
TBP
preparation
Sodium thiosulphate
13481
Sigma-Aldrich,
UK
Von Kossa
Trypsin II
T7409
Sigma-Aldrich,
UK
mPCC
isolation
Trypsin/EDTA
Cell culture
Weigerts haematoxylin HT1079
Sigma-Aldrich,
UK
Histology
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Appendix II: MP Batch manufacturing record
BATCH
NO
PLGA Type
(Lot No)
Triblock Protein PLGA % Homogeniser
Speed (rpm)
Vortex
Speed
BN 01 85 15 lp421 none none 20 9000 N/A
BN 02 85 15 lp421 none none 20 9000 N/A
BN 03 85 15 lp421 none none 20 9000 N/A
BN 04 85 15 lp421 none none 20 19000 N/A
BN 05 85 15 lp421 none none 20 19000 N/A
BN 06 85 15 lp421 none none 20 19000 N/A
BN 07 85 15 lp421 none none 20 9000 N/A
BN 08 85 15 lp421 none none 20 9000 N/A
BN 09 85 15 lp421 none none 20 9000 N/A
BN 10 85 15 lp421 none none 20 19000 N/A
BN 11 85 15 lp421 none none 20 19000 N/A
BN 12 85 15 lp421 none none 20 19000 N/A
BN 13 85 15 lp421 none none 2 19000 N/A
BN 14 85 15 lp421 none none 2 19000 N/A
BN 15 85 15 lp421 none none 2 19000 N/A
BN 16 85 15 lp421 none none 2 N/A 2000
BN 17 85 15 lp421 none none 2 N/A 2000
BN 18 85 15 lp421 none none 20 N/A 2000
BN 19 85 15 lp421 none none 20 N/A 2000
BN 20 85 15 lp421 none none 20 500 N/A
BN 21 85 15 lp421 none none 20 500 N/A
BN 22 85 15 lp421 none none 20 1000 N/A
BN 23 85 15 lp421 none none 20 1000 N/A
BN 24 85 15 lp421 none none 20 2000 N/A
BN 25 85 15 lp421 none none 20 2000 N/A
BN 26 85 15 lp421 none none 20 1000 N/A
BN 27 85 15 lp421 none none 20 2000 N/A
BN 28 85 15 lp421 none none 20 3000 N/A
BN 29 85 15 lp421 none none 20 9000 N/A
BN 30 85 15 lp421 none none 2 24000 N/A
BN 31 85 15 lp421 none none 2 24000 N/A
BN 32 85 15 lp421 none none 2 24000 N/A
BN 33 85 15 lp421 none none 2 24000 N/A
BN 34 85 15 lp421 none none 2 24000 N/A
BN 35 85 15 lp421 none none 2 24000 N/A
BN 36 85 15 lp421 none none 2 11000 N/A
BN 37 85 15 lp421 none none 2 11000 N/A
BN 38 85 15 lp421 none none 2 11000 N/A
BN 39 50 50 lx195-63 none 1% HSA 18 4000/2000 N/A
BN 40 50 50 lx195-63 none 2% HSA 18 4000/2000 N/A
BN 41 50 50 lx195-63 none 1% HSA 20 9000/9000 N/A
BN 42 50 50 lx195-63 none 2% HSA 20 9000/9000 N/A
BN 43 50 50 lx195-63 none 1% HSA 10 4000/9000 N/A
BN 44 50 50 lx195-63 none 2% HSA 10 4000/9000 N/A
BN 45 50 50 lx195-63 none 1% HSA 10 9000/9000 N/A
BN 46 50 50 lx195-63 none 2% HSA 10 9000/9000 N/A
BN 47 50 50 lx195-63 none 1% HSA 2 4000/9000 N/A
BN 48 50 50 lx195-63 none 1% HSA 2 4000/9000 N/A
BN 49 50 50 lx195-63 none 1% HSA 2 9000/9000 N/A
BN 50 50 50 lx195-63 none 2% HSA 2 9000/9000 N/A
BN 51 50 50 lx195-63 none 1% HSA 20 9000/19000 N/A
BN 52 50 50 lx195-63 none 2% HSA 20 9000/19000 N/A
BN 53 85 15 lp421 none none 2 N/A N/A
BN 54 85 15 lp421 none none 2 N/A N/A
BN 55 85 15 lp421 none none 2 9000 N/A
BN 56 85 15 lp421 none none 2 9000 N/A
BN 57 85 15 lp421 none none 2 9000 N/A
BN 58 85 15 lp421 none none 2 24000 N/A
BN 59 85 15 lp421 none none 2 24000 N/A
BN 60 85 15 lp421 none none 2 24000 N/A
BN 61 50 50 lx195-63 none 0% 2 9000/9000 N/A
BN 62 50 50 lx195-63 none 1% HSA 2 9000/9000 N/A
BN 63 50 50 lx195-63 none 0.9% HSA 0.1% Lyso 2 9000/9000 N/A
BN 64 50 50 lx195-63 none 0% 2 9000/9000 N/A
BN 65 50 50 lx195-63 none 10% HSA 2 9000/9000 N/A
BN 66 50 50 lx195-63 none 0.9% HSA 0.1% Lyso 2 9000/9000 N/A
BN67 85 15 lp421 none none 20 9000 N/A
BN68 85 15 lp421 none none 15 9000 N/A
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BATCH
NO
PLGA Type
(Lot No)
Triblock Protein PLGA % Homogeniser
Speed (rpm)
Vortex
Speed
BN69 50 50 lx195-63 none 5% lyso/6k PEG 20 2000 N/A
BN70 50 50 lx195-63 none 5% lyso/6k PEG 20 2000 N/A
BN71 50 50 lx195-63 none 5% lyso/6k PEG 20 2000 N/A
BN72 50 50 lx195-63 none 5% lyso/6k PEG 20 2000 N/A
BN73 50 50 lx195-63 30% TB2-B 5% lyso/6k PEG 20 2000 N/A
BN74 50 50 lx195-63 none 5% lyso/6k PEG 18 9000 N/A
BN75 50 50 lx195-63 none 5% lyso/6k PEG 18 9000 N/A
BN76 50 50 lx195-63 30% TB2-B 5% lyso/6k PEG 18 9000 N/A
BN77 85 15 LP421 none 6KPEG only 10 9000 N/A
BN78 85 15 LP421 none 6KPEG only 15 2000 N/A
BN79 50 50 lx279-133 none 6KPEG only 20 N/A 2000
BN80 50 50 lx279-133 none 5% lyso/6k PEG 20 N/A 2000
BN81 50 50 lx279-133 none 5% lyso/6k PEG 20 N/A 2000
BN82 50 50 lx279-133 none 6KPEG only 20 2000 N/A
BN83 50 50 lx279-133 none 5% lyso/6k PEG 20 2000 N/A
BN84 50 50 lx279-133 none 5% lyso/6k PEG 20 2000 N/A
BN85 50 50 lx195-63 none 5% lyso/6k PEG 20 N/A 2000
BN86 50 50 lx195-63 none 6KPEG only 20 N/A 2000
BN87 50 50 lx195-63 none 1% lyso/4% HSA/ PEG 20 N/A 2000
BN88 50 50 lx195-63 none 6KPEG only 20 N/A 2000
BN89 50 50 lx195-63 10% TB2-B 5% lyso/6k PEG 20 N/A 2000
BN90 50 50 lx195-63 10% TB2-B 6KPEG only 20 N/A 2000
BN91 50 50 lx195-63 none none (H2O) 20 2000/2000 N/A
BN92 50 50 lx195-63 none 1% Lysozyme 20 2000/2000 N/A
BN93 50 50 lx195-63 none none (H2O) 20 4000/2000 N/A
BN94 50 50 lx195-63 none 1% Lysozyme 20 4000/2000 N/A
BN95 50 50 lx195-63 none none (H2O) 20 4000/2000 N/A
BN96 50 50 lx195-63 none 5% lysozyme 20 4000/2000 N/A
BN97 50 50 lx279-133 none 48mg HSA 0.8mg Lyso 268
mg PEG
20 2000 N/A
BN98 50 50 lx279-133 none 50 mg HSA 0.85 mg Lyso
280 mg PEG
20 2000 N/A
BN99 50 50 lx279-133 none 49 mg HSA 1 mg Lyso 400
mg PEG
20 2000 N/A
BN100 50 50 lx279-133 none 50 mg lyso 60 mg PEG 20 2000 N/A
BN101 50 50 lx279-133 none 50 mg lyso 400 mg PEG 20 2000 N/A
BN102 50 50 lx279-133 none 50 mg HSA 400 mg PEG 20 2000 N/A
BN103 50 50 lx279-133 none 400 mg PEG 20 2000 N/A
BN104 50 50 lx279-133 none 48mg HSA 0.8mg Lyso 268
mg PEG
20 2000 N/A
BN105 50 50 lx279-133 none 50 mg HSA 0.85 mg Lyso
280 mg PEG
20 2000 N/A
BN106 50 50 lx279-133 none 49 mg HSA 1 mg Lyso 400
mg PEG
20 2000 N/A
BN107 50 50 lx279-133 none 50 mg lyso 60 mg PEG 20 2000 N/A
BN108 50 50 lx279-133 none 50 mg lyso 400 mg PEG 20 2000 N/A
BN109 50 50 lx279-133 none 50 mg HSA 400 mg PEG 20 2000 N/A
BN110 50 50 lx279-133 none 400 mg PEG 20 2000 N/A
BN111 85 15 lp225 0.3 g 50 mg Lyso and 60 mg PEG 20 2000 N/A
BN112 85 15 lp225 0.1g 50 mg Lyso and 60 mg PEG 20 2000 N/A
BN113 85 15 lp225 0.3 g 50 mg Lyso and 60 mg PEG 20 2000 N/A
BN114 85 15 lp225 0.1 g 50 mg Lyso and 60 mg PEG 20 2000 N/A
BN115 50 50 lx279-133 none none (H2O) 20 4000/2000 N/A
BN116 50 50 lx279-133 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN117 50 50 lx279-133 none 4.5% HSA 0.5% Lyso 20 4000/2000 N/A
BN118 50 50 lx279-133 none none (H2O) 20 4000/2000 N/A
BN119 50 50 lx279-133 none 5% Lyso 20 4000/2000 N/A
BN120 50 50 lx279-133 none 4.5% HSA 0.5% Lyso 20 4000/2000 N/A
BN121 50 50 lx279-133 none none (H2O) 20 4000/2000 N/A
BN122 50 50 lx279-133 none none (H2O) 20 4000/2000 N/A
BN123 50 50 lx279-133 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN124 50 50 lx279-133 10% TB2-B none (H2O) 20 4000/2000 N/A
BN125 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN126 50 50 lx279-133 30% TB2-B none (H2O) 20 4000/2000 N/A
BN127 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN128 85 15 lx195-135 none none (H2O) 20 4000/2000 N/A
BN129 85 15 lx195-135 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN130 85 15 lx195-135 10% TB2-B none (H2O) 20 4000/2000 N/A
BN131 85 15 lx195-135 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN132 85 15 lx195-135 30% TB2-B none (H2O) 20 4000/2000 N/A
BN133 85 15 lx195-135 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
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BATCH
NO
PLGA Type
(Lot No)
Triblock Protein PLGA % Homogeniser
Speed (rpm)
Vortex
Speed
BN134 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN135 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN136 50 50 lx279-133 20% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN137 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN138 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN139 50 50 lx279-133 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN140 85 15 lx195-135 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN141 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN142 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN143 50 50 lx279-133 20% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN144 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN145 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN146 50 50 lx279-133 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN147 85 15 lx195-135 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN148 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN149 50 50 lx279-133 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN150 50 50 lx279-133 20% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN151 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN152 50 50 lx279-133 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN153 50 50 lx279-133 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN154 85 15 lx195-135 30% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN155 50 50 lx279-133 30% TB2-B none (H2O) 20 4000/2000 N/A
BN156 50 50 lx279-133 20% TB2-B none (H2O) 20 4000/2000 N/A
BN157 50 50 lx279-133 10% TB2-B none (H2O) 20 4000/2000 N/A
BN158 50 50 lx279-133 none none (H2O) 20 4000/2000 N/A
BN159 85 15 lx195-135 30% TB2-B none (H2O) 20 4000/2000 N/A
BN160 50 50 lx279-133 combined
BN161 50 50 lx279-133 combined
BN162 50 50 lx279-133 combined
BN163 50 50 lx414-125 20% TB2-B 0.9% HSA 0.1% BMP-2 20 4000/2000 N/A
BN164 50 50 lx414-125 20% TB2-B none (H2O) 20 4000/2000 N/A
BN165 85 15 lx195-135 30% TB2-B 0.9% HSA 0.1% BMP-2 20 4000/2000 N/A
BN166 85 15 lx195-135 30% TB2-B none (H2O) 20 4000/2000 N/A
BN167 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 20 4000/9000 N/A
BN168 50 50 lx414-125 none none (H2O) 20 4000/9000 N/A
BN169 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 5 4000/9000 N/A
BN170 50 50 lx414-125 none none (H2O) 5 4000/9000 N/A
BN171 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 15 4000/9000 N/A
BN172 50 50 lx414-125 none none (H2O) 15 4000/9000 N/A
BN173 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 10 4000/9000 N/A
BN174 50 50 lx414-125 none none (H2O) 10 4000/9000 N/A
BN175 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 5 4000/9000 N/A
BN176 50 50 lx414-125 none none (H2O) 5 4000/9000 N/A
BN177 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 2 4000/9000 N/A
BN178 50 50 lx414-125 none none (H2O) 2 4000/9000 N/A
BN179 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 20 4000/9000 N/A
BN180 50 50 lx414-125 none 0.45% HSA 0.05% Lyso 20 4000/9000 N/A
BN181 50 50 lx414-125 none 0.09% HSA 0.01% Lyso 20 4000/9000 N/A
BN182 50 50 lx414-125 none none (H2O) 20 4000/9000 N/A
BN183 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 5 4000/9000 N/A
BN184 50 50 lx414-125 none 0.45% HSA 0.05% Lyso 5 4000/9000 N/A
BN185 50 50 lx414-125 none 0.09% HSA 0.01% Lyso 5 4000/9000 N/A
BN186 50 50 lx414-125 none none (H2O) 5 4000/9000 N/A
BN187 50 50 lx414-125 none none (H2O) 20 4000/2000 N/A
BN188 50 50 lx414-125 none 0.045% HSA 0.005% Lyso 20 4000/2000 N/A
BN189 50 50 lx414-125 none 0.09% HSA 0.01% Lyso 20 4000/2000 N/A
BN190 50 50 lx414-125 none 0.45% HSA 0.05% Lyso 20 4000/2000 N/A
BN191 50 50 lx414-125 none 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN192 50 50 lx414-125 none 1.8% HSA 0.2% Lyso 20 4000/2000 N/A
BN193 50 50 lx414-125 none 2.7% HSA 0.3% Lyso 20 4000/2000 N/A
BN194 50 50 lx414-125 none 3.6% HSA 0.4% Lyso 20 4000/2000 N/A
BN195 50 50 lx414-125 none 4.5% HSA 0.5% Lyso 20 4000/2000 N/A
BN201 50 50 lx414-125 10% TB2-B none (H2O) 20 4000/2000 N/A
BN202 85 15 lx195-135 10% TB2-B 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN203 85 15 lx195-135 10% TB2-B 0.5% HSA 0.5% Lyso 20 4000/2000 N/A
BN204 85 15 lx195-135 10% TB2-B 0.99% HSA 0.01% Lyso 20 4000/2000 N/A
BN205 85 15 lx195-135 10% TB2-B no protein 20 4000/2000 N/A
BN216 50 50 lx 414-125 none 0.99% HSA 0.01% Lyso 5 4000/9000 N/A
BN217 50 50 lx 414-125 none no protein 5 4000/9000 N/A
BN230 50 50 lx 414-125 10% TB2-C no protein 20 4000/9000 N/A
BN231 50 50 lx 414-125 10% TB2-C 0.9 % HSA and 0.1% lyso 20 4000/9000 N/A
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BATCH
NO
PLGA Type
(Lot No)
Triblock Protein PLGA % Homogeniser
Speed (rpm)
Vortex
Speed
BN232 50 50 lx 414-125 20% TB2-C no protein 20 4000/9000 N/A
BN233 50 50 lx 414-125 20% TB2-C 0.9 % HSA and 0.1% lyso 20 4000/9000 N/A
BN234 50 50 lx 414-125 30% TB2-C no protein 20 4000/9000 N/A
BN235 50 50 lx 414-125 30% TB2-C 0.9 % HSA and 0.1% lyso 20 4000/9000 N/A
BN236 85 15 lx195-135 10% TB2-C 0.9% HSA 0.1% Lyso 20 4000/2000 N/A
BN237 85 15 lx195-135 10% TB2-C 0.99% HSA 0.01% Lyso 20 4000/2000 N/A
BN238 85 15 lx195-135 10% TB2-C no protein 20 4000/2000 N/A
BN242 50 50 lx 414-125 10% TB2-C no protein 20 4000/9000 N/A
BN243 50 50 lx 414-125 10% TB2-C 0.99% HSA 0.01% BMP-2 20 4000/9000 N/A
BN244 50 50 lx 414-125 30% TB2-C no protein 20 4000/9000 N/A
BN245 50 50 lx 414-125 30% TB2-C 0.99% HSA 0.01% BMP-2 20 4000/9000 N/A
BN246 50 50 lx 414-125 20% TB2-C no protein 20 4000/2000 N/A
BN247 50 50 lx 414-125 20% TB2-C 0.99% HSA 0.01% Lyso 20 4000/2000 N/A
BN248 85 15 lx195-136 30% TB2-C no protein 20 4000/2000 N/A
BN249 85 15 lx195-136 30% TB2-C 0.99% HSA 0.01% Lyso 20 4000/2000 N/A
BN250 50 50 lx 414-125 20% TB2-C no protein 20 4000/2000 N/A
BN258 85 15 lx195-136 10% TB2-C 0.9 % HSA and 0.1% BMP 20 4000/2000 N/A
BN259 85 15 lx195-136 10% TB2-C no protein 20 4000/2000 N/A
BN260 50 50 lx 414-125 10% TB2-C 0.9 % HSA and 0.1% BMP 20 4000/2000 N/A
BN261 50 50 lx 414-125 10% TB2-C no protein 20 4000/2000 N/A
BN271 85 15 LP546 none no protein 25 4000/2000
BN272 85 15 LP546 none no protein 20 4000/2000
BN273 85 15 LP546 none no protein 25 N/A 2500
BN274 85 15 LP546 none no protein 20 N/A 2500
BN275 85 15 LP546 none no protein 25 N/A 2500
BN276 85 15 LP546 none no protein 25 N/A 2500
BN277 85 15 LP546 none no protein 25 N/A 2500
BN278 85 15 LP546 none no protein 25 N/A 2500
BN279 50 50 lx 414-125 10% TB2-C 0.99 % HSA 0.01% BMP-2 20 4000/2000 N/A
BN280 50 50 lx 414-125 10% TB2-C 0.995 % HSA 0.005% BMP 20 4000/2000 N/A
BN281 50 50 lx 414-125 10% TB2-C 0.9975 HSA 0.0025% BMP 20 4000/2000 N/A
BN282 50 50 lx 414-125 10% TB2-C no protein 20 4000/2000 N/A
BN288 85 15 LP546 none no protein 20 N/A 2500
BN297 85 15 LP546 none no protein 20 N/A 2500
BN298 50 50 lx 414-125 none no protein 20 4000/2000 N/A
BN299 50 50 lx 414-125 none 4.5% HSA 0.5% Lyso 20 4000/2000 N/A
BN312 50 50 lx 414-125 10% TB2-F no protein 20 4000/9000 N/A
BN313 50 50 lx 414-125 10% TB2-F 0.9% HSA 0.1% Lyso 20 4000/9000 N/A
BN314 50 50 lx 414-125 10% TB2-F 0.99% HSA 0.01% BMP-2 20 4000/9000 N/A
BN315 50 50 lx 414-125 30% TB2-F None 20 9000 N/A
BN331 50 50 lx 414-125 10% TB2-F 0.95% HSA 0.05% BMP-2 20 4000/9000 N/A
BN332 50 50 lx 414-125 10% TB2-F no protein 20 4000/9000 N/A
BN337 50 50 lx 414-125 10% TB2-F 0.95% HSA 0.05% BMP-2 20 4000/9000 N/A
BN341 50 50 lx 414-125 10% TB2-F no protein 20 4000/9000 N/A
BN342 85 15 LP671 20% TB2-F 0.9% HSA 0.1% BMP-2 20 4000/2000 N/A
BN343 85 15 LP671 20% TB2-F no protein 20 4000/2000 N/A
BN344 50 50 lx 414-125 10% TB2-F 0.9% HSA 0.1% BMP-2 20 4000/2000 N/A
BN345 50 50 lx 414-125 10% TB2-F no protein 20 4000/2000 N/A
BN346 50 50 lx 414-125 30% TB2-F 0.9% HSA 0.1% BMP-2 20 4000/2000 N/A
BN347 50 50 lx 414-125 30% TB2-F no protein 20 4000/2000 N/A
BN348 50 50 lx 414-125 10% TB2-F 0.95% HSA 0.05% BMP-2 20 4000/9000 N/A
BN349 50 50 lx 414-125 30% TB2-F Blank 20 4000/2000 N/A
Appendices
276
Appendix III: Reagents for tissue processing and histological staining
Automated tissue processor reagents and incubation times
1: 25 % Ethanol in H2O 1 hr 5 min
2: 50 % Ethanol in H2O 1 hr 5 min
3: 75 % Ethanol in H2O 1 hr 5 min
4: 96 % Ethanol in H2O 1 hr 5 min
5: 100% Ethanol 1 hr 5 min
6: 100% Ethanol 1 hr 5 min
7: Hexane 2 hr
8: Hexane 2 hr
9: Paraffin wax 2 hr
10: Paraffin wax 2 hr
Manufacture of reagents required for alcian blue and picrosirius red staining
Alcian Blue 1.5 g alcian blue 8G
300 ml distilled water
3 ml acetic acid
Phosphomolybdic acid 3 g Phosphomolybdic acid
300 ml distilled water
Picrosirius red F3B 0.3 g picrosirius red F3B
100 ml saturated picric acid
200 ml distilled water
300 ml methanol (50% v/v)
3 ml hydrochloric acid
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timisation of MP size analysis (Coulter L
un time on MPs size
30 secon
71.9 ± 20.6
120 secon
72.8 ± 20.2
90 second
72.8 ± 20.2
60 secon
72.6 ± 20.4
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d run
µm
d run
µm
run
µm
d run
µm
B. Variability betwee
All Coulter measu
measurement
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n multiple runs
rements in this thesis were shown as one 3
First
77.2
Third
77.2
Secon
77.2
Appendices
0 second
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± 20.6 µm
run (30 sec)
± 20.2 µm
d run (30 sec)
± 20.3 µm
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Appendix V: Gel permeation chromatography (GPC) and nuclear
magnetic resonance (NMR) for triblock copolymers
All analyses performed by Natasha Birkin, School of Chemistry, University of
Nottingham
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TBII-B
TBII-C
TBII-F
